
## NB.1.8.1 Variant – Spread Abroad and Potential Impact in Japan

NB.1.8.1 is a newly designated SARS-CoV-2 variant under monitoring (VUM) by the WHO, noted for its rapid increase in prevalence[cidrap.umn.edu](https://www.cidrap.umn.edu/covid-19/who-adds-nb181-sars-cov-2-variant-under-monitoring#:~:text=The%20World%20Health%20Organization%20,1%20sublineage). It has been driving **surges in COVID-19 cases** in several countries. For example, NB.1.8.1 became the dominant strain in China, coinciding with a _large wave of infections_[cbsnews.com](https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/#:~:text=Experts%20have%20been%20closely%20watching,19). Hong Kong experienced its worst COVID-19 levels in a year, with a significant spike in emergency room visits and hospitalizations[cbsnews.com](https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/#:~:text=Experts%20have%20been%20closely%20watching,19). Similarly, Taiwan saw rising emergency visits, severe cases, and deaths, prompting authorities to stockpile vaccines and antivirals[cbsnews.com](https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/#:~:text=While%20authorities%20in%20Hong%20Kong,places%20as%20cases%20have%20climbed). Despite these rapid spread events, health officials report **no clear evidence that NB.1.8.1 causes more severe illness** than other Omicron-lineage variants[cbsnews.com](https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/#:~:text=While%20authorities%20in%20Hong%20Kong,places%20as%20cases%20have%20climbed)[cidrap.umn.edu](https://www.cidrap.umn.edu/covid-19/who-adds-nb181-sars-cov-2-variant-under-monitoring#:~:text=The%20experts%20said%20NB,those%20from%20other%20circulating%20variants). The strain appears to have a **transmissibility advantage**: preliminary data indicate NB.1.8.1 binds more strongly to human ACE2 receptors (which could increase contagiousness), while its ability to evade immunity is only on par with, or marginally worse than, other recent subvariants[cbsnews.com](https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/#:~:text=epidemic%20wave)[cidrap.umn.edu](https://www.cidrap.umn.edu/covid-19/who-adds-nb181-sars-cov-2-variant-under-monitoring#:~:text=The%20World%20Health%20Organization%20,1%20sublineage). In other words, NB.1.8.1 is spreading fast but does not markedly escape existing immunity or cause disproportionate severity.

 

Genetically, NB.1.8.1 is a descendant of a recombinant Omicron lineage (XDV.1.5.1) and clusters within the “JN.1” family of Omicron sublineages[cidrap.umn.edu](https://www.cidrap.umn.edu/covid-19/who-adds-nb181-sars-cov-2-variant-under-monitoring#:~:text=NB,Western%20Pacific%2C%20Americas%2C%20and%20European). By late April 2025 it was rising quickly: about **10.7% of global sequences** were NB.1.8.1, up from 2.5% only a month earlier[cidrap.umn.edu](https://www.cidrap.umn.edu/covid-19/who-adds-nb181-sars-cov-2-variant-under-monitoring#:~:text=NB,Western%20Pacific%2C%20Americas%2C%20and%20European). This increase was observed across regions (Western Pacific, Americas, Europe) that conduct regular sequencing[cidrap.umn.edu](https://www.cidrap.umn.edu/covid-19/who-adds-nb181-sars-cov-2-variant-under-monitoring#:~:text=NB,Western%20Pacific%2C%20Americas%2C%20and%20European). Notably, **Japan is not isolated from this trend** – the U.S. CDC’s airport screening detected NB.1.8.1 in travelers arriving from numerous countries _including Japan_ (as well as South Korea, various European nations, Thailand, Vietnam, China, etc.)[cbsnews.com](https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/#:~:text=and%20the%20New%20York%20City,airport%20testing%20partner%20Ginkgo%20Bioworks). This suggests NB.1.8.1 has already been introduced into Japan via travel, even if it has not yet widely circulated domestically.

 

**Potential displacement of Japan’s current strain (KP.3):** In Japan, the currently predominant variant has been identified as “KP.3,” a subvariant in the JN.1 lineage (KP.3 was a major Omicron strain circulating in early 2025). Given NB.1.8.1’s rapid growth advantage observed elsewhere, there is a realistic possibility that NB.1.8.1 could overtake KP.3 as the dominant strain in Japan. Indeed, globally KP.3’s prevalence was declining as NB.1.8.1 rose[cdn.who.int](https://cdn.who.int/media/docs/default-source/documents/epp/tracking-sars-cov-2/23052025_nb.1.8.1_ire.pdf#:~:text=Lineage%2A%20Countries%C2%A7%20Sequences%C2%A7%202025,6%20Increase). If NB.1.8.1 gains a foothold in Japan, we might expect it to spread swiftly through the population, especially as social and travel activities normalize. **Epidemiological patterns** in many countries have settled into two COVID surges per year (one in summer, one in winter)[cbsnews.com](https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/#:~:text=For%20now%2C%20CDC%20and%20FDA,and%20once%20over%20the%20winter), and a highly transmissible variant like NB.1.8.1 could fuel Japan’s next surge. It is plausible that over the summer or autumn, NB.1.8.1 becomes the mainstream strain domestically. On the positive side, because NB.1.8.1 has not shown increased virulence, a wave driven by it _may not_ produce higher severity than previous Omicron waves – but it could still lead to a substantial number of infections given its growth advantage. In summary, **Japan should be prepared for NB.1.8.1 to emerge as a major strain**, potentially supplanting KP.3, and plan for a possible uptick in cases. Ongoing surveillance (e.g. genomic monitoring of variants) and healthcare readiness are warranted, learning from the overseas situations where healthcare systems saw strain during NB.1.8.1 surges[cbsnews.com](https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/#:~:text=Experts%20have%20been%20closely%20watching,19).

## Effectiveness of Current JN.1-Targeted Vaccines vs NB.1.8.1, and Need for New Vaccines

Japan’s current COVID-19 booster vaccines (as of 2024/25) are **monovalent shots targeting the Omicron JN.1 lineage** (JN.1 is an Omicron variant clade, which includes XBB-lineage descendants). The question is how well these existing vaccines protect against the NB.1.8.1 variant. Encouragingly, experts believe that **JN.1-based vaccines should still provide substantial protection against NB.1.8.1**. The WHO’s COVID-19 Vaccine Composition Advisory group stated in May 2025 that a monovalent vaccine targeting JN.1 (or its close descendant KP.2) “remains appropriate” as it broadly covers circulating strains[cidrap.umn.edu](https://www.cidrap.umn.edu/covid-19/who-adds-nb181-sars-cov-2-variant-under-monitoring#:~:text=On%20May%2015%2C%20the%20WHO%27s,1%20component). This implies that NB.1.8.1 has not drifted far enough antigenically to render JN.1-based immunity ineffective. In fact, laboratory analyses so far show NB.1.8.1 is only **“marginally more immune-evasive”** than the previously dominant subvariant (LP.8.1)[cidrap.umn.edu](https://www.cidrap.umn.edu/covid-19/who-adds-nb181-sars-cov-2-variant-under-monitoring#:~:text=The%20World%20Health%20Organization%20,1%20sublineage). Chinese researchers reported that NB.1.8.1 did _not_ outperform other recent variants in evading antibodies – it was roughly on par with them[cbsnews.com](https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/#:~:text=epidemic%20wave). Therefore, individuals vaccinated against JN.1 or similar Omicron strains should still have neutralizing antibodies that recognize NB.1.8.1, and importantly T-cell immunity from those vaccines will continue to provide protection against severe outcomes. Real-world observations support this: despite NB.1.8.1’s spread, **currently approved vaccines are expected to remain effective against symptomatic infection and severe disease** from this variant[cdn.who.int](https://cdn.who.int/media/docs/default-source/documents/epp/tracking-sars-cov-2/23052025_nb.1.8.1_ire.pdf#:~:text=globally%2C%20while%20LP,than%20other%20variants%20in%20circulation).

 

It is worth noting that NB.1.8.1 is indeed a _member_ of the JN.1 variant family[cidrap.umn.edu](https://www.cidrap.umn.edu/covid-19/who-adds-nb181-sars-cov-2-variant-under-monitoring#:~:text=NB,Western%20Pacific%2C%20Americas%2C%20and%20European). Thus, the immune response induced by a JN.1-targeted shot is closely matched to NB.1.8.1’s Spike protein. For example, NB.1.8.1 carries certain Spike mutations (e.g. at positions 445, 478) that may enhance transmissibility or slightly reduce neutralization, but these changes yield only a modest (~1.5-fold) reduction in neutralizing antibody potency compared to the vaccine strain[cdn.who.int](https://cdn.who.int/media/docs/default-source/documents/epp/tracking-sars-cov-2/23052025_nb.1.8.1_ire.pdf#:~:text=has%20the%20following%20additional%20Spike,evasion%20of%20Class%201%2F2%20antibodies)[cdn.who.int](https://cdn.who.int/media/docs/default-source/documents/epp/tracking-sars-cov-2/23052025_nb.1.8.1_ire.pdf#:~:text=,5%2C6). **No drastic immune escape has been observed.** Indeed, experiments in mice showed that boosting with the current JN.1/KP.2-based vaccines generated only modestly lower antibodies against NB.1.8.1, compared to antibodies against the original vaccine strain[cdn.who.int](https://cdn.who.int/media/docs/default-source/documents/epp/tracking-sars-cov-2/23052025_nb.1.8.1_ire.pdf#:~:text=,5%2C6). All this suggests that the **JN.1-based booster in use should still blunt the impact of NB.1.8.1**, especially for preventing hospitalizations and deaths.

 

**Effectiveness data and expert recommendations:** At a U.S. FDA advisory meeting (June 2025), early data were presented on how well updated vaccines could cover NB.1.8.1. Notably, Pfizer and Moderna showed that if the vaccine strain were switched to a slightly newer JN.1 descendant (called LP.8.1, which has been dominant in recent months), it **“could boost protection against NB.1.8.1”** as well[cbsnews.com](https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/#:~:text=Vaccines%20from%20last%20season%20targeted,1%2C%20too). Moderna’s scientists explained that an LP.8.1-based vaccine induced the highest neutralizing titers against the LP.8.1 virus _and_ also cross-neutralized other circulating variants including NB.1.8.1[cbsnews.com](https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/#:~:text=,19%20program%2C%20told%20the%20panel). This implies that while the current JN.1 (KP.2) vaccine is effective, an updated shot might offer even broader immunity. In line with this, the European Medicines Agency has _recommended_ using an LP.8.1 antigen for upcoming boosters, and the FDA’s panel unanimously agreed that the **next season’s COVID-19 vaccines should target “some kind of JN.1 variant”** (with many experts favoring the LP.8.1 strain as the update)[cidrap.umn.edu](https://www.cidrap.umn.edu/covid-19/who-adds-nb181-sars-cov-2-variant-under-monitoring#:~:text=On%20May%2015%2C%20the%20WHO%27s,1%20component)[cbsnews.com](https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/#:~:text=The%20committee%20unanimously%20backed%20recommending,Pfizer%20and%20Moderna%20have%20prototyped). Importantly, these discussions highlight that **NB.1.8.1 did not necessitate a completely new vaccine on its own** – instead, it can be addressed by tweaking the existing Omicron-based formulations.

 

**NB.1.8.1-specific vaccine – is it needed?** Given the above context, the introduction of a brand-new, NB.1.8.1-specific vaccine does not appear necessary or practical at this time. Global health authorities have not singled out NB.1.8.1 as requiring its own vaccine. Rather, the strategy is to keep pace with SARS-CoV-2 evolution by occasionally updating the vaccine strain to one that offers broad cross-protection. For instance, if NB.1.8.1 (or similar strains) continue to spread, the fall 2025 booster could be formulated as LP.8.1 (or another JN.1-lineage variant that covers NB.1.8.1)[cidrap.umn.edu](https://www.cidrap.umn.edu/covid-19/who-adds-nb181-sars-cov-2-variant-under-monitoring#:~:text=On%20May%2015%2C%20the%20WHO%27s,1%20component)[cbsnews.com](https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/#:~:text=Vaccines%20from%20last%20season%20targeted,1%2C%20too). This approach is analogous to how influenza vaccines are updated – we don’t make a new vaccine for every single variant, but we update to a representative strain. An NB.1.8.1-specific vaccine would have questionable **practicality** because by the time it was developed, tested, and rolled out, the virus might have moved on to a new lineage. Moreover, current evidence says **existing vaccines still work**: the WHO TAG-VE evaluated NB.1.8.1’s risk as low and explicitly noted that _“currently approved COVID-19 vaccines are expected to remain effective”_ against it[cdn.who.int](https://cdn.who.int/media/docs/default-source/documents/epp/tracking-sars-cov-2/23052025_nb.1.8.1_ire.pdf#:~:text=globally%2C%20while%20LP,than%20other%20variants%20in%20circulation). Therefore, from a policy perspective, it makes more sense to continue **promoting the current booster (JN.1/KP.2-based) for at-risk groups, and plan for a variant update in the next seasonal campaign if needed**, rather than rushing out a one-off NB.1.8.1 vaccine. In summary, the **JN.1-directed vaccines offer a solid defense against NB.1.8.1**, and incremental updates (like moving to an LP.8.1-based shot) can be implemented in future if surveillance indicates it’s beneficial[cbsnews.com](https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/#:~:text=,19%20program%2C%20told%20the%20panel). There is no strong indication that a special NB.1.8.1-only vaccine would significantly change the trajectory of the pandemic at this point.

## Annual COVID Vaccination with Replicon Vaccine (「コスタイベ」) – Feasibility and Benefits

Starting in late 2024, Japan transitioned its COVID-19 immunization program to a **routine annual vaccination** paradigm. Essentially, COVID-19 vaccines are now treated similarly to seasonal influenza vaccines – with a planned **one dose per year** for most individuals (administered in the autumn/winter)[kagaya-clinic.jp](https://www.kagaya-clinic.jp/replicon-vaccine/#:~:text=%E5%AF%BE%E3%81%97%E3%81%A6%E3%81%AF%E5%84%AA%E3%82%8C%E3%82%8B%E3%81%93%E3%81%A8%E3%81%8C%E7%A2%BA%E8%AA%8D%E3%81%95%E3%82%8C%E3%81%BE%E3%81%97%E3%81%9F%E3%80%82). Alongside this transition, Japan approved and introduced a next-generation vaccine: the _replicon mRNA vaccine_ known by the brand name **“コスタイベ” (Costaive)**. This vaccine, developed by Arcturus Therapeutics and manufactured domestically by Meiji Seika Pharma, was the world’s first approved replicon COVID-19 vaccine[jmedj.co.jp](https://www.jmedj.co.jp/journal/paper/detail.php?id=23229#:~:text=Meiji%20Seika%E3%83%95%E3%82%A1%E3%83%AB%E3%83%9E%E3%81%AF11%E6%9C%8828%E6%97%A5%E3%80%81%E6%96%B0%E5%9E%8B%E3%82%B3%E3%83%AD%E3%83%8A%E3%82%A6%E3%82%A4%E3%83%AB%E3%82%B9%E6%84%9F%E6%9F%93%E7%97%87%E3%81%AB%E5%AF%BE%E3%81%99%E3%82%8B%E6%AC%A1%E4%B8%96%E4%BB%A3mRNA%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%80%8C%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E7%AD%8B%E6%B3%A8%E7%94%A8%E3%80%8D%E3%81%AB%E3%81%A4%E3%81%84%E3%81%A6%E8%A8%98%E8%80%85%E8%AA%AC%E6%98%8E%E4%BC%9A%E3%82%92%E9%96%8B%E5%82%AC%E3%81%97%E3%81%9F%E3%80%82%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%20%E3%81%AF%E3%80%81%E7%B1%B3%E3%83%90%E3%82%A4%E3%82%AA%E4%BC%81%E6%A5%AD%E3%82%A2%E3%83%BC%E3%82%AF%E3%83%88%E3%82%A5%E3%83%AB%E3%82%B9%E3%83%BB%E3%82%BB%E3%83%A9%E3%83%94%E3%83%A5%E3%83%BC%E3%83%86%E3%82%A3%E3%82%AF%E3%82%B9%E3%81%8C%E9%96%8B%E7%99%BA%E3%81%97%E3%81%9F%E3%80%81%E6%8A%95%E4%B8%8E%E5%BE%8C%E3%81%AB%E4%BD%93%E5%86%85%E3%81%A7mRNA%E3%82%92%E8%87%AA%E5%B7%B1%E8%A4%87%E8%A3%BD%E3%81%99%E3%82%8B%E3%80%8C%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%80%8D%E3%80%82Meiji%20Seika%E3%83%95%E3%82%A1%E3%83%AB%E3%83%9E%E3%81%8C%E5%9B%BD%E5%86%85%E3%81%AE%E4%BE%9B%E7%B5%A6%E3%83%BB%E8%B2%A9%E5%A3%B2%E6%A8%A9%E3%82%92%E5%8F%96%E5%BE%97%E3%81%97%E8%87%A8%E5%BA%8A%E8%A9%A6%E9%A8%93%E3%82%92%E9%80%B2%E3%82%81%E3%80%81%E5%90%8C%E6%97%A5%E3%80%81%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%A8%E3%81%97%E3%81%A6%E4%B8%96%E7%95%8C%E5%88%9D%E3%81%A8%E3%81%AA%E3%82%8B%E8%A3%BD%E9%80%A0%E8%B2%A9%E5%A3%B2%E6%89%BF%E8%AA%8D%E3%82%92%E5%8E%9A%E5%8A%B4%E7%9C%81%E3%82%88%E3%82%8A%E5%8F%96%E5%BE%97%E3%81%97%E3%81%9F%E3%80%82). It targets the Omicron JN.1 strain (as a monovalent formulation) and became available as part of the routine booster program on October 1, 2024[kagaya-clinic.jp](https://www.kagaya-clinic.jp/replicon-vaccine/#:~:text=Image%3A%20%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B32024%E5%B9%B410%E6%9C%881%E6%97%A5%E3%82%88%E3%82%8A%E3%80%81%E6%96%B0%E5%9E%8B%E3%82%B3%E3%83%AD%E3%83%8A%E3%82%A6%E3%82%A4%E3%83%AB%E3%82%B9%E3%81%AE%E3%82%AA%E3%83%9F%E3%82%AF%E3%83%AD%E3%83%B3%E6%A0%AAJN).

 

**What is a replicon vaccine and why is it useful?** A replicon vaccine is a type of mRNA vaccine engineered to **self-amplify inside cells** for a short period after injection. In Costaive’s case, the mRNA includes a replicase enzyme, so once it enters the body’s cells, it keeps copying itself and producing the viral antigen (the Spike protein) for longer than a conventional mRNA vaccine would[kagaya-clinic.jp](https://www.kagaya-clinic.jp/replicon-vaccine/#:~:text=%E3%80%8C%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%EF%BC%88replicon%EF%BC%89%E3%80%8D%E3%81%AF%E3%80%81%E3%80%8C%E8%A4%87%E8%A3%BD%E3%80%8D%E3%82%92%E6%84%8F%E5%91%B3%E3%81%99%E3%82%8B%E5%88%86%E5%AD%90%E7%94%9F%E7%89%A9%E5%AD%A6%E3%81%AE%E7%94%A8%E8%AA%9E%E3%81%A7%E3%80%81%E3%82%B3%E3%83%94%E3%83%BC%E3%81%95%E3%82%8C%E3%81%9FDNA%E3%82%84RNA%E3%82%92%E6%8C%87%E3%81%97%E3%81%BE%E3%81%99%E3%80%82%20%E5%BE%93%E6%9D%A5%E3%81%AEmRNA%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AF%E3%80%81%E4%BD%93%E5%86%85%E3%81%A7%E3%82%A6%E3%82%A4%E3%83%AB%E3%82%B9%E3%81%AE%E3%82%BF%E3%83%B3%E3%83%91%E3%82%AF%E8%B3%AA%E3%82%92%E7%94%9F%E6%88%90%E3%81%99%E3%82%8B%E3%81%93%E3%81%A8%E3%81%A7%E5%85%8D%E7%96%AB%E3%82%92%E8%AA%98%E5%B0%8E%E3%81%97%E3%80%81%E6%8A%97%E4%BD%93%E3%82%92%E5%BE%97%E3%82%8B%E4%BB%95%E7%B5%84%E3%81%BF%E3%81%A7%E3%81%99%E3%81%8C%E3%80%81%E3%81%9D%E3%81%AE%E7%94%9F%E6%88%90%E3%81%AF%E4%B8%80%E9%81%8E%E6%80%A7%E3%81%A7%E3%81%99%E3%80%82%E3%81%93%E3%82%8C%E3%81%AB%E5%AF%BE%E3%81%97%E3%80%81%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%EF%BC%88%20%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%EF%BC%89%E3%81%AFmRNA%E3%81%AB%E8%87%AA%E5%B7%B1%E8%A4%87%E8%A3%BD%E9%85%B5%E7%B4%A0%E3%82%92%E7%B5%84%E3%81%BF%E8%BE%BC%E3%81%BF%E3%80%81%E3%82%BF%E3%83%B3%E3%83%91%E3%82%AF%E8%B3%AA%E7%94%9F%E6%88%90%E3%82%92%E6%8C%81%E7%B6%9A%E7%9A%84%E3%81%AB%E8%A1%8C%E3%81%84%E3%81%BE%E3%81%99%E3%80%82%E3%81%93%E3%81%AE%E3%80%8C%E8%87%AA%E5%B7%B1%E5%A2%97%E5%B9%85%E3%80%8D%E3%81%AB%E3%82%88%E3%82%8A%E3%80%81%E5%BE%93%E6%9D%A5%E3%81%AEmRNA%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AB%E6%AF%94%E3%81%B9%E3%81%A6%E3%80%81%E3%82%88%E3%82%8A%E5%BC%B7%E5%8A%9B%E3%81%A7%E6%8C%81%E7%B6%9A%E7%9A%84%E3%81%AA%E5%85%8D%E7%96%AB%20%E5%BF%9C%E7%AD%94%E3%82%92%E8%AA%98%E5%B0%8E%E3%81%A7%E3%81%8D%E3%82%8B%E3%81%A8%E3%81%95%E3%82%8C%E3%81%A6%E3%81%84%E3%81%BE%E3%81%99%E3%80%82%20%E5%95%86%E5%93%81%E5%90%8D%E3%80%8C%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E3%80%8D%E3%81%AF%E3%80%81%E3%82%A2%E3%83%A1%E3%83%AA%E3%82%AB%E3%81%AEArcturus,Therapeutics%E7%A4%BE%E3%81%8C%E9%96%8B%E7%99%BA%E3%81%97%E3%80%81%E6%97%A5%E6%9C%AC%E3%81%A7%E3%81%AFMeiji%20Seika%E3%83%95%E3%82%A1%E3%83%AB%E3%83%9E%E7%A4%BE%E3%81%8C%E8%A3%BD%E9%80%A0%E3%83%BB%E8%B2%A9%E5%A3%B2%E3%82%92%E6%8B%85%E5%BD%93%E3%81%97%E3%81%A6%E3%81%84%E3%81%BE%E3%81%99%E3%80%82). This prolonged protein expression leads to a more sustained stimulation of the immune system. The practical benefits are twofold: (1) **Much smaller dose needed.** Costaive can achieve a robust immune response with less than one-sixth the mRNA quantity of a standard mRNA shot[kagaya-clinic.jp](https://www.kagaya-clinic.jp/replicon-vaccine/#:~:text=%E7%89%B9%E5%BE%B4%E3%81%A8%E4%BB%8A%E5%BE%8C%E3%81%AE%E5%8F%AF%E8%83%BD%E6%80%A7). (2) **Longer-lasting immunity.** Because the antigen is produced over an extended period, the immune response is stronger and more durable[kagaya-clinic.jp](https://www.kagaya-clinic.jp/replicon-vaccine/#:~:text=%E3%80%8C%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%EF%BC%88replicon%EF%BC%89%E3%80%8D%E3%81%AF%E3%80%81%E3%80%8C%E8%A4%87%E8%A3%BD%E3%80%8D%E3%82%92%E6%84%8F%E5%91%B3%E3%81%99%E3%82%8B%E5%88%86%E5%AD%90%E7%94%9F%E7%89%A9%E5%AD%A6%E3%81%AE%E7%94%A8%E8%AA%9E%E3%81%A7%E3%80%81%E3%82%B3%E3%83%94%E3%83%BC%E3%81%95%E3%82%8C%E3%81%9FDNA%E3%82%84RNA%E3%82%92%E6%8C%87%E3%81%97%E3%81%BE%E3%81%99%E3%80%82%20%E5%BE%93%E6%9D%A5%E3%81%AEmRNA%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AF%E3%80%81%E4%BD%93%E5%86%85%E3%81%A7%E3%82%A6%E3%82%A4%E3%83%AB%E3%82%B9%E3%81%AE%E3%82%BF%E3%83%B3%E3%83%91%E3%82%AF%E8%B3%AA%E3%82%92%E7%94%9F%E6%88%90%E3%81%99%E3%82%8B%E3%81%93%E3%81%A8%E3%81%A7%E5%85%8D%E7%96%AB%E3%82%92%E8%AA%98%E5%B0%8E%E3%81%97%E3%80%81%E6%8A%97%E4%BD%93%E3%82%92%E5%BE%97%E3%82%8B%E4%BB%95%E7%B5%84%E3%81%BF%E3%81%A7%E3%81%99%E3%81%8C%E3%80%81%E3%81%9D%E3%81%AE%E7%94%9F%E6%88%90%E3%81%AF%E4%B8%80%E9%81%8E%E6%80%A7%E3%81%A7%E3%81%99%E3%80%82%E3%81%93%E3%82%8C%E3%81%AB%E5%AF%BE%E3%81%97%E3%80%81%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%EF%BC%88%20%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%EF%BC%89%E3%81%AFmRNA%E3%81%AB%E8%87%AA%E5%B7%B1%E8%A4%87%E8%A3%BD%E9%85%B5%E7%B4%A0%E3%82%92%E7%B5%84%E3%81%BF%E8%BE%BC%E3%81%BF%E3%80%81%E3%82%BF%E3%83%B3%E3%83%91%E3%82%AF%E8%B3%AA%E7%94%9F%E6%88%90%E3%82%92%E6%8C%81%E7%B6%9A%E7%9A%84%E3%81%AB%E8%A1%8C%E3%81%84%E3%81%BE%E3%81%99%E3%80%82%E3%81%93%E3%81%AE%E3%80%8C%E8%87%AA%E5%B7%B1%E5%A2%97%E5%B9%85%E3%80%8D%E3%81%AB%E3%82%88%E3%82%8A%E3%80%81%E5%BE%93%E6%9D%A5%E3%81%AEmRNA%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AB%E6%AF%94%E3%81%B9%E3%81%A6%E3%80%81%E3%82%88%E3%82%8A%E5%BC%B7%E5%8A%9B%E3%81%A7%E6%8C%81%E7%B6%9A%E7%9A%84%E3%81%AA%E5%85%8D%E7%96%AB%20%E5%BF%9C%E7%AD%94%E3%82%92%E8%AA%98%E5%B0%8E%E3%81%A7%E3%81%8D%E3%82%8B%E3%81%A8%E3%81%95%E3%82%8C%E3%81%A6%E3%81%84%E3%81%BE%E3%81%99%E3%80%82%20%E5%95%86%E5%93%81%E5%90%8D%E3%80%8C%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E3%80%8D%E3%81%AF%E3%80%81%E3%82%A2%E3%83%A1%E3%83%AA%E3%82%AB%E3%81%AEArcturus,Therapeutics%E7%A4%BE%E3%81%8C%E9%96%8B%E7%99%BA%E3%81%97%E3%80%81%E6%97%A5%E6%9C%AC%E3%81%A7%E3%81%AFMeiji%20Seika%E3%83%95%E3%82%A1%E3%83%AB%E3%83%9E%E7%A4%BE%E3%81%8C%E8%A3%BD%E9%80%A0%E3%83%BB%E8%B2%A9%E5%A3%B2%E3%82%92%E6%8B%85%E5%BD%93%E3%81%97%E3%81%A6%E3%81%84%E3%81%BE%E3%81%99%E3%80%82)[kagaya-clinic.jp](https://www.kagaya-clinic.jp/replicon-vaccine/#:~:text=%E7%89%B9%E5%BE%B4%E3%81%A8%E4%BB%8A%E5%BE%8C%E3%81%AE%E5%8F%AF%E8%83%BD%E6%80%A7). Clinical trial data support these claims – in a Phase 3 booster trial in Japan, a single dose of Costaive induced neutralizing antibody levels that were _higher and more persistent_ than those from Pfizer’s mRNA booster (Comirnaty) when looking at Omicron-specific immunity[jmedj.co.jp](https://www.jmedj.co.jp/journal/paper/detail.php?id=23229#:~:text=%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AF%E6%97%A2%E5%AD%98%E3%81%AEmRNA%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AB%E6%AF%94%E3%81%B9%E5%B0%91%E9%87%8F%E6%8A%95%E4%B8%8E%E3%81%A7%E6%B8%88%E3%81%BF%E3%80%81%E3%82%88%E3%82%8A%E5%8A%B9%E6%9E%9C%E3%81%8C%E6%8C%81%E7%B6%9A%E3%81%99%E3%82%8B%E3%81%A8%E3%81%95%E3%82%8C%E3%82%8B%E3%80%82%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E3%81%AF%E8%BF%BD%E5%8A%A0%E5%85%8D%E7%96%AB%E3%81%AE%E5%9B%BD%E5%86%85%E7%AC%AC3%E7%9B%B8%E8%A9%A6%E9%A8%93%E3%81%A7%E3%80%81%E3%83%95%E3%82%A1%E3%82%A4%E3%82%B6%E3%83%BC%E3%81%AE%E3%82%B3%E3%83%9F%E3%83%8A%E3%83%86%E3%82%A3%E3%81%AB%E6%AF%94%E3%81%B9%20%E6%8A%97%E4%BD%93%E4%BE%A1%E3%81%8C%E9%AB%98%E3%81%8F%E6%8C%81%E7%B6%9A%E6%80%A7%E3%81%AB%E5%84%AA%E3%82%8C%E3%81%A6%E3%81%84%E3%82%8B%E3%81%93%E3%81%A8%E3%81%8C%E7%A2%BA%E8%AA%8D%E3%81%95%E3%82%8C%E3%81%9F%E3%80%82)[kagaya-clinic.jp](https://www.kagaya-clinic.jp/replicon-vaccine/#:~:text=%E7%89%B9%E5%BE%B4%E3%81%A8%E4%BB%8A%E5%BE%8C%E3%81%AE%E5%8F%AF%E8%83%BD%E6%80%A7). In fact, immunity against Omicron BA.4/5 was superior in the Costaive group compared to Pfizer’s vaccine[kagaya-clinic.jp](https://www.kagaya-clinic.jp/replicon-vaccine/#:~:text=%E7%89%B9%E5%BE%B4%E3%81%A8%E4%BB%8A%E5%BE%8C%E3%81%AE%E5%8F%AF%E8%83%BD%E6%80%A7). These results indicate that **replicon vaccines can maintain protective antibody levels for a longer time**, which aligns perfectly with the **annual vaccination schedule** (one shot providing year-round coverage)[kagaya-clinic.jp](https://www.kagaya-clinic.jp/replicon-vaccine/#:~:text=%E5%AF%BE%E3%81%97%E3%81%A6%E3%81%AF%E5%84%AA%E3%82%8C%E3%82%8B%E3%81%93%E3%81%A8%E3%81%8C%E7%A2%BA%E8%AA%8D%E3%81%95%E3%82%8C%E3%81%BE%E3%81%97%E3%81%9F%E3%80%82).

 

From a **public health perspective**, the proposal to use Costaive as an annual COVID-19 booster (covered by National Health Insurance) and to integrate its delivery with routine health check-ups is quite sound. The annual schedule is justified by both epidemiology and vaccine performance: SARS-CoV-2 has settled into a pattern of causing seasonal waves, and immunity – whether from infection or vaccination – wanes over time. An yearly booster can top up protection, especially for high-risk groups, to reduce hospitalizations and deaths. Costaive’s long-lasting immunity means an annual dose should suffice for most people[kagaya-clinic.jp](https://www.kagaya-clinic.jp/replicon-vaccine/#:~:text=%E5%AF%BE%E3%81%97%E3%81%A6%E3%81%AF%E5%84%AA%E3%82%8C%E3%82%8B%E3%81%93%E3%81%A8%E3%81%8C%E7%A2%BA%E8%AA%8D%E3%81%95%E3%82%8C%E3%81%BE%E3%81%97%E3%81%9F%E3%80%82). Including the COVID booster in National Health Insurance coverage (or as a government-recommended routine vaccination) ensures that **cost is not a barrier**. In Japan, routine immunizations are either free or very low-cost to the individual, which encourages higher uptake. This is critical in a country where vaccine confidence has sometimes been an issue; making the COVID shot a normal, expected part of healthcare (like a flu shot) and covering it financially can improve acceptance.

 

Integrating the vaccination with **“国民健診” (national health check-ups)** or other regular medical visits is an innovative way to raise coverage. Many Japanese residents undergo annual health exams (for example, workplace health check-ups or the Specific Health Checkups for those over 40). Utilizing these existing touchpoints to also offer COVID-19 vaccination could significantly **increase convenience and uptake**. For instance, at a yearly physical or screening, individuals could be informed about the COVID booster and even receive it on-site or schedule an appointment for it. This one-stop approach has multiple benefits:

- **Higher reach:** It captures people who might not actively seek out a vaccine appointment on their own. If a person is already attending a health check, a simple opt-in can get them protected without an extra trip.
    
- **Efficiency:** It leverages existing healthcare infrastructure and appointment systems. Rather than running large separate vaccination drives each year, health authorities can piggyback on the routine check-up system. This can be more cost-effective and logistically simpler, especially in terms of scheduling and record-keeping.
    
- **Public health synergy:** It reinforces the idea of preventive health. Patients see vaccination as a regular part of staying healthy, just like blood pressure checks or blood tests. This normalization can combat vaccine hesitancy by making the experience more routine.
    

Of course, there are **operational considerations** to ensure this integration works smoothly. Timing is one aspect: the annual COVID shot is recommended in fall/winter, so coordinating that with health check schedules (which might be year-round) is important. One approach could be to concentrate vaccination offers in the latter half of the year’s check-ups. Alternatively, check-up providers could take reservations for a vaccine clinic in the appropriate season (e.g., if you do your health check in summer, they might help you schedule a COVID shot for the fall). There are also logistical needs such as having the vaccine supply and trained staff available at the health check site. Many larger companies in Japan already administer influenza vaccines to employees on-site; a similar model could be used for COVID, especially with a vaccine like Costaive that doesn’t have ultra-cold storage requirements (Costaive can be stored at 2–8°C refrigerated conditions, making it easier to handle than some earlier mRNA vaccines). Proper observation space for 15 minutes post-shot would need to be arranged at clinics or check-up venues. These are manageable issues with planning.

 

Another important perspective is **monitoring and data integration**. By linking vaccination to the health check, authorities can better keep track of who has received the vaccine and who hasn’t, possibly through the national vaccine registration system (VRS) or the individual’s electronic health records. This can help identify gaps in coverage and send reminders, etc. Privacy and consent must be handled appropriately, but since vaccination is voluntary, the system would likely ask individuals during their check-up if they want the shot or want to register for it. Such integration has precedent in other public health efforts (for example, some countries use routine doctor visits to offer missing immunizations).

 

In summary, **the proposal to administer the replicon vaccine annually with National Health Insurance coverage, and to utilize the national health check-up framework for scheduling, is well-founded in public health logic**. It takes advantage of a vaccine (Costaive) that is specifically designed to provide long-lasting protection with one dose[kagaya-clinic.jp](https://www.kagaya-clinic.jp/replicon-vaccine/#:~:text=%E7%89%B9%E5%BE%B4%E3%81%A8%E4%BB%8A%E5%BE%8C%E3%81%AE%E5%8F%AF%E8%83%BD%E6%80%A7), and it uses an existing healthcare interaction to maximize convenience. This should improve vaccination rates and, over time, contribute to COVID-19 being a manageable, routine respiratory illness rather than a series of emergencies. From a system operation standpoint, careful planning will be needed to coordinate between preventive services and vaccination providers, but Japan’s healthcare system is quite capable of such coordinated campaigns (as seen in its rollout of vaccines through local clinics and mass sites in 2021–2022). The key will be clear communication to the public that each year’s health check is also an opportunity to get the COVID shot – this could become a **“new normal”** for preventive healthcare in Japan.

## Domestic Replicon Vaccine vs. Foreign mRNA Vaccines – Scientific and Industrial Considerations

Japan’s strategy of **emphasizing a domestically developed replicon vaccine (Costaive)** as a primary tool, as opposed to relying entirely on foreign-made vaccines (like Pfizer’s or Moderna’s mRNA shots), can be evaluated from both scientific and industrial perspectives. Overall, this strategy has strong merit in several ways:

- **Scientific Efficacy and Innovation:** The replicon vaccine is a **next-generation mRNA technology** that has demonstrated high efficacy. As noted, Costaive produced equal or higher antibody responses compared to Pfizer’s vaccine in trials[jmedj.co.jp](https://www.jmedj.co.jp/journal/paper/detail.php?id=23229#:~:text=%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AF%E6%97%A2%E5%AD%98%E3%81%AEmRNA%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AB%E6%AF%94%E3%81%B9%E5%B0%91%E9%87%8F%E6%8A%95%E4%B8%8E%E3%81%A7%E6%B8%88%E3%81%BF%E3%80%81%E3%82%88%E3%82%8A%E5%8A%B9%E6%9E%9C%E3%81%8C%E6%8C%81%E7%B6%9A%E3%81%99%E3%82%8B%E3%81%A8%E3%81%95%E3%82%8C%E3%82%8B%E3%80%82%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E3%81%AF%E8%BF%BD%E5%8A%A0%E5%85%8D%E7%96%AB%E3%81%AE%E5%9B%BD%E5%86%85%E7%AC%AC3%E7%9B%B8%E8%A9%A6%E9%A8%93%E3%81%A7%E3%80%81%E3%83%95%E3%82%A1%E3%82%A4%E3%82%B6%E3%83%BC%E3%81%AE%E3%82%B3%E3%83%9F%E3%83%8A%E3%83%86%E3%82%A3%E3%81%AB%E6%AF%94%E3%81%B9%20%E6%8A%97%E4%BD%93%E4%BE%A1%E3%81%8C%E9%AB%98%E3%81%8F%E6%8C%81%E7%B6%9A%E6%80%A7%E3%81%AB%E5%84%AA%E3%82%8C%E3%81%A6%E3%81%84%E3%82%8B%E3%81%93%E3%81%A8%E3%81%8C%E7%A2%BA%E8%AA%8D%E3%81%95%E3%82%8C%E3%81%9F%E3%80%82), particularly excelling against Omicron variants[kagaya-clinic.jp](https://www.kagaya-clinic.jp/replicon-vaccine/#:~:text=%E7%89%B9%E5%BE%B4%E3%81%A8%E4%BB%8A%E5%BE%8C%E3%81%AE%E5%8F%AF%E8%83%BD%E6%80%A7). This indicates that scientifically, Japan is not sacrificing quality by using a domestic vaccine – on the contrary, it may be gaining an edge in longer-lasting immunity. Moreover, being the first in the world to approve and use a replicon COVID vaccine is a significant innovation milestone[jmedj.co.jp](https://www.jmedj.co.jp/journal/paper/detail.php?id=23229#:~:text=Meiji%20Seika%E3%83%95%E3%82%A1%E3%83%AB%E3%83%9E%E3%81%AF11%E6%9C%8828%E6%97%A5%E3%80%81%E6%96%B0%E5%9E%8B%E3%82%B3%E3%83%AD%E3%83%8A%E3%82%A6%E3%82%A4%E3%83%AB%E3%82%B9%E6%84%9F%E6%9F%93%E7%97%87%E3%81%AB%E5%AF%BE%E3%81%99%E3%82%8B%E6%AC%A1%E4%B8%96%E4%BB%A3mRNA%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%80%8C%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E7%AD%8B%E6%B3%A8%E7%94%A8%E3%80%8D%E3%81%AB%E3%81%A4%E3%81%84%E3%81%A6%E8%A8%98%E8%80%85%E8%AA%AC%E6%98%8E%E4%BC%9A%E3%82%92%E9%96%8B%E5%82%AC%E3%81%97%E3%81%9F%E3%80%82%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%20%E3%81%AF%E3%80%81%E7%B1%B3%E3%83%90%E3%82%A4%E3%82%AA%E4%BC%81%E6%A5%AD%E3%82%A2%E3%83%BC%E3%82%AF%E3%83%88%E3%82%A5%E3%83%AB%E3%82%B9%E3%83%BB%E3%82%BB%E3%83%A9%E3%83%94%E3%83%A5%E3%83%BC%E3%83%86%E3%82%A3%E3%82%AF%E3%82%B9%E3%81%8C%E9%96%8B%E7%99%BA%E3%81%97%E3%81%9F%E3%80%81%E6%8A%95%E4%B8%8E%E5%BE%8C%E3%81%AB%E4%BD%93%E5%86%85%E3%81%A7mRNA%E3%82%92%E8%87%AA%E5%B7%B1%E8%A4%87%E8%A3%BD%E3%81%99%E3%82%8B%E3%80%8C%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%80%8D%E3%80%82Meiji%20Seika%E3%83%95%E3%82%A1%E3%83%AB%E3%83%9E%E3%81%8C%E5%9B%BD%E5%86%85%E3%81%AE%E4%BE%9B%E7%B5%A6%E3%83%BB%E8%B2%A9%E5%A3%B2%E6%A8%A9%E3%82%92%E5%8F%96%E5%BE%97%E3%81%97%E8%87%A8%E5%BA%8A%E8%A9%A6%E9%A8%93%E3%82%92%E9%80%B2%E3%82%81%E3%80%81%E5%90%8C%E6%97%A5%E3%80%81%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%A8%E3%81%97%E3%81%A6%E4%B8%96%E7%95%8C%E5%88%9D%E3%81%A8%E3%81%AA%E3%82%8B%E8%A3%BD%E9%80%A0%E8%B2%A9%E5%A3%B2%E6%89%BF%E8%AA%8D%E3%82%92%E5%8E%9A%E5%8A%B4%E7%9C%81%E3%82%88%E3%82%8A%E5%8F%96%E5%BE%97%E3%81%97%E3%81%9F%E3%80%82). It shows Japanese science contributing to cutting-edge vaccine development. In the long run, this platform can be quickly updated for new variants (similar to standard mRNA vaccines) and even adapted to other diseases, giving Japan a versatile scientific tool. It’s also worth mentioning that replicon vaccines use a smaller dose, which could reduce side effects and increase manufacturing efficiency. **In short, the scientific foundation for using replicon technology is robust, and it may improve vaccine performance for the population.**
    
- **Supply Security and Geopolitical Stability:** A major rationale for focusing on a domestic vaccine is to **ensure a stable supply independent of international uncertainties**. Relying on multi-national pharmaceutical companies can pose risks – for example, during the initial COVID vaccine rollout, countries like Japan had to wait as the U.S. and Europe, where Pfizer/Moderna are based, prioritized their own populations. Political decisions (export restrictions, diplomatic disputes, or corporate priorities) could delay or limit vaccine shipments to Japan. By having a home-grown vaccine produced on Japanese soil, these risks are minimized. If there were future pandemics or variants, Japan could ramp up its own production without being at the mercy of foreign governments or companies. This is especially pertinent given global political instabilities; even hypothetical scenarios like trade wars or geopolitical tension might affect medical supply chains. A domestic vaccine **insulates Japan from such external shocks**. Meiji Seika Pharma has plans to scale up production capacity significantly – building a new manufacturing facility and aiming for an output of ~100 million doses annually by 2027[jmedj.co.jp](https://www.jmedj.co.jp/journal/paper/detail.php?id=23229#:~:text=%E5%90%8C%E7%A4%BE%E3%81%AF%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E3%81%8C%E8%B5%B7%E6%BA%90%E6%A0%AA%E5%AF%BE%E5%BF%9C%E3%81%AE1%E4%BE%A1%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AE%E3%81%9F%E3%82%81%E4%BB%8A%E5%86%AC%E3%81%AF%E8%B2%A9%E5%A3%B2%E3%81%9B%E3%81%9A%E3%80%81%E6%9D%A5%E5%B9%B4%E3%81%AE%E7%A7%8B%E5%86%AC%E6%8E%A5%E7%A8%AE%E3%81%AB%E5%90%91%E3%81%91%E3%81%9F%E4%BE%9B%E7%B5%A6%E9%96%8B%E5%A7%8B%E3%82%92%E6%83%B3%E5%AE%9A%E3%81%97%E3%81%A6%E8%B5%B7%E6%BA%90%E6%A0%AA%E3%81%A8%E3%82%AA%E3%83%9F%E3%82%AF%E3%83%AD%E3%83%B3%E6%A0%AA%E3%81%AB%E3%82%88%E3%82%8B2%E4%BE%A1%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AE%E9%96%8B%E7%99%BA%E3%82%92%E9%80%B2%E3%82%81%E3%82%8B%E3%80%82%E5%8E%9F%20%E8%96%AC%E3%81%AF%E3%82%A2%E3%83%AB%E3%82%AB%E3%83%AA%E3%82%B9%E7%A4%BE%EF%BC%88%E7%A6%8F%E5%B3%B6%E7%9C%8C%E5%8D%97%E7%9B%B8%E9%A6%AC%E5%B8%82%EF%BC%89%E3%81%8B%E3%82%89%E8%AA%BF%E9%81%94%E3%80%81%E4%BB%8A%E5%BE%8C%E5%9B%BD%E5%86%85%E3%81%AB%E6%96%B0%E8%A3%BD%E9%80%A0%E6%A3%9F%E3%82%92%E5%BB%BA%E8%A8%AD%E3%81%97%E3%80%812027%E5%B9%B4%E3%81%AB%E3%81%AF%E7%B4%841%E5%84%84%E5%9B%9E%E6%8E%A5%E7%A8%AE%E5%88%86%E3%81%AE%E7%94%9F%E7%94%A3%E4%BD%93%E5%88%B6%E3%82%92%E6%A7%8B%E7%AF%89%E3%81%99%E3%82%8B%E6%96%B9%E9%87%9D%E3%80%8228%E6%97%A5%E3%81%AE%E8%AA%AC%E6%98%8E%E4%BC%9A%E3%81%A7%E5%90%8C%E7%A4%BE%E3%81%AE%E5%B0%8F%E6%9E%97%E5%A4%A7%E5%90%89%E9%83%8E%E7%A4%BE%20%E9%95%B7%EF%BC%88%E5%86%99%E7%9C%9F%EF%BC%89%E3%81%AF%E3%80%8C%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E6%95%97%E6%88%A6%E3%81%A8%E6%8F%B6%E6%8F%84%E3%81%95%E3%82%8C%E3%81%9F%E6%88%91%E3%81%8C%E5%9B%BD%E3%81%A7%E3%80%81%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E5%AE%9F%E7%94%A8%E5%8C%96%E3%81%AB%E3%81%8A%E3%81%84%E3%81%A6%E4%B8%96%E7%95%8C%E3%81%AB%E5%85%88%E9%A7%86%E3%81%91%E3%82%8B%E3%81%93%E3%81%A8%E3%81%8C%E3%81%A7%E3%81%8D%E3%81%9F%E3%80%82%E4%BD%95%E3%81%A8%E3%81%8B%E3%82%B4%E3%83%BC%E3%83%AB%E3%81%BE%E3%81%A7%E6%8C%81%E3%81%A3%E3%81%A6%E3%81%84%E3%81%8D%E3%81%9F%E3%81%84%E3%80%8D%E3%81%A8%E5%BC%B7%E8%AA%BF%E3%81%97%E3%81%9F%E3%80%82). This would be enough to cover the Japanese population with room to spare. Achieving vaccine self-sufficiency is a strategic asset for national health security.
    
- **Industrial and Economic Benefits:** Emphasizing a domestic vaccine supports Japan’s biotechnology and pharmaceutical industry. After facing criticism for the “vaccine defeat” (ワクチン敗戦) in the early pandemic – a term used when Japan lagged in vaccine development and had to import all doses – the country has been keen to catch up and even lead in vaccine tech[jmedj.co.jp](https://www.jmedj.co.jp/journal/paper/detail.php?id=23229#:~:text=%E5%90%8C%E7%A4%BE%E3%81%AF%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E3%81%8C%E8%B5%B7%E6%BA%90%E6%A0%AA%E5%AF%BE%E5%BF%9C%E3%81%AE1%E4%BE%A1%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AE%E3%81%9F%E3%82%81%E4%BB%8A%E5%86%AC%E3%81%AF%E8%B2%A9%E5%A3%B2%E3%81%9B%E3%81%9A%E3%80%81%E6%9D%A5%E5%B9%B4%E3%81%AE%E7%A7%8B%E5%86%AC%E6%8E%A5%E7%A8%AE%E3%81%AB%E5%90%91%E3%81%91%E3%81%9F%E4%BE%9B%E7%B5%A6%E9%96%8B%E5%A7%8B%E3%82%92%E6%83%B3%E5%AE%9A%E3%81%97%E3%81%A6%E8%B5%B7%E6%BA%90%E6%A0%AA%E3%81%A8%E3%82%AA%E3%83%9F%E3%82%AF%E3%83%AD%E3%83%B3%E6%A0%AA%E3%81%AB%E3%82%88%E3%82%8B2%E4%BE%A1%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AE%E9%96%8B%E7%99%BA%E3%82%92%E9%80%B2%E3%82%81%E3%82%8B%E3%80%82%E5%8E%9F%20%E8%96%AC%E3%81%AF%E3%82%A2%E3%83%AB%E3%82%AB%E3%83%AA%E3%82%B9%E7%A4%BE%EF%BC%88%E7%A6%8F%E5%B3%B6%E7%9C%8C%E5%8D%97%E7%9B%B8%E9%A6%AC%E5%B8%82%EF%BC%89%E3%81%8B%E3%82%89%E8%AA%BF%E9%81%94%E3%80%81%E4%BB%8A%E5%BE%8C%E5%9B%BD%E5%86%85%E3%81%AB%E6%96%B0%E8%A3%BD%E9%80%A0%E6%A3%9F%E3%82%92%E5%BB%BA%E8%A8%AD%E3%81%97%E3%80%812027%E5%B9%B4%E3%81%AB%E3%81%AF%E7%B4%841%E5%84%84%E5%9B%9E%E6%8E%A5%E7%A8%AE%E5%88%86%E3%81%AE%E7%94%9F%E7%94%A3%E4%BD%93%E5%88%B6%E3%82%92%E6%A7%8B%E7%AF%89%E3%81%99%E3%82%8B%E6%96%B9%E9%87%9D%E3%80%8228%E6%97%A5%E3%81%AE%E8%AA%AC%E6%98%8E%E4%BC%9A%E3%81%A7%E5%90%8C%E7%A4%BE%E3%81%AE%E5%B0%8F%E6%9E%97%E5%A4%A7%E5%90%89%E9%83%8E%E7%A4%BE%20%E9%95%B7%EF%BC%88%E5%86%99%E7%9C%9F%EF%BC%89%E3%81%AF%E3%80%8C%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E6%95%97%E6%88%A6%E3%81%A8%E6%8F%B6%E6%8F%84%E3%81%95%E3%82%8C%E3%81%9F%E6%88%91%E3%81%8C%E5%9B%BD%E3%81%A7%E3%80%81%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E5%AE%9F%E7%94%A8%E5%8C%96%E3%81%AB%E3%81%8A%E3%81%84%E3%81%A6%E4%B8%96%E7%95%8C%E3%81%AB%E5%85%88%E9%A7%86%E3%81%91%E3%82%8B%E3%81%93%E3%81%A8%E3%81%8C%E3%81%A7%E3%81%8D%E3%81%9F%E3%80%82%E4%BD%95%E3%81%A8%E3%81%8B%E3%82%B4%E3%83%BC%E3%83%AB%E3%81%BE%E3%81%A7%E6%8C%81%E3%81%A3%E3%81%A6%E3%81%84%E3%81%8D%E3%81%9F%E3%81%84%E3%80%8D%E3%81%A8%E5%BC%B7%E8%AA%BF%E3%81%97%E3%81%9F%E3%80%82). The success of Costaive is a point of national pride and has been highlighted by officials: _“In our country that was ridiculed as having lost the vaccine race, we have now been able to take the lead globally in practical use of a replicon vaccine”_, said Meiji’s CEO upon its approval[jmedj.co.jp](https://www.jmedj.co.jp/journal/paper/detail.php?id=23229#:~:text=%E5%90%8C%E7%A4%BE%E3%81%AF%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E3%81%8C%E8%B5%B7%E6%BA%90%E6%A0%AA%E5%AF%BE%E5%BF%9C%E3%81%AE1%E4%BE%A1%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AE%E3%81%9F%E3%82%81%E4%BB%8A%E5%86%AC%E3%81%AF%E8%B2%A9%E5%A3%B2%E3%81%9B%E3%81%9A%E3%80%81%E6%9D%A5%E5%B9%B4%E3%81%AE%E7%A7%8B%E5%86%AC%E6%8E%A5%E7%A8%AE%E3%81%AB%E5%90%91%E3%81%91%E3%81%9F%E4%BE%9B%E7%B5%A6%E9%96%8B%E5%A7%8B%E3%82%92%E6%83%B3%E5%AE%9A%E3%81%97%E3%81%A6%E8%B5%B7%E6%BA%90%E6%A0%AA%E3%81%A8%E3%82%AA%E3%83%9F%E3%82%AF%E3%83%AD%E3%83%B3%E6%A0%AA%E3%81%AB%E3%82%88%E3%82%8B2%E4%BE%A1%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AE%E9%96%8B%E7%99%BA%E3%82%92%E9%80%B2%E3%82%81%E3%82%8B%E3%80%82%E5%8E%9F%20%E8%96%AC%E3%81%AF%E3%82%A2%E3%83%AB%E3%82%AB%E3%83%AA%E3%82%B9%E7%A4%BE%EF%BC%88%E7%A6%8F%E5%B3%B6%E7%9C%8C%E5%8D%97%E7%9B%B8%E9%A6%AC%E5%B8%82%EF%BC%89%E3%81%8B%E3%82%89%E8%AA%BF%E9%81%94%E3%80%81%E4%BB%8A%E5%BE%8C%E5%9B%BD%E5%86%85%E3%81%AB%E6%96%B0%E8%A3%BD%E9%80%A0%E6%A3%9F%E3%82%92%E5%BB%BA%E8%A8%AD%E3%81%97%E3%80%812027%E5%B9%B4%E3%81%AB%E3%81%AF%E7%B4%841%E5%84%84%E5%9B%9E%E6%8E%A5%E7%A8%AE%E5%88%86%E3%81%AE%E7%94%9F%E7%94%A3%E4%BD%93%E5%88%B6%E3%82%92%E6%A7%8B%E7%AF%89%E3%81%99%E3%82%8B%E6%96%B9%E9%87%9D%E3%80%8228%E6%97%A5%E3%81%AE%E8%AA%AC%E6%98%8E%E4%BC%9A%E3%81%A7%E5%90%8C%E7%A4%BE%E3%81%AE%E5%B0%8F%E6%9E%97%E5%A4%A7%E5%90%89%E9%83%8E%E7%A4%BE%20%E9%95%B7%EF%BC%88%E5%86%99%E7%9C%9F%EF%BC%89%E3%81%AF%E3%80%8C%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E6%95%97%E6%88%A6%E3%81%A8%E6%8F%B6%E6%8F%84%E3%81%95%E3%82%8C%E3%81%9F%E6%88%91%E3%81%8C%E5%9B%BD%E3%81%A7%E3%80%81%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E5%AE%9F%E7%94%A8%E5%8C%96%E3%81%AB%E3%81%8A%E3%81%84%E3%81%A6%E4%B8%96%E7%95%8C%E3%81%AB%E5%85%88%E9%A7%86%E3%81%91%E3%82%8B%E3%81%93%E3%81%A8%E3%81%8C%E3%81%A7%E3%81%8D%E3%81%9F%E3%80%82%E4%BD%95%E3%81%A8%E3%81%8B%E3%82%B4%E3%83%BC%E3%83%AB%E3%81%BE%E3%81%A7%E6%8C%81%E3%81%A3%E3%81%A6%E3%81%84%E3%81%8D%E3%81%9F%E3%81%84%E3%80%8D%E3%81%A8%E5%BC%B7%E8%AA%BF%E3%81%97%E3%81%9F%E3%80%82). Building up this industry means high-tech jobs, research funding, and expertise remain in-country. In the long term, Japan could even export its vaccine or license the technology, bolstering its standing in global health contributions. Industrially, diversifying vaccine production (with platforms like replicon and protein-based vaccines by domestic companies) ensures competition and possibly lower costs. It also avoids over-reliance on a few foreign firms which might dictate prices or terms.
    
- **Reduced Dependency & Political Leverage:** Depending on foreign pharmaceutical companies (Pfizer, Moderna, etc.) also means that Japan is indirectly subject to the political climate of those companies’ home countries. For instance, if there were political pressure in the US or Europe to raise vaccine prices, limit supply, or even leverage vaccine deals in diplomatic negotiations, it could put Japan in a vulnerable position. By establishing a **domestic vaccine as the mainstay**, Japan gains greater control over its vaccination program. The government can make policy decisions (such as the annual free booster program) without worrying about whether overseas shipments will arrive on time or whether contracts will be honored under all circumstances. The COVID pandemic showed how vaccine access could become a geopolitical tool; a domestic strategy avoids being entangled in that. Additionally, a **stable domestic supply** can be more reliably integrated into Japan’s healthcare system and planning. There’s less uncertainty each year about procurement, which helps in logistics (as seen with the smooth start of the 2024 routine program where multiple domestic options, including Costaive, were available).
    

In evaluating the strategy, we should also consider potential **challenges or caveats**. One is that replicon vaccines are new – while trials have shown no major safety issues (the side effect profile of Costaive was similar to Pfizer’s, with common reactions like injection-site pain, fatigue, headache, etc., at comparable rates[kagaya-clinic.jp](https://www.kagaya-clinic.jp/replicon-vaccine/#:~:text=%E8%87%A8%E5%BA%8A%E8%A9%A6%E9%A8%93%E3%81%AB%E3%81%8A%E3%81%84%E3%81%A6%E3%80%81%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%EF%BC%88%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%EF%BC%89%E3%81%AF%E6%9C%89%E5%8A%B9%E6%80%A7%E3%81%A8%E5%85%8D%E7%96%AB%E5%8E%9F%E6%80%A7%E3%81%8C%E7%A2%BA%E8%AA%8D%E3%81%95%E3%82%8C%E3%81%A6%E3%81%84%E3%81%BE%E3%81%99%E3%80%82%20%E4%B8%BB%E3%81%AA%E5%89%AF%E5%8F%8D%E5%BF%9C%E3%81%AF%E4%BB%A5%E4%B8%8B%E3%81%AE%E9%80%9A%E3%82%8A%E3%81%A7%E3%81%99%EF%BC%9A)), we lack long-term safety data simply because the technology is recent[kagaya-clinic.jp](https://www.kagaya-clinic.jp/replicon-vaccine/#:~:text=Image%EF%BC%83%E3%83%88%E3%82%B8%E3%83%8A%E3%83%A1%E3%83%A9%E3%83%B3%3D%E3%83%95%E3%82%A1%E3%82%A4%E3%82%B6%E3%83%BC%E8%A3%BD%E3%82%B3%E3%83%AD%E3%83%8A%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3). Ongoing pharmacovigilance is important to maintain public trust. Japan’s heightened scrutiny of vaccine safety means any adverse events will be closely watched. Another consideration is flexibility: even with a domestic focus, Japan should remain open to using foreign vaccines if needed (for example, if a radically new variant emerged and a foreign company’s vaccine addressed it first, or if additional doses were needed quickly). In other words, the **best strategy is not isolationist but rather “domestic-first, with diversity as backup.”** Fortunately, Japan has approved multiple vaccines (Pfizer, Moderna, Novavax, Daiichi Sankyo’s protein vaccine, etc., in addition to Meiji’s)[mhlw.go.jp](https://www.mhlw.go.jp/content/10900000/001305412.pdf#:~:text=Meiji%20Seika%E3%83%95%E3%82%A1%E3%83%AB%E3%83%9E%20%E6%A0%AA%E5%BC%8F%E4%BC%9A%E7%A4%BE%20%E8%B2%A9%E5%A3%B2%E5%90%8D%20%E3%82%B3%E3%83%9F%E3%83%8A%E3%83%86%E3%82%A3%C2%AE,%EF%BD%8DRNA%EF%BC%88%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%EF%BC%89%20%E8%96%AC%E4%BA%8B%E6%89%BF%E8%AA%8D%E3%81%AE%20%E7%8A%B6%E6%B3%81%20%E4%BB%A4%E5%92%8C%EF%BC%96%E5%B9%B4%EF%BC%98%E6%9C%88%EF%BC%98%E6%97%A5%20%E4%B8%80%E5%A4%89%E6%89%BF%E8%AA%8D%EF%BC%8A)[mhlw.go.jp](https://www.mhlw.go.jp/content/10900000/001305412.pdf#:~:text=%E8%B2%A9%E5%A3%B2%E5%90%8D%20%E3%82%B3%E3%83%9F%E3%83%8A%E3%83%86%E3%82%A3%C2%AE%20%E3%82%B9%E3%83%91%E3%82%A4%E3%82%AF%E3%83%90%E3%83%83%E3%82%AF%E3%82%B9%C2%AE%20%E3%83%80%E3%82%A4%E3%83%81%E3%83%AD%E3%83%8A%C2%AE%20%E3%83%8C%E3%83%90%E3%82%AD%E3%82%BD%E3%83%93%E3%83%83%E3%83%89%C2%AE,%E7%8A%B6%E6%B3%81%20%E4%BB%A4%E5%92%8C%EF%BC%96%E5%B9%B4%EF%BC%98%E6%9C%88%EF%BC%98%E6%97%A5%20%E4%B8%80%E5%A4%89%E6%89%BF%E8%AA%8D%EF%BC%8A%20%E4%BB%A4%E5%92%8C%EF%BC%96%E5%B9%B4%EF%BC%98%E6%9C%8823%E6%97%A5%20%E4%B8%80%E5%A4%89%E6%89%BF%E8%AA%8D%EF%BC%8A). This diversified portfolio is wise. Costaive may be the backbone, but others can be called upon as needed – for example, people who cannot take mRNA-type vaccines might use Novavax.

 

Comparing to the scenario of continued reliance on Pfizer/Moderna: those mRNA vaccines are highly effective as well, but there have been instances of supply fluctuations and they are expensive (often requiring government negotiation each year for purchase). There’s also the aspect of national pride and public trust: a domestically made vaccine could improve confidence among a segment of the population that is skeptical of foreign vaccines. (However, it must be noted that _any_ vaccine can face skepticism – in fact, Costaive itself was subject to some misinformation online, such as unfounded rumors about “shedding,” which Meiji had to actively dispel[fsight.jp](https://www.fsight.jp/articles/-/50989#:~:text=%E6%98%8E%E6%B2%BBHD%E4%BA%8B%E6%A5%AD%E5%AD%90%E4%BC%9A%E7%A4%BE%E3%81%AEMeiji%20Seika%20%E3%83%95%E3%82%A1%E3%83%AB%E3%83%9E%E3%81%8C%E9%96%8B%E7%99%BA%E3%81%97%E3%81%9F%E3%82%B3%E3%83%AD%E3%83%8A%E3%82%A6%E3%82%A4%E3%83%AB%E3%82%B9%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%80%8C%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E3%80%8D%E3%81%8C%E4%B8%96%E9%96%93%E3%81%AE%E9%96%A2%E5%BF%83%E3%82%92%E9%9B%86%E3%82%81%E3%81%A6%E3%81%84%E3%82%8B%E3%80%82SNS%E3%81%AB%E3%81%AF%E3%80%81%E3%80%8C%E3%82%B7%E3%82%A7%E3%83%87%E3%82%A3%E3%83%B3%E3%82%B0%E3%81%AB%E3%82%88%E3%82%8A%E3%80%81%E3%83%AF%20%E3%82%AF%E3%83%81%E3%83%B3%E6%8E%A5%E7%A8%AE%E8%80%85%E3%81%8B%E3%82%89%E5%91%A8%E5%9B%B2%E3%81%AB%E6%84%9F%E6%9F%93%E3%81%95%E3%81%9B%E3%82%8B%E3%80%8D%E3%81%AA%E3%81%A9%E3%81%AE%E3%83%87%E3%83%9E%E3%81%8C%E6%B0%BE%E6%BF%AB%E3%81%97%E3%81%A6%E3%81%84%E3%82%8B%E3%80%82%E3%80%8C%E3%82%B7%E3%82%A7%E3%83%87%E3%82%A3%E3%83%B3%E3%82%B0%E3%80%8D%E3%81%A8%E3%81%AF%E3%80%81%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E3%81%8C%E4%BD%93%E5%86%85%E3%81%A7%E5%A2%97%E6%AE%96%E3%81%97%E3%81%9F%E5%BE%8C%E3%80%81%E3%81%9D%E3%81%AE%E4%B8%80%E9%83%A8%E3%81%8C%E5%AF%BE%E5%A4%96%E3%81%AB%E6%94%BE%E5%87%BA%E3%81%95%E3%82%8C%E3%80%81%E5%91%A8%E5%9B%B2%E3%81%AB%E3%81%84%E3%82%8B%E4%BA%BA%E3%81%AB%E6%82%AA%E5%BD%B1%E9%9F%BF%E3%82%92%20%E4%B8%8E%E3%81%88%E3%82%8B%E3%81%93%E3%81%A8%E3%81%A0%E3%81%8C%E3%80%81%E3%81%93%E3%81%AE%E3%81%93%E3%81%A8%E3%82%92%E6%94%AF%E6%8C%81%E3%81%99%E3%82%8B%E7%A7%91%E5%AD%A6%E7%9A%84%E3%81%AA%E6%A0%B9%E6%8B%A0%E3%81%AF%E3%81%AA%E3%81%84%E3%80%82). Building trust will require transparency and education irrespective of origin.)

 

**In conclusion**, emphasizing a domestic replicon vaccine as Japan’s main COVID-19 vaccine is **both scientifically and strategically justified**. It provides an effective, cutting-edge solution to protect public health, while also strengthening Japan’s biosecurity and pharmaceutical independence. The strategy mitigates political risks associated with foreign supply chains and ensures that Japan can manage its vaccination needs even amid global uncertainties. It also turns a lesson from the pandemic (the need for domestic R&D capacity) into a forward-looking policy. As long as authorities continue to rigorously monitor safety and remain adaptable, the focus on a domestic replicon vaccine like Costaive stands out as a prudent approach with significant public health and industrial benefits for Japan[jmedj.co.jp](https://www.jmedj.co.jp/journal/paper/detail.php?id=23229#:~:text=%E5%90%8C%E7%A4%BE%E3%81%AF%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E3%81%8C%E8%B5%B7%E6%BA%90%E6%A0%AA%E5%AF%BE%E5%BF%9C%E3%81%AE1%E4%BE%A1%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AE%E3%81%9F%E3%82%81%E4%BB%8A%E5%86%AC%E3%81%AF%E8%B2%A9%E5%A3%B2%E3%81%9B%E3%81%9A%E3%80%81%E6%9D%A5%E5%B9%B4%E3%81%AE%E7%A7%8B%E5%86%AC%E6%8E%A5%E7%A8%AE%E3%81%AB%E5%90%91%E3%81%91%E3%81%9F%E4%BE%9B%E7%B5%A6%E9%96%8B%E5%A7%8B%E3%82%92%E6%83%B3%E5%AE%9A%E3%81%97%E3%81%A6%E8%B5%B7%E6%BA%90%E6%A0%AA%E3%81%A8%E3%82%AA%E3%83%9F%E3%82%AF%E3%83%AD%E3%83%B3%E6%A0%AA%E3%81%AB%E3%82%88%E3%82%8B2%E4%BE%A1%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AE%E9%96%8B%E7%99%BA%E3%82%92%E9%80%B2%E3%82%81%E3%82%8B%E3%80%82%E5%8E%9F%20%E8%96%AC%E3%81%AF%E3%82%A2%E3%83%AB%E3%82%AB%E3%83%AA%E3%82%B9%E7%A4%BE%EF%BC%88%E7%A6%8F%E5%B3%B6%E7%9C%8C%E5%8D%97%E7%9B%B8%E9%A6%AC%E5%B8%82%EF%BC%89%E3%81%8B%E3%82%89%E8%AA%BF%E9%81%94%E3%80%81%E4%BB%8A%E5%BE%8C%E5%9B%BD%E5%86%85%E3%81%AB%E6%96%B0%E8%A3%BD%E9%80%A0%E6%A3%9F%E3%82%92%E5%BB%BA%E8%A8%AD%E3%81%97%E3%80%812027%E5%B9%B4%E3%81%AB%E3%81%AF%E7%B4%841%E5%84%84%E5%9B%9E%E6%8E%A5%E7%A8%AE%E5%88%86%E3%81%AE%E7%94%9F%E7%94%A3%E4%BD%93%E5%88%B6%E3%82%92%E6%A7%8B%E7%AF%89%E3%81%99%E3%82%8B%E6%96%B9%E9%87%9D%E3%80%8228%E6%97%A5%E3%81%AE%E8%AA%AC%E6%98%8E%E4%BC%9A%E3%81%A7%E5%90%8C%E7%A4%BE%E3%81%AE%E5%B0%8F%E6%9E%97%E5%A4%A7%E5%90%89%E9%83%8E%E7%A4%BE%20%E9%95%B7%EF%BC%88%E5%86%99%E7%9C%9F%EF%BC%89%E3%81%AF%E3%80%8C%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E6%95%97%E6%88%A6%E3%81%A8%E6%8F%B6%E6%8F%84%E3%81%95%E3%82%8C%E3%81%9F%E6%88%91%E3%81%8C%E5%9B%BD%E3%81%A7%E3%80%81%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E5%AE%9F%E7%94%A8%E5%8C%96%E3%81%AB%E3%81%8A%E3%81%84%E3%81%A6%E4%B8%96%E7%95%8C%E3%81%AB%E5%85%88%E9%A7%86%E3%81%91%E3%82%8B%E3%81%93%E3%81%A8%E3%81%8C%E3%81%A7%E3%81%8D%E3%81%9F%E3%80%82%E4%BD%95%E3%81%A8%E3%81%8B%E3%82%B4%E3%83%BC%E3%83%AB%E3%81%BE%E3%81%A7%E6%8C%81%E3%81%A3%E3%81%A6%E3%81%84%E3%81%8D%E3%81%9F%E3%81%84%E3%80%8D%E3%81%A8%E5%BC%B7%E8%AA%BF%E3%81%97%E3%81%9F%E3%80%82)[jmedj.co.jp](https://www.jmedj.co.jp/journal/paper/detail.php?id=23229#:~:text=%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AF%E6%97%A2%E5%AD%98%E3%81%AEmRNA%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AB%E6%AF%94%E3%81%B9%E5%B0%91%E9%87%8F%E6%8A%95%E4%B8%8E%E3%81%A7%E6%B8%88%E3%81%BF%E3%80%81%E3%82%88%E3%82%8A%E5%8A%B9%E6%9E%9C%E3%81%8C%E6%8C%81%E7%B6%9A%E3%81%99%E3%82%8B%E3%81%A8%E3%81%95%E3%82%8C%E3%82%8B%E3%80%82%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E3%81%AF%E8%BF%BD%E5%8A%A0%E5%85%8D%E7%96%AB%E3%81%AE%E5%9B%BD%E5%86%85%E7%AC%AC3%E7%9B%B8%E8%A9%A6%E9%A8%93%E3%81%A7%E3%80%81%E3%83%95%E3%82%A1%E3%82%A4%E3%82%B6%E3%83%BC%E3%81%AE%E3%82%B3%E3%83%9F%E3%83%8A%E3%83%86%E3%82%A3%E3%81%AB%E6%AF%94%E3%81%B9%20%E6%8A%97%E4%BD%93%E4%BE%A1%E3%81%8C%E9%AB%98%E3%81%8F%E6%8C%81%E7%B6%9A%E6%80%A7%E3%81%AB%E5%84%AA%E3%82%8C%E3%81%A6%E3%81%84%E3%82%8B%E3%81%93%E3%81%A8%E3%81%8C%E7%A2%BA%E8%AA%8D%E3%81%95%E3%82%8C%E3%81%9F%E3%80%82).

 

**Sources:**

1. WHO TAG-VE announcement on NB.1.8.1 variant under monitoring (May 2025)[cidrap.umn.edu](https://www.cidrap.umn.edu/covid-19/who-adds-nb181-sars-cov-2-variant-under-monitoring#:~:text=The%20World%20Health%20Organization%20,1%20sublineage)[cidrap.umn.edu](https://www.cidrap.umn.edu/covid-19/who-adds-nb181-sars-cov-2-variant-under-monitoring#:~:text=The%20experts%20said%20NB,those%20from%20other%20circulating%20variants)[cidrap.umn.edu](https://www.cidrap.umn.edu/covid-19/who-adds-nb181-sars-cov-2-variant-under-monitoring#:~:text=On%20May%2015%2C%20the%20WHO%27s,1%20component).
    
2. CBS News – _“New COVID variant NB.1.8.1 behind surge in China, now detected in U.S.”_ (May 23, 2025)[cbsnews.com](https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/#:~:text=Experts%20have%20been%20closely%20watching,19)[cbsnews.com](https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/#:~:text=While%20authorities%20in%20Hong%20Kong,places%20as%20cases%20have%20climbed)[cbsnews.com](https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/#:~:text=epidemic%20wave)[cbsnews.com](https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/#:~:text=Vaccines%20from%20last%20season%20targeted,1%2C%20too).
    
3. WHO Initial Risk Evaluation for NB.1.8.1 (May 2025)[cdn.who.int](https://cdn.who.int/media/docs/default-source/documents/epp/tracking-sars-cov-2/23052025_nb.1.8.1_ire.pdf#:~:text=globally%2C%20while%20LP,than%20other%20variants%20in%20circulation)[cdn.who.int](https://cdn.who.int/media/docs/default-source/documents/epp/tracking-sars-cov-2/23052025_nb.1.8.1_ire.pdf#:~:text=,5%2C6).
    
4. Ministry of Health, Labour and Welfare (Japan) – Materials on routine COVID-19 vaccination (Sept 2024)[mhlw.go.jp](https://www.mhlw.go.jp/content/10900000/001305412.pdf#:~:text=Meiji%20Seika%E3%83%95%E3%82%A1%E3%83%AB%E3%83%9E%20%E6%A0%AA%E5%BC%8F%E4%BC%9A%E7%A4%BE%20%E8%B2%A9%E5%A3%B2%E5%90%8D%20%E3%82%B3%E3%83%9F%E3%83%8A%E3%83%86%E3%82%A3%C2%AE,%EF%BD%8DRNA%EF%BC%88%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%EF%BC%89%20%E8%96%AC%E4%BA%8B%E6%89%BF%E8%AA%8D%E3%81%AE%20%E7%8A%B6%E6%B3%81%20%E4%BB%A4%E5%92%8C%EF%BC%96%E5%B9%B4%EF%BC%98%E6%9C%88%EF%BC%98%E6%97%A5%20%E4%B8%80%E5%A4%89%E6%89%BF%E8%AA%8D%EF%BC%8A)[mhlw.go.jp](https://www.mhlw.go.jp/content/10900000/001305412.pdf#:~:text=%E2%97%8B%20%E3%83%95%E3%82%A1%E3%82%A4%E3%82%B6%E3%83%BC%E7%A4%BE%E3%80%81%E3%83%A2%E3%83%87%E3%83%AB%E3%83%8A%E7%A4%BE%E3%80%81%E7%AC%AC%E4%B8%80%E4%B8%89%E5%85%B1%E7%A4%BE%E3%80%81%E6%AD%A6%E7%94%B0%E8%96%AC%E5%93%81%E5%B7%A5%E6%A5%AD%E7%A4%BE%E3%81%AE%EF%BC%94%E7%A4%BE%E3%81%AB%E3%81%A4%E3%81%84%E3%81%A6%E3%81%AF%E3%80%81%E4%BB%A4%E5%92%8C%EF%BC%95%E5%B9%B4%E5%BA%A6%E3%81%BE%E3%81%A7%E3%81%AE%E8%87%A8%E6%99%82%E6%8E%A5%E7%A8%AE%E3%81%A7%E3%81%99%E3%81%A7%E3%81%AB%E4%BD%BF%E7%94%A8%E3%81%97%E3%81%9F%E3%83%AF%E3%82%AF%E3%83%81%20%E3%83%B3%E3%81%AB%E3%81%8A%E3%81%91%E3%82%8B%E3%80%81JN,1%E7%B3%BB%E7%B5%B1%E5%AF%BE%E5%BF%9C%E3%81%AB%E4%BF%82%E3%82%8B%E6%89%BF%E8%AA%8D%E4%BA%8B%E9%A0%85%E4%B8%80%E9%83%A8%E5%A4%89%E6%9B%B4%E3%82%92%E5%8F%96%E5%BE%97%E3%81%97%E3%81%9F%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%8C%E4%BE%9B%E7%B5%A6%E3%81%95%E3%82%8C%E3%82%8B%E8%A6%8B%E9%80%9A%E3%81%97%E3%81%A7%E3%81%82%E3%82%8B%E3%80%82%2017).
    
5. Kagaya Clinic (Chiba) – Explanation of replicon vaccine (Costaive) and its use in routine vaccination[kagaya-clinic.jp](https://www.kagaya-clinic.jp/replicon-vaccine/#:~:text=%E7%89%B9%E5%BE%B4%E3%81%A8%E4%BB%8A%E5%BE%8C%E3%81%AE%E5%8F%AF%E8%83%BD%E6%80%A7)[kagaya-clinic.jp](https://www.kagaya-clinic.jp/replicon-vaccine/#:~:text=%E5%AF%BE%E3%81%97%E3%81%A6%E3%81%AF%E5%84%AA%E3%82%8C%E3%82%8B%E3%81%93%E3%81%A8%E3%81%8C%E7%A2%BA%E8%AA%8D%E3%81%95%E3%82%8C%E3%81%BE%E3%81%97%E3%81%9F%E3%80%82).
    
6. JMED News – Meiji’s press briefing on Costaive approval (Nov 28, 2023)[jmedj.co.jp](https://www.jmedj.co.jp/journal/paper/detail.php?id=23229#:~:text=%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AF%E6%97%A2%E5%AD%98%E3%81%AEmRNA%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AB%E6%AF%94%E3%81%B9%E5%B0%91%E9%87%8F%E6%8A%95%E4%B8%8E%E3%81%A7%E6%B8%88%E3%81%BF%E3%80%81%E3%82%88%E3%82%8A%E5%8A%B9%E6%9E%9C%E3%81%8C%E6%8C%81%E7%B6%9A%E3%81%99%E3%82%8B%E3%81%A8%E3%81%95%E3%82%8C%E3%82%8B%E3%80%82%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E3%81%AF%E8%BF%BD%E5%8A%A0%E5%85%8D%E7%96%AB%E3%81%AE%E5%9B%BD%E5%86%85%E7%AC%AC3%E7%9B%B8%E8%A9%A6%E9%A8%93%E3%81%A7%E3%80%81%E3%83%95%E3%82%A1%E3%82%A4%E3%82%B6%E3%83%BC%E3%81%AE%E3%82%B3%E3%83%9F%E3%83%8A%E3%83%86%E3%82%A3%E3%81%AB%E6%AF%94%E3%81%B9%20%E6%8A%97%E4%BD%93%E4%BE%A1%E3%81%8C%E9%AB%98%E3%81%8F%E6%8C%81%E7%B6%9A%E6%80%A7%E3%81%AB%E5%84%AA%E3%82%8C%E3%81%A6%E3%81%84%E3%82%8B%E3%81%93%E3%81%A8%E3%81%8C%E7%A2%BA%E8%AA%8D%E3%81%95%E3%82%8C%E3%81%9F%E3%80%82)[jmedj.co.jp](https://www.jmedj.co.jp/journal/paper/detail.php?id=23229#:~:text=%E5%90%8C%E7%A4%BE%E3%81%AF%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E3%81%8C%E8%B5%B7%E6%BA%90%E6%A0%AA%E5%AF%BE%E5%BF%9C%E3%81%AE1%E4%BE%A1%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AE%E3%81%9F%E3%82%81%E4%BB%8A%E5%86%AC%E3%81%AF%E8%B2%A9%E5%A3%B2%E3%81%9B%E3%81%9A%E3%80%81%E6%9D%A5%E5%B9%B4%E3%81%AE%E7%A7%8B%E5%86%AC%E6%8E%A5%E7%A8%AE%E3%81%AB%E5%90%91%E3%81%91%E3%81%9F%E4%BE%9B%E7%B5%A6%E9%96%8B%E5%A7%8B%E3%82%92%E6%83%B3%E5%AE%9A%E3%81%97%E3%81%A6%E8%B5%B7%E6%BA%90%E6%A0%AA%E3%81%A8%E3%82%AA%E3%83%9F%E3%82%AF%E3%83%AD%E3%83%B3%E6%A0%AA%E3%81%AB%E3%82%88%E3%82%8B2%E4%BE%A1%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AE%E9%96%8B%E7%99%BA%E3%82%92%E9%80%B2%E3%82%81%E3%82%8B%E3%80%82%E5%8E%9F%20%E8%96%AC%E3%81%AF%E3%82%A2%E3%83%AB%E3%82%AB%E3%83%AA%E3%82%B9%E7%A4%BE%EF%BC%88%E7%A6%8F%E5%B3%B6%E7%9C%8C%E5%8D%97%E7%9B%B8%E9%A6%AC%E5%B8%82%EF%BC%89%E3%81%8B%E3%82%89%E8%AA%BF%E9%81%94%E3%80%81%E4%BB%8A%E5%BE%8C%E5%9B%BD%E5%86%85%E3%81%AB%E6%96%B0%E8%A3%BD%E9%80%A0%E6%A3%9F%E3%82%92%E5%BB%BA%E8%A8%AD%E3%81%97%E3%80%812027%E5%B9%B4%E3%81%AB%E3%81%AF%E7%B4%841%E5%84%84%E5%9B%9E%E6%8E%A5%E7%A8%AE%E5%88%86%E3%81%AE%E7%94%9F%E7%94%A3%E4%BD%93%E5%88%B6%E3%82%92%E6%A7%8B%E7%AF%89%E3%81%99%E3%82%8B%E6%96%B9%E9%87%9D%E3%80%8228%E6%97%A5%E3%81%AE%E8%AA%AC%E6%98%8E%E4%BC%9A%E3%81%A7%E5%90%8C%E7%A4%BE%E3%81%AE%E5%B0%8F%E6%9E%97%E5%A4%A7%E5%90%89%E9%83%8E%E7%A4%BE%20%E9%95%B7%EF%BC%88%E5%86%99%E7%9C%9F%EF%BC%89%E3%81%AF%E3%80%8C%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E6%95%97%E6%88%A6%E3%81%A8%E6%8F%B6%E6%8F%84%E3%81%95%E3%82%8C%E3%81%9F%E6%88%91%E3%81%8C%E5%9B%BD%E3%81%A7%E3%80%81%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E5%AE%9F%E7%94%A8%E5%8C%96%E3%81%AB%E3%81%8A%E3%81%84%E3%81%A6%E4%B8%96%E7%95%8C%E3%81%AB%E5%85%88%E9%A7%86%E3%81%91%E3%82%8B%E3%81%93%E3%81%A8%E3%81%8C%E3%81%A7%E3%81%8D%E3%81%9F%E3%80%82%E4%BD%95%E3%81%A8%E3%81%8B%E3%82%B4%E3%83%BC%E3%83%AB%E3%81%BE%E3%81%A7%E6%8C%81%E3%81%A3%E3%81%A6%E3%81%84%E3%81%8D%E3%81%9F%E3%81%84%E3%80%8D%E3%81%A8%E5%BC%B7%E8%AA%BF%E3%81%97%E3%81%9F%E3%80%82).
    
7. Foresight (Shinchosha) – Commentary on Costaive and vaccine policy (Nov 2024)[fsight.jp](https://www.fsight.jp/articles/-/50989#:~:text=%E5%8C%BB%E7%99%82%E7%8F%BE%E5%A0%B4%E3%81%AF%E7%8F%BE%E6%99%82%E7%82%B9%E3%81%A7%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E3%82%92%E6%B1%82%E3%82%81%E3%81%A6%E3%81%84%E3%81%AA%E3%81%84%E3%80%82%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E3%81%AE%E5%8F%AF%E8%83%BD%E6%80%A7%E3%81%AF%E9%AB%98%E3%81%8F%E8%A9%95%E4%BE%A1%E3%81%95%E3%82%8C%E3%82%8B%E3%81%B9%E3%81%8D%E3%81%A0%E3%81%8C%E3%80%81%E4%B8%8D%E5%8D%81%E5%88%86%E3%81%AA%E8%87%A8%E5%BA%8A%E8%A9%A6%E9%A8%93%E3%81%A7%E3%80%8C%E4%BB%AE%E5%85%8D%E8%A8%B1%E3%80%8D%E3%82%92%E4%B8%8E%E3%81%88%E3%82%8B%E7%90%86%E7%94%B1%E3%81%AF%E3%81%AA%E3%81%84%E3%80%82%E3%81%93%E3%82%8C%E3%81%AF2015%E5%B9%B4%E3%81%AB%E7%99%BA%E8%A6%9A%E3%81%97%20%E3%81%9F%E5%8C%96%E5%AD%A6%E5%8F%8A%E8%A1%80%E6%B8%85%E7%99%82%E6%B3%95%E7%A0%94%E7%A9%B6%E6%89%80%EF%BC%88%E5%8C%96%E8%A1%80%E7%A0%94%EF%BC%89%E3%81%AE%E4%B8%8D%E7%A5%A5%E4%BA%8B%E3%81%A7%E3%80%81%E6%98%8E%E6%B2%BBHD%E3%81%8C%E5%8E%9A%E5%8A%B4%E7%9C%81%E3%81%AB%E4%BD%9C%E3%81%A3%E3%81%9F%E3%80%8C%E8%B2%B8%E3%81%97%E3%80%8D%E3%81%8C%E8%BF%94%E3%81%95%E3%82%8C%E3%81%9F%E3%81%A8%E3%81%84%E3%81%86%E3%81%93%E3%81%A8%E3%81%8B%E3%80%82%E4%BB%AE%E3%81%AB%E3%81%9D%E3%81%86%E3%81%AA%E3%82%89%E3%80%81%E4%B8%96%E7%95%8C%E3%81%A7%E6%9C%80%E3%82%82%E6%A0%B9%E6%B7%B1%E3%81%84%E6%97%A5%E6%9C%AC%E7%A4%BE%E4%BC%9A%E3%81%AE%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AB%E5%AF%BE%E3%81%99%E3%82%8B%E4%B8%8D%E4%BF%A1%20%E6%84%9F%E3%81%AF%E3%80%81%E3%81%95%E3%82%89%E3%81%AB%E5%A2%97%E3%81%99%E3%81%B0%E3%81%8B%E3%82%8A%E3%81%A0%E3%82%8D%E3%81%86%E3%80%82)[fsight.jp](https://www.fsight.jp/articles/-/50989#:~:text=%E6%98%8E%E6%B2%BBHD%E4%BA%8B%E6%A5%AD%E5%AD%90%E4%BC%9A%E7%A4%BE%E3%81%AEMeiji%20Seika%20%E3%83%95%E3%82%A1%E3%83%AB%E3%83%9E%E3%81%8C%E9%96%8B%E7%99%BA%E3%81%97%E3%81%9F%E3%82%B3%E3%83%AD%E3%83%8A%E3%82%A6%E3%82%A4%E3%83%AB%E3%82%B9%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%80%8C%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E3%80%8D%E3%81%8C%E4%B8%96%E9%96%93%E3%81%AE%E9%96%A2%E5%BF%83%E3%82%92%E9%9B%86%E3%82%81%E3%81%A6%E3%81%84%E3%82%8B%E3%80%82SNS%E3%81%AB%E3%81%AF%E3%80%81%E3%80%8C%E3%82%B7%E3%82%A7%E3%83%87%E3%82%A3%E3%83%B3%E3%82%B0%E3%81%AB%E3%82%88%E3%82%8A%E3%80%81%E3%83%AF%20%E3%82%AF%E3%83%81%E3%83%B3%E6%8E%A5%E7%A8%AE%E8%80%85%E3%81%8B%E3%82%89%E5%91%A8%E5%9B%B2%E3%81%AB%E6%84%9F%E6%9F%93%E3%81%95%E3%81%9B%E3%82%8B%E3%80%8D%E3%81%AA%E3%81%A9%E3%81%AE%E3%83%87%E3%83%9E%E3%81%8C%E6%B0%BE%E6%BF%AB%E3%81%97%E3%81%A6%E3%81%84%E3%82%8B%E3%80%82%E3%80%8C%E3%82%B7%E3%82%A7%E3%83%87%E3%82%A3%E3%83%B3%E3%82%B0%E3%80%8D%E3%81%A8%E3%81%AF%E3%80%81%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E3%81%8C%E4%BD%93%E5%86%85%E3%81%A7%E5%A2%97%E6%AE%96%E3%81%97%E3%81%9F%E5%BE%8C%E3%80%81%E3%81%9D%E3%81%AE%E4%B8%80%E9%83%A8%E3%81%8C%E5%AF%BE%E5%A4%96%E3%81%AB%E6%94%BE%E5%87%BA%E3%81%95%E3%82%8C%E3%80%81%E5%91%A8%E5%9B%B2%E3%81%AB%E3%81%84%E3%82%8B%E4%BA%BA%E3%81%AB%E6%82%AA%E5%BD%B1%E9%9F%BF%E3%82%92%20%E4%B8%8E%E3%81%88%E3%82%8B%E3%81%93%E3%81%A8%E3%81%A0%E3%81%8C%E3%80%81%E3%81%93%E3%81%AE%E3%81%93%E3%81%A8%E3%82%92%E6%94%AF%E6%8C%81%E3%81%99%E3%82%8B%E7%A7%91%E5%AD%A6%E7%9A%84%E3%81%AA%E6%A0%B9%E6%8B%A0%E3%81%AF%E3%81%AA%E3%81%84%E3%80%82).
    

![Favicon](https://www.google.com/s2/favicons?domain=https://www.jmedj.co.jp&sz=32)

![Favicon](https://www.google.com/s2/favicons?domain=https://www.kagaya-clinic.jp&sz=32)

![Favicon](https://www.google.com/s2/favicons?domain=https://cdn.who.int&sz=32)

![Favicon](https://www.google.com/s2/favicons?domain=https://www.cbsnews.com&sz=32)

![Favicon](https://www.google.com/s2/favicons?domain=https://www.cidrap.umn.edu&sz=32)

情報源

ツール

ChatGPT の回答は必ずしも正しいとは限りません。重要な情報は確認するようにしてください。

## 

プレビュー

PDF をダウンロードする

リンクを共有する

## NB.1.8.1 Variant – Spread Abroad and Potential Impact in Japan

NB.1.8.1 is a newly designated SARS-CoV-2 variant under monitoring (VUM) by the WHO, noted for its rapid increase in prevalence[cidrap.umn.edu](https://www.cidrap.umn.edu/covid-19/who-adds-nb181-sars-cov-2-variant-under-monitoring#:~:text=The%20World%20Health%20Organization%20,1%20sublineage). It has been driving **surges in COVID-19 cases** in several countries. For example, NB.1.8.1 became the dominant strain in China, coinciding with a _large wave of infections_[cbsnews.com](https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/#:~:text=Experts%20have%20been%20closely%20watching,19). Hong Kong experienced its worst COVID-19 levels in a year, with a significant spike in emergency room visits and hospitalizations[cbsnews.com](https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/#:~:text=Experts%20have%20been%20closely%20watching,19). Similarly, Taiwan saw rising emergency visits, severe cases, and deaths, prompting authorities to stockpile vaccines and antivirals[cbsnews.com](https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/#:~:text=While%20authorities%20in%20Hong%20Kong,places%20as%20cases%20have%20climbed). Despite these rapid spread events, health officials report **no clear evidence that NB.1.8.1 causes more severe illness** than other Omicron-lineage variants[cbsnews.com](https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/#:~:text=While%20authorities%20in%20Hong%20Kong,places%20as%20cases%20have%20climbed)[cidrap.umn.edu](https://www.cidrap.umn.edu/covid-19/who-adds-nb181-sars-cov-2-variant-under-monitoring#:~:text=The%20experts%20said%20NB,those%20from%20other%20circulating%20variants). The strain appears to have a **transmissibility advantage**: preliminary data indicate NB.1.8.1 binds more strongly to human ACE2 receptors (which could increase contagiousness), while its ability to evade immunity is only on par with, or marginally worse than, other recent subvariants[cbsnews.com](https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/#:~:text=epidemic%20wave)[cidrap.umn.edu](https://www.cidrap.umn.edu/covid-19/who-adds-nb181-sars-cov-2-variant-under-monitoring#:~:text=The%20World%20Health%20Organization%20,1%20sublineage). In other words, NB.1.8.1 is spreading fast but does not markedly escape existing immunity or cause disproportionate severity.

 

Genetically, NB.1.8.1 is a descendant of a recombinant Omicron lineage (XDV.1.5.1) and clusters within the “JN.1” family of Omicron sublineages[cidrap.umn.edu](https://www.cidrap.umn.edu/covid-19/who-adds-nb181-sars-cov-2-variant-under-monitoring#:~:text=NB,Western%20Pacific%2C%20Americas%2C%20and%20European). By late April 2025 it was rising quickly: about **10.7% of global sequences** were NB.1.8.1, up from 2.5% only a month earlier[cidrap.umn.edu](https://www.cidrap.umn.edu/covid-19/who-adds-nb181-sars-cov-2-variant-under-monitoring#:~:text=NB,Western%20Pacific%2C%20Americas%2C%20and%20European). This increase was observed across regions (Western Pacific, Americas, Europe) that conduct regular sequencing[cidrap.umn.edu](https://www.cidrap.umn.edu/covid-19/who-adds-nb181-sars-cov-2-variant-under-monitoring#:~:text=NB,Western%20Pacific%2C%20Americas%2C%20and%20European). Notably, **Japan is not isolated from this trend** – the U.S. CDC’s airport screening detected NB.1.8.1 in travelers arriving from numerous countries _including Japan_ (as well as South Korea, various European nations, Thailand, Vietnam, China, etc.)[cbsnews.com](https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/#:~:text=and%20the%20New%20York%20City,airport%20testing%20partner%20Ginkgo%20Bioworks). This suggests NB.1.8.1 has already been introduced into Japan via travel, even if it has not yet widely circulated domestically.

 

**Potential displacement of Japan’s current strain (KP.3):** In Japan, the currently predominant variant has been identified as “KP.3,” a subvariant in the JN.1 lineage (KP.3 was a major Omicron strain circulating in early 2025). Given NB.1.8.1’s rapid growth advantage observed elsewhere, there is a realistic possibility that NB.1.8.1 could overtake KP.3 as the dominant strain in Japan. Indeed, globally KP.3’s prevalence was declining as NB.1.8.1 rose[cdn.who.int](https://cdn.who.int/media/docs/default-source/documents/epp/tracking-sars-cov-2/23052025_nb.1.8.1_ire.pdf#:~:text=Lineage%2A%20Countries%C2%A7%20Sequences%C2%A7%202025,6%20Increase). If NB.1.8.1 gains a foothold in Japan, we might expect it to spread swiftly through the population, especially as social and travel activities normalize. **Epidemiological patterns** in many countries have settled into two COVID surges per year (one in summer, one in winter)[cbsnews.com](https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/#:~:text=For%20now%2C%20CDC%20and%20FDA,and%20once%20over%20the%20winter), and a highly transmissible variant like NB.1.8.1 could fuel Japan’s next surge. It is plausible that over the summer or autumn, NB.1.8.1 becomes the mainstream strain domestically. On the positive side, because NB.1.8.1 has not shown increased virulence, a wave driven by it _may not_ produce higher severity than previous Omicron waves – but it could still lead to a substantial number of infections given its growth advantage. In summary, **Japan should be prepared for NB.1.8.1 to emerge as a major strain**, potentially supplanting KP.3, and plan for a possible uptick in cases. Ongoing surveillance (e.g. genomic monitoring of variants) and healthcare readiness are warranted, learning from the overseas situations where healthcare systems saw strain during NB.1.8.1 surges[cbsnews.com](https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/#:~:text=Experts%20have%20been%20closely%20watching,19).

## Effectiveness of Current JN.1-Targeted Vaccines vs NB.1.8.1, and Need for New Vaccines

Japan’s current COVID-19 booster vaccines (as of 2024/25) are **monovalent shots targeting the Omicron JN.1 lineage** (JN.1 is an Omicron variant clade, which includes XBB-lineage descendants). The question is how well these existing vaccines protect against the NB.1.8.1 variant. Encouragingly, experts believe that **JN.1-based vaccines should still provide substantial protection against NB.1.8.1**. The WHO’s COVID-19 Vaccine Composition Advisory group stated in May 2025 that a monovalent vaccine targeting JN.1 (or its close descendant KP.2) “remains appropriate” as it broadly covers circulating strains[cidrap.umn.edu](https://www.cidrap.umn.edu/covid-19/who-adds-nb181-sars-cov-2-variant-under-monitoring#:~:text=On%20May%2015%2C%20the%20WHO%27s,1%20component). This implies that NB.1.8.1 has not drifted far enough antigenically to render JN.1-based immunity ineffective. In fact, laboratory analyses so far show NB.1.8.1 is only **“marginally more immune-evasive”** than the previously dominant subvariant (LP.8.1)[cidrap.umn.edu](https://www.cidrap.umn.edu/covid-19/who-adds-nb181-sars-cov-2-variant-under-monitoring#:~:text=The%20World%20Health%20Organization%20,1%20sublineage). Chinese researchers reported that NB.1.8.1 did _not_ outperform other recent variants in evading antibodies – it was roughly on par with them[cbsnews.com](https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/#:~:text=epidemic%20wave). Therefore, individuals vaccinated against JN.1 or similar Omicron strains should still have neutralizing antibodies that recognize NB.1.8.1, and importantly T-cell immunity from those vaccines will continue to provide protection against severe outcomes. Real-world observations support this: despite NB.1.8.1’s spread, **currently approved vaccines are expected to remain effective against symptomatic infection and severe disease** from this variant[cdn.who.int](https://cdn.who.int/media/docs/default-source/documents/epp/tracking-sars-cov-2/23052025_nb.1.8.1_ire.pdf#:~:text=globally%2C%20while%20LP,than%20other%20variants%20in%20circulation).

 

It is worth noting that NB.1.8.1 is indeed a _member_ of the JN.1 variant family[cidrap.umn.edu](https://www.cidrap.umn.edu/covid-19/who-adds-nb181-sars-cov-2-variant-under-monitoring#:~:text=NB,Western%20Pacific%2C%20Americas%2C%20and%20European). Thus, the immune response induced by a JN.1-targeted shot is closely matched to NB.1.8.1’s Spike protein. For example, NB.1.8.1 carries certain Spike mutations (e.g. at positions 445, 478) that may enhance transmissibility or slightly reduce neutralization, but these changes yield only a modest (~1.5-fold) reduction in neutralizing antibody potency compared to the vaccine strain[cdn.who.int](https://cdn.who.int/media/docs/default-source/documents/epp/tracking-sars-cov-2/23052025_nb.1.8.1_ire.pdf#:~:text=has%20the%20following%20additional%20Spike,evasion%20of%20Class%201%2F2%20antibodies)[cdn.who.int](https://cdn.who.int/media/docs/default-source/documents/epp/tracking-sars-cov-2/23052025_nb.1.8.1_ire.pdf#:~:text=,5%2C6). **No drastic immune escape has been observed.** Indeed, experiments in mice showed that boosting with the current JN.1/KP.2-based vaccines generated only modestly lower antibodies against NB.1.8.1, compared to antibodies against the original vaccine strain[cdn.who.int](https://cdn.who.int/media/docs/default-source/documents/epp/tracking-sars-cov-2/23052025_nb.1.8.1_ire.pdf#:~:text=,5%2C6). All this suggests that the **JN.1-based booster in use should still blunt the impact of NB.1.8.1**, especially for preventing hospitalizations and deaths.

 

**Effectiveness data and expert recommendations:** At a U.S. FDA advisory meeting (June 2025), early data were presented on how well updated vaccines could cover NB.1.8.1. Notably, Pfizer and Moderna showed that if the vaccine strain were switched to a slightly newer JN.1 descendant (called LP.8.1, which has been dominant in recent months), it **“could boost protection against NB.1.8.1”** as well[cbsnews.com](https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/#:~:text=Vaccines%20from%20last%20season%20targeted,1%2C%20too). Moderna’s scientists explained that an LP.8.1-based vaccine induced the highest neutralizing titers against the LP.8.1 virus _and_ also cross-neutralized other circulating variants including NB.1.8.1[cbsnews.com](https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/#:~:text=,19%20program%2C%20told%20the%20panel). This implies that while the current JN.1 (KP.2) vaccine is effective, an updated shot might offer even broader immunity. In line with this, the European Medicines Agency has _recommended_ using an LP.8.1 antigen for upcoming boosters, and the FDA’s panel unanimously agreed that the **next season’s COVID-19 vaccines should target “some kind of JN.1 variant”** (with many experts favoring the LP.8.1 strain as the update)[cidrap.umn.edu](https://www.cidrap.umn.edu/covid-19/who-adds-nb181-sars-cov-2-variant-under-monitoring#:~:text=On%20May%2015%2C%20the%20WHO%27s,1%20component)[cbsnews.com](https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/#:~:text=The%20committee%20unanimously%20backed%20recommending,Pfizer%20and%20Moderna%20have%20prototyped). Importantly, these discussions highlight that **NB.1.8.1 did not necessitate a completely new vaccine on its own** – instead, it can be addressed by tweaking the existing Omicron-based formulations.

 

**NB.1.8.1-specific vaccine – is it needed?** Given the above context, the introduction of a brand-new, NB.1.8.1-specific vaccine does not appear necessary or practical at this time. Global health authorities have not singled out NB.1.8.1 as requiring its own vaccine. Rather, the strategy is to keep pace with SARS-CoV-2 evolution by occasionally updating the vaccine strain to one that offers broad cross-protection. For instance, if NB.1.8.1 (or similar strains) continue to spread, the fall 2025 booster could be formulated as LP.8.1 (or another JN.1-lineage variant that covers NB.1.8.1)[cidrap.umn.edu](https://www.cidrap.umn.edu/covid-19/who-adds-nb181-sars-cov-2-variant-under-monitoring#:~:text=On%20May%2015%2C%20the%20WHO%27s,1%20component)[cbsnews.com](https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/#:~:text=Vaccines%20from%20last%20season%20targeted,1%2C%20too). This approach is analogous to how influenza vaccines are updated – we don’t make a new vaccine for every single variant, but we update to a representative strain. An NB.1.8.1-specific vaccine would have questionable **practicality** because by the time it was developed, tested, and rolled out, the virus might have moved on to a new lineage. Moreover, current evidence says **existing vaccines still work**: the WHO TAG-VE evaluated NB.1.8.1’s risk as low and explicitly noted that _“currently approved COVID-19 vaccines are expected to remain effective”_ against it[cdn.who.int](https://cdn.who.int/media/docs/default-source/documents/epp/tracking-sars-cov-2/23052025_nb.1.8.1_ire.pdf#:~:text=globally%2C%20while%20LP,than%20other%20variants%20in%20circulation). Therefore, from a policy perspective, it makes more sense to continue **promoting the current booster (JN.1/KP.2-based) for at-risk groups, and plan for a variant update in the next seasonal campaign if needed**, rather than rushing out a one-off NB.1.8.1 vaccine. In summary, the **JN.1-directed vaccines offer a solid defense against NB.1.8.1**, and incremental updates (like moving to an LP.8.1-based shot) can be implemented in future if surveillance indicates it’s beneficial[cbsnews.com](https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/#:~:text=,19%20program%2C%20told%20the%20panel). There is no strong indication that a special NB.1.8.1-only vaccine would significantly change the trajectory of the pandemic at this point.

## Annual COVID Vaccination with Replicon Vaccine (「コスタイベ」) – Feasibility and Benefits

Starting in late 2024, Japan transitioned its COVID-19 immunization program to a **routine annual vaccination** paradigm. Essentially, COVID-19 vaccines are now treated similarly to seasonal influenza vaccines – with a planned **one dose per year** for most individuals (administered in the autumn/winter)[kagaya-clinic.jp](https://www.kagaya-clinic.jp/replicon-vaccine/#:~:text=%E5%AF%BE%E3%81%97%E3%81%A6%E3%81%AF%E5%84%AA%E3%82%8C%E3%82%8B%E3%81%93%E3%81%A8%E3%81%8C%E7%A2%BA%E8%AA%8D%E3%81%95%E3%82%8C%E3%81%BE%E3%81%97%E3%81%9F%E3%80%82). Alongside this transition, Japan approved and introduced a next-generation vaccine: the _replicon mRNA vaccine_ known by the brand name **“コスタイベ” (Costaive)**. This vaccine, developed by Arcturus Therapeutics and manufactured domestically by Meiji Seika Pharma, was the world’s first approved replicon COVID-19 vaccine[jmedj.co.jp](https://www.jmedj.co.jp/journal/paper/detail.php?id=23229#:~:text=Meiji%20Seika%E3%83%95%E3%82%A1%E3%83%AB%E3%83%9E%E3%81%AF11%E6%9C%8828%E6%97%A5%E3%80%81%E6%96%B0%E5%9E%8B%E3%82%B3%E3%83%AD%E3%83%8A%E3%82%A6%E3%82%A4%E3%83%AB%E3%82%B9%E6%84%9F%E6%9F%93%E7%97%87%E3%81%AB%E5%AF%BE%E3%81%99%E3%82%8B%E6%AC%A1%E4%B8%96%E4%BB%A3mRNA%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%80%8C%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E7%AD%8B%E6%B3%A8%E7%94%A8%E3%80%8D%E3%81%AB%E3%81%A4%E3%81%84%E3%81%A6%E8%A8%98%E8%80%85%E8%AA%AC%E6%98%8E%E4%BC%9A%E3%82%92%E9%96%8B%E5%82%AC%E3%81%97%E3%81%9F%E3%80%82%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%20%E3%81%AF%E3%80%81%E7%B1%B3%E3%83%90%E3%82%A4%E3%82%AA%E4%BC%81%E6%A5%AD%E3%82%A2%E3%83%BC%E3%82%AF%E3%83%88%E3%82%A5%E3%83%AB%E3%82%B9%E3%83%BB%E3%82%BB%E3%83%A9%E3%83%94%E3%83%A5%E3%83%BC%E3%83%86%E3%82%A3%E3%82%AF%E3%82%B9%E3%81%8C%E9%96%8B%E7%99%BA%E3%81%97%E3%81%9F%E3%80%81%E6%8A%95%E4%B8%8E%E5%BE%8C%E3%81%AB%E4%BD%93%E5%86%85%E3%81%A7mRNA%E3%82%92%E8%87%AA%E5%B7%B1%E8%A4%87%E8%A3%BD%E3%81%99%E3%82%8B%E3%80%8C%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%80%8D%E3%80%82Meiji%20Seika%E3%83%95%E3%82%A1%E3%83%AB%E3%83%9E%E3%81%8C%E5%9B%BD%E5%86%85%E3%81%AE%E4%BE%9B%E7%B5%A6%E3%83%BB%E8%B2%A9%E5%A3%B2%E6%A8%A9%E3%82%92%E5%8F%96%E5%BE%97%E3%81%97%E8%87%A8%E5%BA%8A%E8%A9%A6%E9%A8%93%E3%82%92%E9%80%B2%E3%82%81%E3%80%81%E5%90%8C%E6%97%A5%E3%80%81%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%A8%E3%81%97%E3%81%A6%E4%B8%96%E7%95%8C%E5%88%9D%E3%81%A8%E3%81%AA%E3%82%8B%E8%A3%BD%E9%80%A0%E8%B2%A9%E5%A3%B2%E6%89%BF%E8%AA%8D%E3%82%92%E5%8E%9A%E5%8A%B4%E7%9C%81%E3%82%88%E3%82%8A%E5%8F%96%E5%BE%97%E3%81%97%E3%81%9F%E3%80%82). It targets the Omicron JN.1 strain (as a monovalent formulation) and became available as part of the routine booster program on October 1, 2024[kagaya-clinic.jp](https://www.kagaya-clinic.jp/replicon-vaccine/#:~:text=Image%3A%20%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B32024%E5%B9%B410%E6%9C%881%E6%97%A5%E3%82%88%E3%82%8A%E3%80%81%E6%96%B0%E5%9E%8B%E3%82%B3%E3%83%AD%E3%83%8A%E3%82%A6%E3%82%A4%E3%83%AB%E3%82%B9%E3%81%AE%E3%82%AA%E3%83%9F%E3%82%AF%E3%83%AD%E3%83%B3%E6%A0%AAJN).

 

**What is a replicon vaccine and why is it useful?** A replicon vaccine is a type of mRNA vaccine engineered to **self-amplify inside cells** for a short period after injection. In Costaive’s case, the mRNA includes a replicase enzyme, so once it enters the body’s cells, it keeps copying itself and producing the viral antigen (the Spike protein) for longer than a conventional mRNA vaccine would[kagaya-clinic.jp](https://www.kagaya-clinic.jp/replicon-vaccine/#:~:text=%E3%80%8C%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%EF%BC%88replicon%EF%BC%89%E3%80%8D%E3%81%AF%E3%80%81%E3%80%8C%E8%A4%87%E8%A3%BD%E3%80%8D%E3%82%92%E6%84%8F%E5%91%B3%E3%81%99%E3%82%8B%E5%88%86%E5%AD%90%E7%94%9F%E7%89%A9%E5%AD%A6%E3%81%AE%E7%94%A8%E8%AA%9E%E3%81%A7%E3%80%81%E3%82%B3%E3%83%94%E3%83%BC%E3%81%95%E3%82%8C%E3%81%9FDNA%E3%82%84RNA%E3%82%92%E6%8C%87%E3%81%97%E3%81%BE%E3%81%99%E3%80%82%20%E5%BE%93%E6%9D%A5%E3%81%AEmRNA%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AF%E3%80%81%E4%BD%93%E5%86%85%E3%81%A7%E3%82%A6%E3%82%A4%E3%83%AB%E3%82%B9%E3%81%AE%E3%82%BF%E3%83%B3%E3%83%91%E3%82%AF%E8%B3%AA%E3%82%92%E7%94%9F%E6%88%90%E3%81%99%E3%82%8B%E3%81%93%E3%81%A8%E3%81%A7%E5%85%8D%E7%96%AB%E3%82%92%E8%AA%98%E5%B0%8E%E3%81%97%E3%80%81%E6%8A%97%E4%BD%93%E3%82%92%E5%BE%97%E3%82%8B%E4%BB%95%E7%B5%84%E3%81%BF%E3%81%A7%E3%81%99%E3%81%8C%E3%80%81%E3%81%9D%E3%81%AE%E7%94%9F%E6%88%90%E3%81%AF%E4%B8%80%E9%81%8E%E6%80%A7%E3%81%A7%E3%81%99%E3%80%82%E3%81%93%E3%82%8C%E3%81%AB%E5%AF%BE%E3%81%97%E3%80%81%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%EF%BC%88%20%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%EF%BC%89%E3%81%AFmRNA%E3%81%AB%E8%87%AA%E5%B7%B1%E8%A4%87%E8%A3%BD%E9%85%B5%E7%B4%A0%E3%82%92%E7%B5%84%E3%81%BF%E8%BE%BC%E3%81%BF%E3%80%81%E3%82%BF%E3%83%B3%E3%83%91%E3%82%AF%E8%B3%AA%E7%94%9F%E6%88%90%E3%82%92%E6%8C%81%E7%B6%9A%E7%9A%84%E3%81%AB%E8%A1%8C%E3%81%84%E3%81%BE%E3%81%99%E3%80%82%E3%81%93%E3%81%AE%E3%80%8C%E8%87%AA%E5%B7%B1%E5%A2%97%E5%B9%85%E3%80%8D%E3%81%AB%E3%82%88%E3%82%8A%E3%80%81%E5%BE%93%E6%9D%A5%E3%81%AEmRNA%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AB%E6%AF%94%E3%81%B9%E3%81%A6%E3%80%81%E3%82%88%E3%82%8A%E5%BC%B7%E5%8A%9B%E3%81%A7%E6%8C%81%E7%B6%9A%E7%9A%84%E3%81%AA%E5%85%8D%E7%96%AB%20%E5%BF%9C%E7%AD%94%E3%82%92%E8%AA%98%E5%B0%8E%E3%81%A7%E3%81%8D%E3%82%8B%E3%81%A8%E3%81%95%E3%82%8C%E3%81%A6%E3%81%84%E3%81%BE%E3%81%99%E3%80%82%20%E5%95%86%E5%93%81%E5%90%8D%E3%80%8C%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E3%80%8D%E3%81%AF%E3%80%81%E3%82%A2%E3%83%A1%E3%83%AA%E3%82%AB%E3%81%AEArcturus,Therapeutics%E7%A4%BE%E3%81%8C%E9%96%8B%E7%99%BA%E3%81%97%E3%80%81%E6%97%A5%E6%9C%AC%E3%81%A7%E3%81%AFMeiji%20Seika%E3%83%95%E3%82%A1%E3%83%AB%E3%83%9E%E7%A4%BE%E3%81%8C%E8%A3%BD%E9%80%A0%E3%83%BB%E8%B2%A9%E5%A3%B2%E3%82%92%E6%8B%85%E5%BD%93%E3%81%97%E3%81%A6%E3%81%84%E3%81%BE%E3%81%99%E3%80%82). This prolonged protein expression leads to a more sustained stimulation of the immune system. The practical benefits are twofold: (1) **Much smaller dose needed.** Costaive can achieve a robust immune response with less than one-sixth the mRNA quantity of a standard mRNA shot[kagaya-clinic.jp](https://www.kagaya-clinic.jp/replicon-vaccine/#:~:text=%E7%89%B9%E5%BE%B4%E3%81%A8%E4%BB%8A%E5%BE%8C%E3%81%AE%E5%8F%AF%E8%83%BD%E6%80%A7). (2) **Longer-lasting immunity.** Because the antigen is produced over an extended period, the immune response is stronger and more durable[kagaya-clinic.jp](https://www.kagaya-clinic.jp/replicon-vaccine/#:~:text=%E3%80%8C%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%EF%BC%88replicon%EF%BC%89%E3%80%8D%E3%81%AF%E3%80%81%E3%80%8C%E8%A4%87%E8%A3%BD%E3%80%8D%E3%82%92%E6%84%8F%E5%91%B3%E3%81%99%E3%82%8B%E5%88%86%E5%AD%90%E7%94%9F%E7%89%A9%E5%AD%A6%E3%81%AE%E7%94%A8%E8%AA%9E%E3%81%A7%E3%80%81%E3%82%B3%E3%83%94%E3%83%BC%E3%81%95%E3%82%8C%E3%81%9FDNA%E3%82%84RNA%E3%82%92%E6%8C%87%E3%81%97%E3%81%BE%E3%81%99%E3%80%82%20%E5%BE%93%E6%9D%A5%E3%81%AEmRNA%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AF%E3%80%81%E4%BD%93%E5%86%85%E3%81%A7%E3%82%A6%E3%82%A4%E3%83%AB%E3%82%B9%E3%81%AE%E3%82%BF%E3%83%B3%E3%83%91%E3%82%AF%E8%B3%AA%E3%82%92%E7%94%9F%E6%88%90%E3%81%99%E3%82%8B%E3%81%93%E3%81%A8%E3%81%A7%E5%85%8D%E7%96%AB%E3%82%92%E8%AA%98%E5%B0%8E%E3%81%97%E3%80%81%E6%8A%97%E4%BD%93%E3%82%92%E5%BE%97%E3%82%8B%E4%BB%95%E7%B5%84%E3%81%BF%E3%81%A7%E3%81%99%E3%81%8C%E3%80%81%E3%81%9D%E3%81%AE%E7%94%9F%E6%88%90%E3%81%AF%E4%B8%80%E9%81%8E%E6%80%A7%E3%81%A7%E3%81%99%E3%80%82%E3%81%93%E3%82%8C%E3%81%AB%E5%AF%BE%E3%81%97%E3%80%81%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%EF%BC%88%20%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%EF%BC%89%E3%81%AFmRNA%E3%81%AB%E8%87%AA%E5%B7%B1%E8%A4%87%E8%A3%BD%E9%85%B5%E7%B4%A0%E3%82%92%E7%B5%84%E3%81%BF%E8%BE%BC%E3%81%BF%E3%80%81%E3%82%BF%E3%83%B3%E3%83%91%E3%82%AF%E8%B3%AA%E7%94%9F%E6%88%90%E3%82%92%E6%8C%81%E7%B6%9A%E7%9A%84%E3%81%AB%E8%A1%8C%E3%81%84%E3%81%BE%E3%81%99%E3%80%82%E3%81%93%E3%81%AE%E3%80%8C%E8%87%AA%E5%B7%B1%E5%A2%97%E5%B9%85%E3%80%8D%E3%81%AB%E3%82%88%E3%82%8A%E3%80%81%E5%BE%93%E6%9D%A5%E3%81%AEmRNA%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AB%E6%AF%94%E3%81%B9%E3%81%A6%E3%80%81%E3%82%88%E3%82%8A%E5%BC%B7%E5%8A%9B%E3%81%A7%E6%8C%81%E7%B6%9A%E7%9A%84%E3%81%AA%E5%85%8D%E7%96%AB%20%E5%BF%9C%E7%AD%94%E3%82%92%E8%AA%98%E5%B0%8E%E3%81%A7%E3%81%8D%E3%82%8B%E3%81%A8%E3%81%95%E3%82%8C%E3%81%A6%E3%81%84%E3%81%BE%E3%81%99%E3%80%82%20%E5%95%86%E5%93%81%E5%90%8D%E3%80%8C%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E3%80%8D%E3%81%AF%E3%80%81%E3%82%A2%E3%83%A1%E3%83%AA%E3%82%AB%E3%81%AEArcturus,Therapeutics%E7%A4%BE%E3%81%8C%E9%96%8B%E7%99%BA%E3%81%97%E3%80%81%E6%97%A5%E6%9C%AC%E3%81%A7%E3%81%AFMeiji%20Seika%E3%83%95%E3%82%A1%E3%83%AB%E3%83%9E%E7%A4%BE%E3%81%8C%E8%A3%BD%E9%80%A0%E3%83%BB%E8%B2%A9%E5%A3%B2%E3%82%92%E6%8B%85%E5%BD%93%E3%81%97%E3%81%A6%E3%81%84%E3%81%BE%E3%81%99%E3%80%82)[kagaya-clinic.jp](https://www.kagaya-clinic.jp/replicon-vaccine/#:~:text=%E7%89%B9%E5%BE%B4%E3%81%A8%E4%BB%8A%E5%BE%8C%E3%81%AE%E5%8F%AF%E8%83%BD%E6%80%A7). Clinical trial data support these claims – in a Phase 3 booster trial in Japan, a single dose of Costaive induced neutralizing antibody levels that were _higher and more persistent_ than those from Pfizer’s mRNA booster (Comirnaty) when looking at Omicron-specific immunity[jmedj.co.jp](https://www.jmedj.co.jp/journal/paper/detail.php?id=23229#:~:text=%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AF%E6%97%A2%E5%AD%98%E3%81%AEmRNA%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AB%E6%AF%94%E3%81%B9%E5%B0%91%E9%87%8F%E6%8A%95%E4%B8%8E%E3%81%A7%E6%B8%88%E3%81%BF%E3%80%81%E3%82%88%E3%82%8A%E5%8A%B9%E6%9E%9C%E3%81%8C%E6%8C%81%E7%B6%9A%E3%81%99%E3%82%8B%E3%81%A8%E3%81%95%E3%82%8C%E3%82%8B%E3%80%82%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E3%81%AF%E8%BF%BD%E5%8A%A0%E5%85%8D%E7%96%AB%E3%81%AE%E5%9B%BD%E5%86%85%E7%AC%AC3%E7%9B%B8%E8%A9%A6%E9%A8%93%E3%81%A7%E3%80%81%E3%83%95%E3%82%A1%E3%82%A4%E3%82%B6%E3%83%BC%E3%81%AE%E3%82%B3%E3%83%9F%E3%83%8A%E3%83%86%E3%82%A3%E3%81%AB%E6%AF%94%E3%81%B9%20%E6%8A%97%E4%BD%93%E4%BE%A1%E3%81%8C%E9%AB%98%E3%81%8F%E6%8C%81%E7%B6%9A%E6%80%A7%E3%81%AB%E5%84%AA%E3%82%8C%E3%81%A6%E3%81%84%E3%82%8B%E3%81%93%E3%81%A8%E3%81%8C%E7%A2%BA%E8%AA%8D%E3%81%95%E3%82%8C%E3%81%9F%E3%80%82)[kagaya-clinic.jp](https://www.kagaya-clinic.jp/replicon-vaccine/#:~:text=%E7%89%B9%E5%BE%B4%E3%81%A8%E4%BB%8A%E5%BE%8C%E3%81%AE%E5%8F%AF%E8%83%BD%E6%80%A7). In fact, immunity against Omicron BA.4/5 was superior in the Costaive group compared to Pfizer’s vaccine[kagaya-clinic.jp](https://www.kagaya-clinic.jp/replicon-vaccine/#:~:text=%E7%89%B9%E5%BE%B4%E3%81%A8%E4%BB%8A%E5%BE%8C%E3%81%AE%E5%8F%AF%E8%83%BD%E6%80%A7). These results indicate that **replicon vaccines can maintain protective antibody levels for a longer time**, which aligns perfectly with the **annual vaccination schedule** (one shot providing year-round coverage)[kagaya-clinic.jp](https://www.kagaya-clinic.jp/replicon-vaccine/#:~:text=%E5%AF%BE%E3%81%97%E3%81%A6%E3%81%AF%E5%84%AA%E3%82%8C%E3%82%8B%E3%81%93%E3%81%A8%E3%81%8C%E7%A2%BA%E8%AA%8D%E3%81%95%E3%82%8C%E3%81%BE%E3%81%97%E3%81%9F%E3%80%82).

 

From a **public health perspective**, the proposal to use Costaive as an annual COVID-19 booster (covered by National Health Insurance) and to integrate its delivery with routine health check-ups is quite sound. The annual schedule is justified by both epidemiology and vaccine performance: SARS-CoV-2 has settled into a pattern of causing seasonal waves, and immunity – whether from infection or vaccination – wanes over time. An yearly booster can top up protection, especially for high-risk groups, to reduce hospitalizations and deaths. Costaive’s long-lasting immunity means an annual dose should suffice for most people[kagaya-clinic.jp](https://www.kagaya-clinic.jp/replicon-vaccine/#:~:text=%E5%AF%BE%E3%81%97%E3%81%A6%E3%81%AF%E5%84%AA%E3%82%8C%E3%82%8B%E3%81%93%E3%81%A8%E3%81%8C%E7%A2%BA%E8%AA%8D%E3%81%95%E3%82%8C%E3%81%BE%E3%81%97%E3%81%9F%E3%80%82). Including the COVID booster in National Health Insurance coverage (or as a government-recommended routine vaccination) ensures that **cost is not a barrier**. In Japan, routine immunizations are either free or very low-cost to the individual, which encourages higher uptake. This is critical in a country where vaccine confidence has sometimes been an issue; making the COVID shot a normal, expected part of healthcare (like a flu shot) and covering it financially can improve acceptance.

 

Integrating the vaccination with **“国民健診” (national health check-ups)** or other regular medical visits is an innovative way to raise coverage. Many Japanese residents undergo annual health exams (for example, workplace health check-ups or the Specific Health Checkups for those over 40). Utilizing these existing touchpoints to also offer COVID-19 vaccination could significantly **increase convenience and uptake**. For instance, at a yearly physical or screening, individuals could be informed about the COVID booster and even receive it on-site or schedule an appointment for it. This one-stop approach has multiple benefits:

- **Higher reach:** It captures people who might not actively seek out a vaccine appointment on their own. If a person is already attending a health check, a simple opt-in can get them protected without an extra trip.
    
- **Efficiency:** It leverages existing healthcare infrastructure and appointment systems. Rather than running large separate vaccination drives each year, health authorities can piggyback on the routine check-up system. This can be more cost-effective and logistically simpler, especially in terms of scheduling and record-keeping.
    
- **Public health synergy:** It reinforces the idea of preventive health. Patients see vaccination as a regular part of staying healthy, just like blood pressure checks or blood tests. This normalization can combat vaccine hesitancy by making the experience more routine.
    

Of course, there are **operational considerations** to ensure this integration works smoothly. Timing is one aspect: the annual COVID shot is recommended in fall/winter, so coordinating that with health check schedules (which might be year-round) is important. One approach could be to concentrate vaccination offers in the latter half of the year’s check-ups. Alternatively, check-up providers could take reservations for a vaccine clinic in the appropriate season (e.g., if you do your health check in summer, they might help you schedule a COVID shot for the fall). There are also logistical needs such as having the vaccine supply and trained staff available at the health check site. Many larger companies in Japan already administer influenza vaccines to employees on-site; a similar model could be used for COVID, especially with a vaccine like Costaive that doesn’t have ultra-cold storage requirements (Costaive can be stored at 2–8°C refrigerated conditions, making it easier to handle than some earlier mRNA vaccines). Proper observation space for 15 minutes post-shot would need to be arranged at clinics or check-up venues. These are manageable issues with planning.

 

Another important perspective is **monitoring and data integration**. By linking vaccination to the health check, authorities can better keep track of who has received the vaccine and who hasn’t, possibly through the national vaccine registration system (VRS) or the individual’s electronic health records. This can help identify gaps in coverage and send reminders, etc. Privacy and consent must be handled appropriately, but since vaccination is voluntary, the system would likely ask individuals during their check-up if they want the shot or want to register for it. Such integration has precedent in other public health efforts (for example, some countries use routine doctor visits to offer missing immunizations).

 

In summary, **the proposal to administer the replicon vaccine annually with National Health Insurance coverage, and to utilize the national health check-up framework for scheduling, is well-founded in public health logic**. It takes advantage of a vaccine (Costaive) that is specifically designed to provide long-lasting protection with one dose[kagaya-clinic.jp](https://www.kagaya-clinic.jp/replicon-vaccine/#:~:text=%E7%89%B9%E5%BE%B4%E3%81%A8%E4%BB%8A%E5%BE%8C%E3%81%AE%E5%8F%AF%E8%83%BD%E6%80%A7), and it uses an existing healthcare interaction to maximize convenience. This should improve vaccination rates and, over time, contribute to COVID-19 being a manageable, routine respiratory illness rather than a series of emergencies. From a system operation standpoint, careful planning will be needed to coordinate between preventive services and vaccination providers, but Japan’s healthcare system is quite capable of such coordinated campaigns (as seen in its rollout of vaccines through local clinics and mass sites in 2021–2022). The key will be clear communication to the public that each year’s health check is also an opportunity to get the COVID shot – this could become a **“new normal”** for preventive healthcare in Japan.

## Domestic Replicon Vaccine vs. Foreign mRNA Vaccines – Scientific and Industrial Considerations

Japan’s strategy of **emphasizing a domestically developed replicon vaccine (Costaive)** as a primary tool, as opposed to relying entirely on foreign-made vaccines (like Pfizer’s or Moderna’s mRNA shots), can be evaluated from both scientific and industrial perspectives. Overall, this strategy has strong merit in several ways:

- **Scientific Efficacy and Innovation:** The replicon vaccine is a **next-generation mRNA technology** that has demonstrated high efficacy. As noted, Costaive produced equal or higher antibody responses compared to Pfizer’s vaccine in trials[jmedj.co.jp](https://www.jmedj.co.jp/journal/paper/detail.php?id=23229#:~:text=%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AF%E6%97%A2%E5%AD%98%E3%81%AEmRNA%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AB%E6%AF%94%E3%81%B9%E5%B0%91%E9%87%8F%E6%8A%95%E4%B8%8E%E3%81%A7%E6%B8%88%E3%81%BF%E3%80%81%E3%82%88%E3%82%8A%E5%8A%B9%E6%9E%9C%E3%81%8C%E6%8C%81%E7%B6%9A%E3%81%99%E3%82%8B%E3%81%A8%E3%81%95%E3%82%8C%E3%82%8B%E3%80%82%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E3%81%AF%E8%BF%BD%E5%8A%A0%E5%85%8D%E7%96%AB%E3%81%AE%E5%9B%BD%E5%86%85%E7%AC%AC3%E7%9B%B8%E8%A9%A6%E9%A8%93%E3%81%A7%E3%80%81%E3%83%95%E3%82%A1%E3%82%A4%E3%82%B6%E3%83%BC%E3%81%AE%E3%82%B3%E3%83%9F%E3%83%8A%E3%83%86%E3%82%A3%E3%81%AB%E6%AF%94%E3%81%B9%20%E6%8A%97%E4%BD%93%E4%BE%A1%E3%81%8C%E9%AB%98%E3%81%8F%E6%8C%81%E7%B6%9A%E6%80%A7%E3%81%AB%E5%84%AA%E3%82%8C%E3%81%A6%E3%81%84%E3%82%8B%E3%81%93%E3%81%A8%E3%81%8C%E7%A2%BA%E8%AA%8D%E3%81%95%E3%82%8C%E3%81%9F%E3%80%82), particularly excelling against Omicron variants[kagaya-clinic.jp](https://www.kagaya-clinic.jp/replicon-vaccine/#:~:text=%E7%89%B9%E5%BE%B4%E3%81%A8%E4%BB%8A%E5%BE%8C%E3%81%AE%E5%8F%AF%E8%83%BD%E6%80%A7). This indicates that scientifically, Japan is not sacrificing quality by using a domestic vaccine – on the contrary, it may be gaining an edge in longer-lasting immunity. Moreover, being the first in the world to approve and use a replicon COVID vaccine is a significant innovation milestone[jmedj.co.jp](https://www.jmedj.co.jp/journal/paper/detail.php?id=23229#:~:text=Meiji%20Seika%E3%83%95%E3%82%A1%E3%83%AB%E3%83%9E%E3%81%AF11%E6%9C%8828%E6%97%A5%E3%80%81%E6%96%B0%E5%9E%8B%E3%82%B3%E3%83%AD%E3%83%8A%E3%82%A6%E3%82%A4%E3%83%AB%E3%82%B9%E6%84%9F%E6%9F%93%E7%97%87%E3%81%AB%E5%AF%BE%E3%81%99%E3%82%8B%E6%AC%A1%E4%B8%96%E4%BB%A3mRNA%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%80%8C%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E7%AD%8B%E6%B3%A8%E7%94%A8%E3%80%8D%E3%81%AB%E3%81%A4%E3%81%84%E3%81%A6%E8%A8%98%E8%80%85%E8%AA%AC%E6%98%8E%E4%BC%9A%E3%82%92%E9%96%8B%E5%82%AC%E3%81%97%E3%81%9F%E3%80%82%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%20%E3%81%AF%E3%80%81%E7%B1%B3%E3%83%90%E3%82%A4%E3%82%AA%E4%BC%81%E6%A5%AD%E3%82%A2%E3%83%BC%E3%82%AF%E3%83%88%E3%82%A5%E3%83%AB%E3%82%B9%E3%83%BB%E3%82%BB%E3%83%A9%E3%83%94%E3%83%A5%E3%83%BC%E3%83%86%E3%82%A3%E3%82%AF%E3%82%B9%E3%81%8C%E9%96%8B%E7%99%BA%E3%81%97%E3%81%9F%E3%80%81%E6%8A%95%E4%B8%8E%E5%BE%8C%E3%81%AB%E4%BD%93%E5%86%85%E3%81%A7mRNA%E3%82%92%E8%87%AA%E5%B7%B1%E8%A4%87%E8%A3%BD%E3%81%99%E3%82%8B%E3%80%8C%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%80%8D%E3%80%82Meiji%20Seika%E3%83%95%E3%82%A1%E3%83%AB%E3%83%9E%E3%81%8C%E5%9B%BD%E5%86%85%E3%81%AE%E4%BE%9B%E7%B5%A6%E3%83%BB%E8%B2%A9%E5%A3%B2%E6%A8%A9%E3%82%92%E5%8F%96%E5%BE%97%E3%81%97%E8%87%A8%E5%BA%8A%E8%A9%A6%E9%A8%93%E3%82%92%E9%80%B2%E3%82%81%E3%80%81%E5%90%8C%E6%97%A5%E3%80%81%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%A8%E3%81%97%E3%81%A6%E4%B8%96%E7%95%8C%E5%88%9D%E3%81%A8%E3%81%AA%E3%82%8B%E8%A3%BD%E9%80%A0%E8%B2%A9%E5%A3%B2%E6%89%BF%E8%AA%8D%E3%82%92%E5%8E%9A%E5%8A%B4%E7%9C%81%E3%82%88%E3%82%8A%E5%8F%96%E5%BE%97%E3%81%97%E3%81%9F%E3%80%82). It shows Japanese science contributing to cutting-edge vaccine development. In the long run, this platform can be quickly updated for new variants (similar to standard mRNA vaccines) and even adapted to other diseases, giving Japan a versatile scientific tool. It’s also worth mentioning that replicon vaccines use a smaller dose, which could reduce side effects and increase manufacturing efficiency. **In short, the scientific foundation for using replicon technology is robust, and it may improve vaccine performance for the population.**
    
- **Supply Security and Geopolitical Stability:** A major rationale for focusing on a domestic vaccine is to **ensure a stable supply independent of international uncertainties**. Relying on multi-national pharmaceutical companies can pose risks – for example, during the initial COVID vaccine rollout, countries like Japan had to wait as the U.S. and Europe, where Pfizer/Moderna are based, prioritized their own populations. Political decisions (export restrictions, diplomatic disputes, or corporate priorities) could delay or limit vaccine shipments to Japan. By having a home-grown vaccine produced on Japanese soil, these risks are minimized. If there were future pandemics or variants, Japan could ramp up its own production without being at the mercy of foreign governments or companies. This is especially pertinent given global political instabilities; even hypothetical scenarios like trade wars or geopolitical tension might affect medical supply chains. A domestic vaccine **insulates Japan from such external shocks**. Meiji Seika Pharma has plans to scale up production capacity significantly – building a new manufacturing facility and aiming for an output of ~100 million doses annually by 2027[jmedj.co.jp](https://www.jmedj.co.jp/journal/paper/detail.php?id=23229#:~:text=%E5%90%8C%E7%A4%BE%E3%81%AF%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E3%81%8C%E8%B5%B7%E6%BA%90%E6%A0%AA%E5%AF%BE%E5%BF%9C%E3%81%AE1%E4%BE%A1%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AE%E3%81%9F%E3%82%81%E4%BB%8A%E5%86%AC%E3%81%AF%E8%B2%A9%E5%A3%B2%E3%81%9B%E3%81%9A%E3%80%81%E6%9D%A5%E5%B9%B4%E3%81%AE%E7%A7%8B%E5%86%AC%E6%8E%A5%E7%A8%AE%E3%81%AB%E5%90%91%E3%81%91%E3%81%9F%E4%BE%9B%E7%B5%A6%E9%96%8B%E5%A7%8B%E3%82%92%E6%83%B3%E5%AE%9A%E3%81%97%E3%81%A6%E8%B5%B7%E6%BA%90%E6%A0%AA%E3%81%A8%E3%82%AA%E3%83%9F%E3%82%AF%E3%83%AD%E3%83%B3%E6%A0%AA%E3%81%AB%E3%82%88%E3%82%8B2%E4%BE%A1%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AE%E9%96%8B%E7%99%BA%E3%82%92%E9%80%B2%E3%82%81%E3%82%8B%E3%80%82%E5%8E%9F%20%E8%96%AC%E3%81%AF%E3%82%A2%E3%83%AB%E3%82%AB%E3%83%AA%E3%82%B9%E7%A4%BE%EF%BC%88%E7%A6%8F%E5%B3%B6%E7%9C%8C%E5%8D%97%E7%9B%B8%E9%A6%AC%E5%B8%82%EF%BC%89%E3%81%8B%E3%82%89%E8%AA%BF%E9%81%94%E3%80%81%E4%BB%8A%E5%BE%8C%E5%9B%BD%E5%86%85%E3%81%AB%E6%96%B0%E8%A3%BD%E9%80%A0%E6%A3%9F%E3%82%92%E5%BB%BA%E8%A8%AD%E3%81%97%E3%80%812027%E5%B9%B4%E3%81%AB%E3%81%AF%E7%B4%841%E5%84%84%E5%9B%9E%E6%8E%A5%E7%A8%AE%E5%88%86%E3%81%AE%E7%94%9F%E7%94%A3%E4%BD%93%E5%88%B6%E3%82%92%E6%A7%8B%E7%AF%89%E3%81%99%E3%82%8B%E6%96%B9%E9%87%9D%E3%80%8228%E6%97%A5%E3%81%AE%E8%AA%AC%E6%98%8E%E4%BC%9A%E3%81%A7%E5%90%8C%E7%A4%BE%E3%81%AE%E5%B0%8F%E6%9E%97%E5%A4%A7%E5%90%89%E9%83%8E%E7%A4%BE%20%E9%95%B7%EF%BC%88%E5%86%99%E7%9C%9F%EF%BC%89%E3%81%AF%E3%80%8C%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E6%95%97%E6%88%A6%E3%81%A8%E6%8F%B6%E6%8F%84%E3%81%95%E3%82%8C%E3%81%9F%E6%88%91%E3%81%8C%E5%9B%BD%E3%81%A7%E3%80%81%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E5%AE%9F%E7%94%A8%E5%8C%96%E3%81%AB%E3%81%8A%E3%81%84%E3%81%A6%E4%B8%96%E7%95%8C%E3%81%AB%E5%85%88%E9%A7%86%E3%81%91%E3%82%8B%E3%81%93%E3%81%A8%E3%81%8C%E3%81%A7%E3%81%8D%E3%81%9F%E3%80%82%E4%BD%95%E3%81%A8%E3%81%8B%E3%82%B4%E3%83%BC%E3%83%AB%E3%81%BE%E3%81%A7%E6%8C%81%E3%81%A3%E3%81%A6%E3%81%84%E3%81%8D%E3%81%9F%E3%81%84%E3%80%8D%E3%81%A8%E5%BC%B7%E8%AA%BF%E3%81%97%E3%81%9F%E3%80%82). This would be enough to cover the Japanese population with room to spare. Achieving vaccine self-sufficiency is a strategic asset for national health security.
    
- **Industrial and Economic Benefits:** Emphasizing a domestic vaccine supports Japan’s biotechnology and pharmaceutical industry. After facing criticism for the “vaccine defeat” (ワクチン敗戦) in the early pandemic – a term used when Japan lagged in vaccine development and had to import all doses – the country has been keen to catch up and even lead in vaccine tech[jmedj.co.jp](https://www.jmedj.co.jp/journal/paper/detail.php?id=23229#:~:text=%E5%90%8C%E7%A4%BE%E3%81%AF%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E3%81%8C%E8%B5%B7%E6%BA%90%E6%A0%AA%E5%AF%BE%E5%BF%9C%E3%81%AE1%E4%BE%A1%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AE%E3%81%9F%E3%82%81%E4%BB%8A%E5%86%AC%E3%81%AF%E8%B2%A9%E5%A3%B2%E3%81%9B%E3%81%9A%E3%80%81%E6%9D%A5%E5%B9%B4%E3%81%AE%E7%A7%8B%E5%86%AC%E6%8E%A5%E7%A8%AE%E3%81%AB%E5%90%91%E3%81%91%E3%81%9F%E4%BE%9B%E7%B5%A6%E9%96%8B%E5%A7%8B%E3%82%92%E6%83%B3%E5%AE%9A%E3%81%97%E3%81%A6%E8%B5%B7%E6%BA%90%E6%A0%AA%E3%81%A8%E3%82%AA%E3%83%9F%E3%82%AF%E3%83%AD%E3%83%B3%E6%A0%AA%E3%81%AB%E3%82%88%E3%82%8B2%E4%BE%A1%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AE%E9%96%8B%E7%99%BA%E3%82%92%E9%80%B2%E3%82%81%E3%82%8B%E3%80%82%E5%8E%9F%20%E8%96%AC%E3%81%AF%E3%82%A2%E3%83%AB%E3%82%AB%E3%83%AA%E3%82%B9%E7%A4%BE%EF%BC%88%E7%A6%8F%E5%B3%B6%E7%9C%8C%E5%8D%97%E7%9B%B8%E9%A6%AC%E5%B8%82%EF%BC%89%E3%81%8B%E3%82%89%E8%AA%BF%E9%81%94%E3%80%81%E4%BB%8A%E5%BE%8C%E5%9B%BD%E5%86%85%E3%81%AB%E6%96%B0%E8%A3%BD%E9%80%A0%E6%A3%9F%E3%82%92%E5%BB%BA%E8%A8%AD%E3%81%97%E3%80%812027%E5%B9%B4%E3%81%AB%E3%81%AF%E7%B4%841%E5%84%84%E5%9B%9E%E6%8E%A5%E7%A8%AE%E5%88%86%E3%81%AE%E7%94%9F%E7%94%A3%E4%BD%93%E5%88%B6%E3%82%92%E6%A7%8B%E7%AF%89%E3%81%99%E3%82%8B%E6%96%B9%E9%87%9D%E3%80%8228%E6%97%A5%E3%81%AE%E8%AA%AC%E6%98%8E%E4%BC%9A%E3%81%A7%E5%90%8C%E7%A4%BE%E3%81%AE%E5%B0%8F%E6%9E%97%E5%A4%A7%E5%90%89%E9%83%8E%E7%A4%BE%20%E9%95%B7%EF%BC%88%E5%86%99%E7%9C%9F%EF%BC%89%E3%81%AF%E3%80%8C%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E6%95%97%E6%88%A6%E3%81%A8%E6%8F%B6%E6%8F%84%E3%81%95%E3%82%8C%E3%81%9F%E6%88%91%E3%81%8C%E5%9B%BD%E3%81%A7%E3%80%81%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E5%AE%9F%E7%94%A8%E5%8C%96%E3%81%AB%E3%81%8A%E3%81%84%E3%81%A6%E4%B8%96%E7%95%8C%E3%81%AB%E5%85%88%E9%A7%86%E3%81%91%E3%82%8B%E3%81%93%E3%81%A8%E3%81%8C%E3%81%A7%E3%81%8D%E3%81%9F%E3%80%82%E4%BD%95%E3%81%A8%E3%81%8B%E3%82%B4%E3%83%BC%E3%83%AB%E3%81%BE%E3%81%A7%E6%8C%81%E3%81%A3%E3%81%A6%E3%81%84%E3%81%8D%E3%81%9F%E3%81%84%E3%80%8D%E3%81%A8%E5%BC%B7%E8%AA%BF%E3%81%97%E3%81%9F%E3%80%82). The success of Costaive is a point of national pride and has been highlighted by officials: _“In our country that was ridiculed as having lost the vaccine race, we have now been able to take the lead globally in practical use of a replicon vaccine”_, said Meiji’s CEO upon its approval[jmedj.co.jp](https://www.jmedj.co.jp/journal/paper/detail.php?id=23229#:~:text=%E5%90%8C%E7%A4%BE%E3%81%AF%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E3%81%8C%E8%B5%B7%E6%BA%90%E6%A0%AA%E5%AF%BE%E5%BF%9C%E3%81%AE1%E4%BE%A1%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AE%E3%81%9F%E3%82%81%E4%BB%8A%E5%86%AC%E3%81%AF%E8%B2%A9%E5%A3%B2%E3%81%9B%E3%81%9A%E3%80%81%E6%9D%A5%E5%B9%B4%E3%81%AE%E7%A7%8B%E5%86%AC%E6%8E%A5%E7%A8%AE%E3%81%AB%E5%90%91%E3%81%91%E3%81%9F%E4%BE%9B%E7%B5%A6%E9%96%8B%E5%A7%8B%E3%82%92%E6%83%B3%E5%AE%9A%E3%81%97%E3%81%A6%E8%B5%B7%E6%BA%90%E6%A0%AA%E3%81%A8%E3%82%AA%E3%83%9F%E3%82%AF%E3%83%AD%E3%83%B3%E6%A0%AA%E3%81%AB%E3%82%88%E3%82%8B2%E4%BE%A1%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AE%E9%96%8B%E7%99%BA%E3%82%92%E9%80%B2%E3%82%81%E3%82%8B%E3%80%82%E5%8E%9F%20%E8%96%AC%E3%81%AF%E3%82%A2%E3%83%AB%E3%82%AB%E3%83%AA%E3%82%B9%E7%A4%BE%EF%BC%88%E7%A6%8F%E5%B3%B6%E7%9C%8C%E5%8D%97%E7%9B%B8%E9%A6%AC%E5%B8%82%EF%BC%89%E3%81%8B%E3%82%89%E8%AA%BF%E9%81%94%E3%80%81%E4%BB%8A%E5%BE%8C%E5%9B%BD%E5%86%85%E3%81%AB%E6%96%B0%E8%A3%BD%E9%80%A0%E6%A3%9F%E3%82%92%E5%BB%BA%E8%A8%AD%E3%81%97%E3%80%812027%E5%B9%B4%E3%81%AB%E3%81%AF%E7%B4%841%E5%84%84%E5%9B%9E%E6%8E%A5%E7%A8%AE%E5%88%86%E3%81%AE%E7%94%9F%E7%94%A3%E4%BD%93%E5%88%B6%E3%82%92%E6%A7%8B%E7%AF%89%E3%81%99%E3%82%8B%E6%96%B9%E9%87%9D%E3%80%8228%E6%97%A5%E3%81%AE%E8%AA%AC%E6%98%8E%E4%BC%9A%E3%81%A7%E5%90%8C%E7%A4%BE%E3%81%AE%E5%B0%8F%E6%9E%97%E5%A4%A7%E5%90%89%E9%83%8E%E7%A4%BE%20%E9%95%B7%EF%BC%88%E5%86%99%E7%9C%9F%EF%BC%89%E3%81%AF%E3%80%8C%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E6%95%97%E6%88%A6%E3%81%A8%E6%8F%B6%E6%8F%84%E3%81%95%E3%82%8C%E3%81%9F%E6%88%91%E3%81%8C%E5%9B%BD%E3%81%A7%E3%80%81%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E5%AE%9F%E7%94%A8%E5%8C%96%E3%81%AB%E3%81%8A%E3%81%84%E3%81%A6%E4%B8%96%E7%95%8C%E3%81%AB%E5%85%88%E9%A7%86%E3%81%91%E3%82%8B%E3%81%93%E3%81%A8%E3%81%8C%E3%81%A7%E3%81%8D%E3%81%9F%E3%80%82%E4%BD%95%E3%81%A8%E3%81%8B%E3%82%B4%E3%83%BC%E3%83%AB%E3%81%BE%E3%81%A7%E6%8C%81%E3%81%A3%E3%81%A6%E3%81%84%E3%81%8D%E3%81%9F%E3%81%84%E3%80%8D%E3%81%A8%E5%BC%B7%E8%AA%BF%E3%81%97%E3%81%9F%E3%80%82). Building up this industry means high-tech jobs, research funding, and expertise remain in-country. In the long term, Japan could even export its vaccine or license the technology, bolstering its standing in global health contributions. Industrially, diversifying vaccine production (with platforms like replicon and protein-based vaccines by domestic companies) ensures competition and possibly lower costs. It also avoids over-reliance on a few foreign firms which might dictate prices or terms.
    
- **Reduced Dependency & Political Leverage:** Depending on foreign pharmaceutical companies (Pfizer, Moderna, etc.) also means that Japan is indirectly subject to the political climate of those companies’ home countries. For instance, if there were political pressure in the US or Europe to raise vaccine prices, limit supply, or even leverage vaccine deals in diplomatic negotiations, it could put Japan in a vulnerable position. By establishing a **domestic vaccine as the mainstay**, Japan gains greater control over its vaccination program. The government can make policy decisions (such as the annual free booster program) without worrying about whether overseas shipments will arrive on time or whether contracts will be honored under all circumstances. The COVID pandemic showed how vaccine access could become a geopolitical tool; a domestic strategy avoids being entangled in that. Additionally, a **stable domestic supply** can be more reliably integrated into Japan’s healthcare system and planning. There’s less uncertainty each year about procurement, which helps in logistics (as seen with the smooth start of the 2024 routine program where multiple domestic options, including Costaive, were available).
    

In evaluating the strategy, we should also consider potential **challenges or caveats**. One is that replicon vaccines are new – while trials have shown no major safety issues (the side effect profile of Costaive was similar to Pfizer’s, with common reactions like injection-site pain, fatigue, headache, etc., at comparable rates[kagaya-clinic.jp](https://www.kagaya-clinic.jp/replicon-vaccine/#:~:text=%E8%87%A8%E5%BA%8A%E8%A9%A6%E9%A8%93%E3%81%AB%E3%81%8A%E3%81%84%E3%81%A6%E3%80%81%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%EF%BC%88%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%EF%BC%89%E3%81%AF%E6%9C%89%E5%8A%B9%E6%80%A7%E3%81%A8%E5%85%8D%E7%96%AB%E5%8E%9F%E6%80%A7%E3%81%8C%E7%A2%BA%E8%AA%8D%E3%81%95%E3%82%8C%E3%81%A6%E3%81%84%E3%81%BE%E3%81%99%E3%80%82%20%E4%B8%BB%E3%81%AA%E5%89%AF%E5%8F%8D%E5%BF%9C%E3%81%AF%E4%BB%A5%E4%B8%8B%E3%81%AE%E9%80%9A%E3%82%8A%E3%81%A7%E3%81%99%EF%BC%9A)), we lack long-term safety data simply because the technology is recent[kagaya-clinic.jp](https://www.kagaya-clinic.jp/replicon-vaccine/#:~:text=Image%EF%BC%83%E3%83%88%E3%82%B8%E3%83%8A%E3%83%A1%E3%83%A9%E3%83%B3%3D%E3%83%95%E3%82%A1%E3%82%A4%E3%82%B6%E3%83%BC%E8%A3%BD%E3%82%B3%E3%83%AD%E3%83%8A%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3). Ongoing pharmacovigilance is important to maintain public trust. Japan’s heightened scrutiny of vaccine safety means any adverse events will be closely watched. Another consideration is flexibility: even with a domestic focus, Japan should remain open to using foreign vaccines if needed (for example, if a radically new variant emerged and a foreign company’s vaccine addressed it first, or if additional doses were needed quickly). In other words, the **best strategy is not isolationist but rather “domestic-first, with diversity as backup.”** Fortunately, Japan has approved multiple vaccines (Pfizer, Moderna, Novavax, Daiichi Sankyo’s protein vaccine, etc., in addition to Meiji’s)[mhlw.go.jp](https://www.mhlw.go.jp/content/10900000/001305412.pdf#:~:text=Meiji%20Seika%E3%83%95%E3%82%A1%E3%83%AB%E3%83%9E%20%E6%A0%AA%E5%BC%8F%E4%BC%9A%E7%A4%BE%20%E8%B2%A9%E5%A3%B2%E5%90%8D%20%E3%82%B3%E3%83%9F%E3%83%8A%E3%83%86%E3%82%A3%C2%AE,%EF%BD%8DRNA%EF%BC%88%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%EF%BC%89%20%E8%96%AC%E4%BA%8B%E6%89%BF%E8%AA%8D%E3%81%AE%20%E7%8A%B6%E6%B3%81%20%E4%BB%A4%E5%92%8C%EF%BC%96%E5%B9%B4%EF%BC%98%E6%9C%88%EF%BC%98%E6%97%A5%20%E4%B8%80%E5%A4%89%E6%89%BF%E8%AA%8D%EF%BC%8A)[mhlw.go.jp](https://www.mhlw.go.jp/content/10900000/001305412.pdf#:~:text=%E8%B2%A9%E5%A3%B2%E5%90%8D%20%E3%82%B3%E3%83%9F%E3%83%8A%E3%83%86%E3%82%A3%C2%AE%20%E3%82%B9%E3%83%91%E3%82%A4%E3%82%AF%E3%83%90%E3%83%83%E3%82%AF%E3%82%B9%C2%AE%20%E3%83%80%E3%82%A4%E3%83%81%E3%83%AD%E3%83%8A%C2%AE%20%E3%83%8C%E3%83%90%E3%82%AD%E3%82%BD%E3%83%93%E3%83%83%E3%83%89%C2%AE,%E7%8A%B6%E6%B3%81%20%E4%BB%A4%E5%92%8C%EF%BC%96%E5%B9%B4%EF%BC%98%E6%9C%88%EF%BC%98%E6%97%A5%20%E4%B8%80%E5%A4%89%E6%89%BF%E8%AA%8D%EF%BC%8A%20%E4%BB%A4%E5%92%8C%EF%BC%96%E5%B9%B4%EF%BC%98%E6%9C%8823%E6%97%A5%20%E4%B8%80%E5%A4%89%E6%89%BF%E8%AA%8D%EF%BC%8A). This diversified portfolio is wise. Costaive may be the backbone, but others can be called upon as needed – for example, people who cannot take mRNA-type vaccines might use Novavax.

 

Comparing to the scenario of continued reliance on Pfizer/Moderna: those mRNA vaccines are highly effective as well, but there have been instances of supply fluctuations and they are expensive (often requiring government negotiation each year for purchase). There’s also the aspect of national pride and public trust: a domestically made vaccine could improve confidence among a segment of the population that is skeptical of foreign vaccines. (However, it must be noted that _any_ vaccine can face skepticism – in fact, Costaive itself was subject to some misinformation online, such as unfounded rumors about “shedding,” which Meiji had to actively dispel[fsight.jp](https://www.fsight.jp/articles/-/50989#:~:text=%E6%98%8E%E6%B2%BBHD%E4%BA%8B%E6%A5%AD%E5%AD%90%E4%BC%9A%E7%A4%BE%E3%81%AEMeiji%20Seika%20%E3%83%95%E3%82%A1%E3%83%AB%E3%83%9E%E3%81%8C%E9%96%8B%E7%99%BA%E3%81%97%E3%81%9F%E3%82%B3%E3%83%AD%E3%83%8A%E3%82%A6%E3%82%A4%E3%83%AB%E3%82%B9%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%80%8C%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E3%80%8D%E3%81%8C%E4%B8%96%E9%96%93%E3%81%AE%E9%96%A2%E5%BF%83%E3%82%92%E9%9B%86%E3%82%81%E3%81%A6%E3%81%84%E3%82%8B%E3%80%82SNS%E3%81%AB%E3%81%AF%E3%80%81%E3%80%8C%E3%82%B7%E3%82%A7%E3%83%87%E3%82%A3%E3%83%B3%E3%82%B0%E3%81%AB%E3%82%88%E3%82%8A%E3%80%81%E3%83%AF%20%E3%82%AF%E3%83%81%E3%83%B3%E6%8E%A5%E7%A8%AE%E8%80%85%E3%81%8B%E3%82%89%E5%91%A8%E5%9B%B2%E3%81%AB%E6%84%9F%E6%9F%93%E3%81%95%E3%81%9B%E3%82%8B%E3%80%8D%E3%81%AA%E3%81%A9%E3%81%AE%E3%83%87%E3%83%9E%E3%81%8C%E6%B0%BE%E6%BF%AB%E3%81%97%E3%81%A6%E3%81%84%E3%82%8B%E3%80%82%E3%80%8C%E3%82%B7%E3%82%A7%E3%83%87%E3%82%A3%E3%83%B3%E3%82%B0%E3%80%8D%E3%81%A8%E3%81%AF%E3%80%81%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E3%81%8C%E4%BD%93%E5%86%85%E3%81%A7%E5%A2%97%E6%AE%96%E3%81%97%E3%81%9F%E5%BE%8C%E3%80%81%E3%81%9D%E3%81%AE%E4%B8%80%E9%83%A8%E3%81%8C%E5%AF%BE%E5%A4%96%E3%81%AB%E6%94%BE%E5%87%BA%E3%81%95%E3%82%8C%E3%80%81%E5%91%A8%E5%9B%B2%E3%81%AB%E3%81%84%E3%82%8B%E4%BA%BA%E3%81%AB%E6%82%AA%E5%BD%B1%E9%9F%BF%E3%82%92%20%E4%B8%8E%E3%81%88%E3%82%8B%E3%81%93%E3%81%A8%E3%81%A0%E3%81%8C%E3%80%81%E3%81%93%E3%81%AE%E3%81%93%E3%81%A8%E3%82%92%E6%94%AF%E6%8C%81%E3%81%99%E3%82%8B%E7%A7%91%E5%AD%A6%E7%9A%84%E3%81%AA%E6%A0%B9%E6%8B%A0%E3%81%AF%E3%81%AA%E3%81%84%E3%80%82). Building trust will require transparency and education irrespective of origin.)

 

**In conclusion**, emphasizing a domestic replicon vaccine as Japan’s main COVID-19 vaccine is **both scientifically and strategically justified**. It provides an effective, cutting-edge solution to protect public health, while also strengthening Japan’s biosecurity and pharmaceutical independence. The strategy mitigates political risks associated with foreign supply chains and ensures that Japan can manage its vaccination needs even amid global uncertainties. It also turns a lesson from the pandemic (the need for domestic R&D capacity) into a forward-looking policy. As long as authorities continue to rigorously monitor safety and remain adaptable, the focus on a domestic replicon vaccine like Costaive stands out as a prudent approach with significant public health and industrial benefits for Japan[jmedj.co.jp](https://www.jmedj.co.jp/journal/paper/detail.php?id=23229#:~:text=%E5%90%8C%E7%A4%BE%E3%81%AF%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E3%81%8C%E8%B5%B7%E6%BA%90%E6%A0%AA%E5%AF%BE%E5%BF%9C%E3%81%AE1%E4%BE%A1%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AE%E3%81%9F%E3%82%81%E4%BB%8A%E5%86%AC%E3%81%AF%E8%B2%A9%E5%A3%B2%E3%81%9B%E3%81%9A%E3%80%81%E6%9D%A5%E5%B9%B4%E3%81%AE%E7%A7%8B%E5%86%AC%E6%8E%A5%E7%A8%AE%E3%81%AB%E5%90%91%E3%81%91%E3%81%9F%E4%BE%9B%E7%B5%A6%E9%96%8B%E5%A7%8B%E3%82%92%E6%83%B3%E5%AE%9A%E3%81%97%E3%81%A6%E8%B5%B7%E6%BA%90%E6%A0%AA%E3%81%A8%E3%82%AA%E3%83%9F%E3%82%AF%E3%83%AD%E3%83%B3%E6%A0%AA%E3%81%AB%E3%82%88%E3%82%8B2%E4%BE%A1%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AE%E9%96%8B%E7%99%BA%E3%82%92%E9%80%B2%E3%82%81%E3%82%8B%E3%80%82%E5%8E%9F%20%E8%96%AC%E3%81%AF%E3%82%A2%E3%83%AB%E3%82%AB%E3%83%AA%E3%82%B9%E7%A4%BE%EF%BC%88%E7%A6%8F%E5%B3%B6%E7%9C%8C%E5%8D%97%E7%9B%B8%E9%A6%AC%E5%B8%82%EF%BC%89%E3%81%8B%E3%82%89%E8%AA%BF%E9%81%94%E3%80%81%E4%BB%8A%E5%BE%8C%E5%9B%BD%E5%86%85%E3%81%AB%E6%96%B0%E8%A3%BD%E9%80%A0%E6%A3%9F%E3%82%92%E5%BB%BA%E8%A8%AD%E3%81%97%E3%80%812027%E5%B9%B4%E3%81%AB%E3%81%AF%E7%B4%841%E5%84%84%E5%9B%9E%E6%8E%A5%E7%A8%AE%E5%88%86%E3%81%AE%E7%94%9F%E7%94%A3%E4%BD%93%E5%88%B6%E3%82%92%E6%A7%8B%E7%AF%89%E3%81%99%E3%82%8B%E6%96%B9%E9%87%9D%E3%80%8228%E6%97%A5%E3%81%AE%E8%AA%AC%E6%98%8E%E4%BC%9A%E3%81%A7%E5%90%8C%E7%A4%BE%E3%81%AE%E5%B0%8F%E6%9E%97%E5%A4%A7%E5%90%89%E9%83%8E%E7%A4%BE%20%E9%95%B7%EF%BC%88%E5%86%99%E7%9C%9F%EF%BC%89%E3%81%AF%E3%80%8C%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E6%95%97%E6%88%A6%E3%81%A8%E6%8F%B6%E6%8F%84%E3%81%95%E3%82%8C%E3%81%9F%E6%88%91%E3%81%8C%E5%9B%BD%E3%81%A7%E3%80%81%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E5%AE%9F%E7%94%A8%E5%8C%96%E3%81%AB%E3%81%8A%E3%81%84%E3%81%A6%E4%B8%96%E7%95%8C%E3%81%AB%E5%85%88%E9%A7%86%E3%81%91%E3%82%8B%E3%81%93%E3%81%A8%E3%81%8C%E3%81%A7%E3%81%8D%E3%81%9F%E3%80%82%E4%BD%95%E3%81%A8%E3%81%8B%E3%82%B4%E3%83%BC%E3%83%AB%E3%81%BE%E3%81%A7%E6%8C%81%E3%81%A3%E3%81%A6%E3%81%84%E3%81%8D%E3%81%9F%E3%81%84%E3%80%8D%E3%81%A8%E5%BC%B7%E8%AA%BF%E3%81%97%E3%81%9F%E3%80%82)[jmedj.co.jp](https://www.jmedj.co.jp/journal/paper/detail.php?id=23229#:~:text=%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AF%E6%97%A2%E5%AD%98%E3%81%AEmRNA%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AB%E6%AF%94%E3%81%B9%E5%B0%91%E9%87%8F%E6%8A%95%E4%B8%8E%E3%81%A7%E6%B8%88%E3%81%BF%E3%80%81%E3%82%88%E3%82%8A%E5%8A%B9%E6%9E%9C%E3%81%8C%E6%8C%81%E7%B6%9A%E3%81%99%E3%82%8B%E3%81%A8%E3%81%95%E3%82%8C%E3%82%8B%E3%80%82%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E3%81%AF%E8%BF%BD%E5%8A%A0%E5%85%8D%E7%96%AB%E3%81%AE%E5%9B%BD%E5%86%85%E7%AC%AC3%E7%9B%B8%E8%A9%A6%E9%A8%93%E3%81%A7%E3%80%81%E3%83%95%E3%82%A1%E3%82%A4%E3%82%B6%E3%83%BC%E3%81%AE%E3%82%B3%E3%83%9F%E3%83%8A%E3%83%86%E3%82%A3%E3%81%AB%E6%AF%94%E3%81%B9%20%E6%8A%97%E4%BD%93%E4%BE%A1%E3%81%8C%E9%AB%98%E3%81%8F%E6%8C%81%E7%B6%9A%E6%80%A7%E3%81%AB%E5%84%AA%E3%82%8C%E3%81%A6%E3%81%84%E3%82%8B%E3%81%93%E3%81%A8%E3%81%8C%E7%A2%BA%E8%AA%8D%E3%81%95%E3%82%8C%E3%81%9F%E3%80%82).

 

**Sources:**

1. WHO TAG-VE announcement on NB.1.8.1 variant under monitoring (May 2025)[cidrap.umn.edu](https://www.cidrap.umn.edu/covid-19/who-adds-nb181-sars-cov-2-variant-under-monitoring#:~:text=The%20World%20Health%20Organization%20,1%20sublineage)[cidrap.umn.edu](https://www.cidrap.umn.edu/covid-19/who-adds-nb181-sars-cov-2-variant-under-monitoring#:~:text=The%20experts%20said%20NB,those%20from%20other%20circulating%20variants)[cidrap.umn.edu](https://www.cidrap.umn.edu/covid-19/who-adds-nb181-sars-cov-2-variant-under-monitoring#:~:text=On%20May%2015%2C%20the%20WHO%27s,1%20component).
    
2. CBS News – _“New COVID variant NB.1.8.1 behind surge in China, now detected in U.S.”_ (May 23, 2025)[cbsnews.com](https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/#:~:text=Experts%20have%20been%20closely%20watching,19)[cbsnews.com](https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/#:~:text=While%20authorities%20in%20Hong%20Kong,places%20as%20cases%20have%20climbed)[cbsnews.com](https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/#:~:text=epidemic%20wave)[cbsnews.com](https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/#:~:text=Vaccines%20from%20last%20season%20targeted,1%2C%20too).
    
3. WHO Initial Risk Evaluation for NB.1.8.1 (May 2025)[cdn.who.int](https://cdn.who.int/media/docs/default-source/documents/epp/tracking-sars-cov-2/23052025_nb.1.8.1_ire.pdf#:~:text=globally%2C%20while%20LP,than%20other%20variants%20in%20circulation)[cdn.who.int](https://cdn.who.int/media/docs/default-source/documents/epp/tracking-sars-cov-2/23052025_nb.1.8.1_ire.pdf#:~:text=,5%2C6).
    
4. Ministry of Health, Labour and Welfare (Japan) – Materials on routine COVID-19 vaccination (Sept 2024)[mhlw.go.jp](https://www.mhlw.go.jp/content/10900000/001305412.pdf#:~:text=Meiji%20Seika%E3%83%95%E3%82%A1%E3%83%AB%E3%83%9E%20%E6%A0%AA%E5%BC%8F%E4%BC%9A%E7%A4%BE%20%E8%B2%A9%E5%A3%B2%E5%90%8D%20%E3%82%B3%E3%83%9F%E3%83%8A%E3%83%86%E3%82%A3%C2%AE,%EF%BD%8DRNA%EF%BC%88%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%EF%BC%89%20%E8%96%AC%E4%BA%8B%E6%89%BF%E8%AA%8D%E3%81%AE%20%E7%8A%B6%E6%B3%81%20%E4%BB%A4%E5%92%8C%EF%BC%96%E5%B9%B4%EF%BC%98%E6%9C%88%EF%BC%98%E6%97%A5%20%E4%B8%80%E5%A4%89%E6%89%BF%E8%AA%8D%EF%BC%8A)[mhlw.go.jp](https://www.mhlw.go.jp/content/10900000/001305412.pdf#:~:text=%E2%97%8B%20%E3%83%95%E3%82%A1%E3%82%A4%E3%82%B6%E3%83%BC%E7%A4%BE%E3%80%81%E3%83%A2%E3%83%87%E3%83%AB%E3%83%8A%E7%A4%BE%E3%80%81%E7%AC%AC%E4%B8%80%E4%B8%89%E5%85%B1%E7%A4%BE%E3%80%81%E6%AD%A6%E7%94%B0%E8%96%AC%E5%93%81%E5%B7%A5%E6%A5%AD%E7%A4%BE%E3%81%AE%EF%BC%94%E7%A4%BE%E3%81%AB%E3%81%A4%E3%81%84%E3%81%A6%E3%81%AF%E3%80%81%E4%BB%A4%E5%92%8C%EF%BC%95%E5%B9%B4%E5%BA%A6%E3%81%BE%E3%81%A7%E3%81%AE%E8%87%A8%E6%99%82%E6%8E%A5%E7%A8%AE%E3%81%A7%E3%81%99%E3%81%A7%E3%81%AB%E4%BD%BF%E7%94%A8%E3%81%97%E3%81%9F%E3%83%AF%E3%82%AF%E3%83%81%20%E3%83%B3%E3%81%AB%E3%81%8A%E3%81%91%E3%82%8B%E3%80%81JN,1%E7%B3%BB%E7%B5%B1%E5%AF%BE%E5%BF%9C%E3%81%AB%E4%BF%82%E3%82%8B%E6%89%BF%E8%AA%8D%E4%BA%8B%E9%A0%85%E4%B8%80%E9%83%A8%E5%A4%89%E6%9B%B4%E3%82%92%E5%8F%96%E5%BE%97%E3%81%97%E3%81%9F%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%8C%E4%BE%9B%E7%B5%A6%E3%81%95%E3%82%8C%E3%82%8B%E8%A6%8B%E9%80%9A%E3%81%97%E3%81%A7%E3%81%82%E3%82%8B%E3%80%82%2017).
    
5. Kagaya Clinic (Chiba) – Explanation of replicon vaccine (Costaive) and its use in routine vaccination[kagaya-clinic.jp](https://www.kagaya-clinic.jp/replicon-vaccine/#:~:text=%E7%89%B9%E5%BE%B4%E3%81%A8%E4%BB%8A%E5%BE%8C%E3%81%AE%E5%8F%AF%E8%83%BD%E6%80%A7)[kagaya-clinic.jp](https://www.kagaya-clinic.jp/replicon-vaccine/#:~:text=%E5%AF%BE%E3%81%97%E3%81%A6%E3%81%AF%E5%84%AA%E3%82%8C%E3%82%8B%E3%81%93%E3%81%A8%E3%81%8C%E7%A2%BA%E8%AA%8D%E3%81%95%E3%82%8C%E3%81%BE%E3%81%97%E3%81%9F%E3%80%82).
    
6. JMED News – Meiji’s press briefing on Costaive approval (Nov 28, 2023)[jmedj.co.jp](https://www.jmedj.co.jp/journal/paper/detail.php?id=23229#:~:text=%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AF%E6%97%A2%E5%AD%98%E3%81%AEmRNA%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AB%E6%AF%94%E3%81%B9%E5%B0%91%E9%87%8F%E6%8A%95%E4%B8%8E%E3%81%A7%E6%B8%88%E3%81%BF%E3%80%81%E3%82%88%E3%82%8A%E5%8A%B9%E6%9E%9C%E3%81%8C%E6%8C%81%E7%B6%9A%E3%81%99%E3%82%8B%E3%81%A8%E3%81%95%E3%82%8C%E3%82%8B%E3%80%82%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E3%81%AF%E8%BF%BD%E5%8A%A0%E5%85%8D%E7%96%AB%E3%81%AE%E5%9B%BD%E5%86%85%E7%AC%AC3%E7%9B%B8%E8%A9%A6%E9%A8%93%E3%81%A7%E3%80%81%E3%83%95%E3%82%A1%E3%82%A4%E3%82%B6%E3%83%BC%E3%81%AE%E3%82%B3%E3%83%9F%E3%83%8A%E3%83%86%E3%82%A3%E3%81%AB%E6%AF%94%E3%81%B9%20%E6%8A%97%E4%BD%93%E4%BE%A1%E3%81%8C%E9%AB%98%E3%81%8F%E6%8C%81%E7%B6%9A%E6%80%A7%E3%81%AB%E5%84%AA%E3%82%8C%E3%81%A6%E3%81%84%E3%82%8B%E3%81%93%E3%81%A8%E3%81%8C%E7%A2%BA%E8%AA%8D%E3%81%95%E3%82%8C%E3%81%9F%E3%80%82)[jmedj.co.jp](https://www.jmedj.co.jp/journal/paper/detail.php?id=23229#:~:text=%E5%90%8C%E7%A4%BE%E3%81%AF%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E3%81%8C%E8%B5%B7%E6%BA%90%E6%A0%AA%E5%AF%BE%E5%BF%9C%E3%81%AE1%E4%BE%A1%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AE%E3%81%9F%E3%82%81%E4%BB%8A%E5%86%AC%E3%81%AF%E8%B2%A9%E5%A3%B2%E3%81%9B%E3%81%9A%E3%80%81%E6%9D%A5%E5%B9%B4%E3%81%AE%E7%A7%8B%E5%86%AC%E6%8E%A5%E7%A8%AE%E3%81%AB%E5%90%91%E3%81%91%E3%81%9F%E4%BE%9B%E7%B5%A6%E9%96%8B%E5%A7%8B%E3%82%92%E6%83%B3%E5%AE%9A%E3%81%97%E3%81%A6%E8%B5%B7%E6%BA%90%E6%A0%AA%E3%81%A8%E3%82%AA%E3%83%9F%E3%82%AF%E3%83%AD%E3%83%B3%E6%A0%AA%E3%81%AB%E3%82%88%E3%82%8B2%E4%BE%A1%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AE%E9%96%8B%E7%99%BA%E3%82%92%E9%80%B2%E3%82%81%E3%82%8B%E3%80%82%E5%8E%9F%20%E8%96%AC%E3%81%AF%E3%82%A2%E3%83%AB%E3%82%AB%E3%83%AA%E3%82%B9%E7%A4%BE%EF%BC%88%E7%A6%8F%E5%B3%B6%E7%9C%8C%E5%8D%97%E7%9B%B8%E9%A6%AC%E5%B8%82%EF%BC%89%E3%81%8B%E3%82%89%E8%AA%BF%E9%81%94%E3%80%81%E4%BB%8A%E5%BE%8C%E5%9B%BD%E5%86%85%E3%81%AB%E6%96%B0%E8%A3%BD%E9%80%A0%E6%A3%9F%E3%82%92%E5%BB%BA%E8%A8%AD%E3%81%97%E3%80%812027%E5%B9%B4%E3%81%AB%E3%81%AF%E7%B4%841%E5%84%84%E5%9B%9E%E6%8E%A5%E7%A8%AE%E5%88%86%E3%81%AE%E7%94%9F%E7%94%A3%E4%BD%93%E5%88%B6%E3%82%92%E6%A7%8B%E7%AF%89%E3%81%99%E3%82%8B%E6%96%B9%E9%87%9D%E3%80%8228%E6%97%A5%E3%81%AE%E8%AA%AC%E6%98%8E%E4%BC%9A%E3%81%A7%E5%90%8C%E7%A4%BE%E3%81%AE%E5%B0%8F%E6%9E%97%E5%A4%A7%E5%90%89%E9%83%8E%E7%A4%BE%20%E9%95%B7%EF%BC%88%E5%86%99%E7%9C%9F%EF%BC%89%E3%81%AF%E3%80%8C%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E6%95%97%E6%88%A6%E3%81%A8%E6%8F%B6%E6%8F%84%E3%81%95%E3%82%8C%E3%81%9F%E6%88%91%E3%81%8C%E5%9B%BD%E3%81%A7%E3%80%81%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E5%AE%9F%E7%94%A8%E5%8C%96%E3%81%AB%E3%81%8A%E3%81%84%E3%81%A6%E4%B8%96%E7%95%8C%E3%81%AB%E5%85%88%E9%A7%86%E3%81%91%E3%82%8B%E3%81%93%E3%81%A8%E3%81%8C%E3%81%A7%E3%81%8D%E3%81%9F%E3%80%82%E4%BD%95%E3%81%A8%E3%81%8B%E3%82%B4%E3%83%BC%E3%83%AB%E3%81%BE%E3%81%A7%E6%8C%81%E3%81%A3%E3%81%A6%E3%81%84%E3%81%8D%E3%81%9F%E3%81%84%E3%80%8D%E3%81%A8%E5%BC%B7%E8%AA%BF%E3%81%97%E3%81%9F%E3%80%82).
    
7. Foresight (Shinchosha) – Commentary on Costaive and vaccine policy (Nov 2024)[fsight.jp](https://www.fsight.jp/articles/-/50989#:~:text=%E5%8C%BB%E7%99%82%E7%8F%BE%E5%A0%B4%E3%81%AF%E7%8F%BE%E6%99%82%E7%82%B9%E3%81%A7%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E3%82%92%E6%B1%82%E3%82%81%E3%81%A6%E3%81%84%E3%81%AA%E3%81%84%E3%80%82%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E3%81%AE%E5%8F%AF%E8%83%BD%E6%80%A7%E3%81%AF%E9%AB%98%E3%81%8F%E8%A9%95%E4%BE%A1%E3%81%95%E3%82%8C%E3%82%8B%E3%81%B9%E3%81%8D%E3%81%A0%E3%81%8C%E3%80%81%E4%B8%8D%E5%8D%81%E5%88%86%E3%81%AA%E8%87%A8%E5%BA%8A%E8%A9%A6%E9%A8%93%E3%81%A7%E3%80%8C%E4%BB%AE%E5%85%8D%E8%A8%B1%E3%80%8D%E3%82%92%E4%B8%8E%E3%81%88%E3%82%8B%E7%90%86%E7%94%B1%E3%81%AF%E3%81%AA%E3%81%84%E3%80%82%E3%81%93%E3%82%8C%E3%81%AF2015%E5%B9%B4%E3%81%AB%E7%99%BA%E8%A6%9A%E3%81%97%20%E3%81%9F%E5%8C%96%E5%AD%A6%E5%8F%8A%E8%A1%80%E6%B8%85%E7%99%82%E6%B3%95%E7%A0%94%E7%A9%B6%E6%89%80%EF%BC%88%E5%8C%96%E8%A1%80%E7%A0%94%EF%BC%89%E3%81%AE%E4%B8%8D%E7%A5%A5%E4%BA%8B%E3%81%A7%E3%80%81%E6%98%8E%E6%B2%BBHD%E3%81%8C%E5%8E%9A%E5%8A%B4%E7%9C%81%E3%81%AB%E4%BD%9C%E3%81%A3%E3%81%9F%E3%80%8C%E8%B2%B8%E3%81%97%E3%80%8D%E3%81%8C%E8%BF%94%E3%81%95%E3%82%8C%E3%81%9F%E3%81%A8%E3%81%84%E3%81%86%E3%81%93%E3%81%A8%E3%81%8B%E3%80%82%E4%BB%AE%E3%81%AB%E3%81%9D%E3%81%86%E3%81%AA%E3%82%89%E3%80%81%E4%B8%96%E7%95%8C%E3%81%A7%E6%9C%80%E3%82%82%E6%A0%B9%E6%B7%B1%E3%81%84%E6%97%A5%E6%9C%AC%E7%A4%BE%E4%BC%9A%E3%81%AE%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AB%E5%AF%BE%E3%81%99%E3%82%8B%E4%B8%8D%E4%BF%A1%20%E6%84%9F%E3%81%AF%E3%80%81%E3%81%95%E3%82%89%E3%81%AB%E5%A2%97%E3%81%99%E3%81%B0%E3%81%8B%E3%82%8A%E3%81%A0%E3%82%8D%E3%81%86%E3%80%82)[fsight.jp](https://www.fsight.jp/articles/-/50989#:~:text=%E6%98%8E%E6%B2%BBHD%E4%BA%8B%E6%A5%AD%E5%AD%90%E4%BC%9A%E7%A4%BE%E3%81%AEMeiji%20Seika%20%E3%83%95%E3%82%A1%E3%83%AB%E3%83%9E%E3%81%8C%E9%96%8B%E7%99%BA%E3%81%97%E3%81%9F%E3%82%B3%E3%83%AD%E3%83%8A%E3%82%A6%E3%82%A4%E3%83%AB%E3%82%B9%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%80%8C%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E3%80%8D%E3%81%8C%E4%B8%96%E9%96%93%E3%81%AE%E9%96%A2%E5%BF%83%E3%82%92%E9%9B%86%E3%82%81%E3%81%A6%E3%81%84%E3%82%8B%E3%80%82SNS%E3%81%AB%E3%81%AF%E3%80%81%E3%80%8C%E3%82%B7%E3%82%A7%E3%83%87%E3%82%A3%E3%83%B3%E3%82%B0%E3%81%AB%E3%82%88%E3%82%8A%E3%80%81%E3%83%AF%20%E3%82%AF%E3%83%81%E3%83%B3%E6%8E%A5%E7%A8%AE%E8%80%85%E3%81%8B%E3%82%89%E5%91%A8%E5%9B%B2%E3%81%AB%E6%84%9F%E6%9F%93%E3%81%95%E3%81%9B%E3%82%8B%E3%80%8D%E3%81%AA%E3%81%A9%E3%81%AE%E3%83%87%E3%83%9E%E3%81%8C%E6%B0%BE%E6%BF%AB%E3%81%97%E3%81%A6%E3%81%84%E3%82%8B%E3%80%82%E3%80%8C%E3%82%B7%E3%82%A7%E3%83%87%E3%82%A3%E3%83%B3%E3%82%B0%E3%80%8D%E3%81%A8%E3%81%AF%E3%80%81%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E3%81%8C%E4%BD%93%E5%86%85%E3%81%A7%E5%A2%97%E6%AE%96%E3%81%97%E3%81%9F%E5%BE%8C%E3%80%81%E3%81%9D%E3%81%AE%E4%B8%80%E9%83%A8%E3%81%8C%E5%AF%BE%E5%A4%96%E3%81%AB%E6%94%BE%E5%87%BA%E3%81%95%E3%82%8C%E3%80%81%E5%91%A8%E5%9B%B2%E3%81%AB%E3%81%84%E3%82%8B%E4%BA%BA%E3%81%AB%E6%82%AA%E5%BD%B1%E9%9F%BF%E3%82%92%20%E4%B8%8E%E3%81%88%E3%82%8B%E3%81%93%E3%81%A8%E3%81%A0%E3%81%8C%E3%80%81%E3%81%93%E3%81%AE%E3%81%93%E3%81%A8%E3%82%92%E6%94%AF%E6%8C%81%E3%81%99%E3%82%8B%E7%A7%91%E5%AD%A6%E7%9A%84%E3%81%AA%E6%A0%B9%E6%8B%A0%E3%81%AF%E3%81%AA%E3%81%84%E3%80%82).
    

引用

[

WHO adds NB.1.8.1 as SARS-CoV-2 variant under monitoring | CIDRAP

https://www.cidrap.umn.edu/covid-19/who-adds-nb181-sars-cov-2-variant-under-monitoring

](https://www.cidrap.umn.edu/covid-19/who-adds-nb181-sars-cov-2-variant-under-monitoring#:~:text=The%20World%20Health%20Organization%20,1%20sublineage)[

![Favicon](https://www.google.com/s2/favicons?domain=https://www.cbsnews.com&sz=32)

New COVID variant NB.1.8.1 behind surge in China, now detected in U.S. - CBS News

https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/

](https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/#:~:text=Experts%20have%20been%20closely%20watching,19)[

![Favicon](https://www.google.com/s2/favicons?domain=https://www.cbsnews.com&sz=32)

New COVID variant NB.1.8.1 behind surge in China, now detected in U.S. - CBS News

https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/

](https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/#:~:text=While%20authorities%20in%20Hong%20Kong,places%20as%20cases%20have%20climbed)[

WHO adds NB.1.8.1 as SARS-CoV-2 variant under monitoring | CIDRAP

https://www.cidrap.umn.edu/covid-19/who-adds-nb181-sars-cov-2-variant-under-monitoring

](https://www.cidrap.umn.edu/covid-19/who-adds-nb181-sars-cov-2-variant-under-monitoring#:~:text=The%20experts%20said%20NB,those%20from%20other%20circulating%20variants)[

![Favicon](https://www.google.com/s2/favicons?domain=https://www.cbsnews.com&sz=32)

New COVID variant NB.1.8.1 behind surge in China, now detected in U.S. - CBS News

https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/

](https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/#:~:text=epidemic%20wave)[

WHO adds NB.1.8.1 as SARS-CoV-2 variant under monitoring | CIDRAP

https://www.cidrap.umn.edu/covid-19/who-adds-nb181-sars-cov-2-variant-under-monitoring

](https://www.cidrap.umn.edu/covid-19/who-adds-nb181-sars-cov-2-variant-under-monitoring#:~:text=NB,Western%20Pacific%2C%20Americas%2C%20and%20European)[

WHO adds NB.1.8.1 as SARS-CoV-2 variant under monitoring | CIDRAP

https://www.cidrap.umn.edu/covid-19/who-adds-nb181-sars-cov-2-variant-under-monitoring

](https://www.cidrap.umn.edu/covid-19/who-adds-nb181-sars-cov-2-variant-under-monitoring#:~:text=NB,Western%20Pacific%2C%20Americas%2C%20and%20European)[

![Favicon](https://www.google.com/s2/favicons?domain=https://www.cbsnews.com&sz=32)

New COVID variant NB.1.8.1 behind surge in China, now detected in U.S. - CBS News

https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/

](https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/#:~:text=and%20the%20New%20York%20City,airport%20testing%20partner%20Ginkgo%20Bioworks)[

https://cdn.who.int/media/docs/default-source/documents/epp/tracking-sars-cov-2/23052025_nb.1.8.1_ire.pdf

](https://cdn.who.int/media/docs/default-source/documents/epp/tracking-sars-cov-2/23052025_nb.1.8.1_ire.pdf#:~:text=Lineage%2A%20Countries%C2%A7%20Sequences%C2%A7%202025,6%20Increase)[

![Favicon](https://www.google.com/s2/favicons?domain=https://www.cbsnews.com&sz=32)

New COVID variant NB.1.8.1 behind surge in China, now detected in U.S. - CBS News

https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/

](https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/#:~:text=For%20now%2C%20CDC%20and%20FDA,and%20once%20over%20the%20winter)[

WHO adds NB.1.8.1 as SARS-CoV-2 variant under monitoring | CIDRAP

https://www.cidrap.umn.edu/covid-19/who-adds-nb181-sars-cov-2-variant-under-monitoring

](https://www.cidrap.umn.edu/covid-19/who-adds-nb181-sars-cov-2-variant-under-monitoring#:~:text=On%20May%2015%2C%20the%20WHO%27s,1%20component)[

https://cdn.who.int/media/docs/default-source/documents/epp/tracking-sars-cov-2/23052025_nb.1.8.1_ire.pdf

](https://cdn.who.int/media/docs/default-source/documents/epp/tracking-sars-cov-2/23052025_nb.1.8.1_ire.pdf#:~:text=globally%2C%20while%20LP,than%20other%20variants%20in%20circulation)[

https://cdn.who.int/media/docs/default-source/documents/epp/tracking-sars-cov-2/23052025_nb.1.8.1_ire.pdf

](https://cdn.who.int/media/docs/default-source/documents/epp/tracking-sars-cov-2/23052025_nb.1.8.1_ire.pdf#:~:text=has%20the%20following%20additional%20Spike,evasion%20of%20Class%201%2F2%20antibodies)[

https://cdn.who.int/media/docs/default-source/documents/epp/tracking-sars-cov-2/23052025_nb.1.8.1_ire.pdf

](https://cdn.who.int/media/docs/default-source/documents/epp/tracking-sars-cov-2/23052025_nb.1.8.1_ire.pdf#:~:text=,5%2C6)[

![Favicon](https://www.google.com/s2/favicons?domain=https://www.cbsnews.com&sz=32)

New COVID variant NB.1.8.1 behind surge in China, now detected in U.S. - CBS News

https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/

](https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/#:~:text=Vaccines%20from%20last%20season%20targeted,1%2C%20too)[

![Favicon](https://www.google.com/s2/favicons?domain=https://www.cbsnews.com&sz=32)

New COVID variant NB.1.8.1 behind surge in China, now detected in U.S. - CBS News

https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/

](https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/#:~:text=,19%20program%2C%20told%20the%20panel)[

![Favicon](https://www.google.com/s2/favicons?domain=https://www.cbsnews.com&sz=32)

New COVID variant NB.1.8.1 behind surge in China, now detected in U.S. - CBS News

https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/

](https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/#:~:text=The%20committee%20unanimously%20backed%20recommending,Pfizer%20and%20Moderna%20have%20prototyped)[

![Favicon](https://www.google.com/s2/favicons?domain=https://www.kagaya-clinic.jp&sz=32)

レプリコンワクチン（コスタイベ）（コロナワクチン定期予防接種）｜千葉県松戸市東松戸駅の加賀谷正クリニック

https://www.kagaya-clinic.jp/replicon-vaccine/

](https://www.kagaya-clinic.jp/replicon-vaccine/#:~:text=%E5%AF%BE%E3%81%97%E3%81%A6%E3%81%AF%E5%84%AA%E3%82%8C%E3%82%8B%E3%81%93%E3%81%A8%E3%81%8C%E7%A2%BA%E8%AA%8D%E3%81%95%E3%82%8C%E3%81%BE%E3%81%97%E3%81%9F%E3%80%82)[

Meiji Seikaファルマ：次世代型mRNAワクチン「コスタイベ」、世界に先駆け承認［新薬開発・販売 FRONTLINE］｜Web医事新報|日本医事新報社

https://www.jmedj.co.jp/journal/paper/detail.php?id=23229

](https://www.jmedj.co.jp/journal/paper/detail.php?id=23229#:~:text=Meiji%20Seika%E3%83%95%E3%82%A1%E3%83%AB%E3%83%9E%E3%81%AF11%E6%9C%8828%E6%97%A5%E3%80%81%E6%96%B0%E5%9E%8B%E3%82%B3%E3%83%AD%E3%83%8A%E3%82%A6%E3%82%A4%E3%83%AB%E3%82%B9%E6%84%9F%E6%9F%93%E7%97%87%E3%81%AB%E5%AF%BE%E3%81%99%E3%82%8B%E6%AC%A1%E4%B8%96%E4%BB%A3mRNA%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%80%8C%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E7%AD%8B%E6%B3%A8%E7%94%A8%E3%80%8D%E3%81%AB%E3%81%A4%E3%81%84%E3%81%A6%E8%A8%98%E8%80%85%E8%AA%AC%E6%98%8E%E4%BC%9A%E3%82%92%E9%96%8B%E5%82%AC%E3%81%97%E3%81%9F%E3%80%82%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%20%E3%81%AF%E3%80%81%E7%B1%B3%E3%83%90%E3%82%A4%E3%82%AA%E4%BC%81%E6%A5%AD%E3%82%A2%E3%83%BC%E3%82%AF%E3%83%88%E3%82%A5%E3%83%AB%E3%82%B9%E3%83%BB%E3%82%BB%E3%83%A9%E3%83%94%E3%83%A5%E3%83%BC%E3%83%86%E3%82%A3%E3%82%AF%E3%82%B9%E3%81%8C%E9%96%8B%E7%99%BA%E3%81%97%E3%81%9F%E3%80%81%E6%8A%95%E4%B8%8E%E5%BE%8C%E3%81%AB%E4%BD%93%E5%86%85%E3%81%A7mRNA%E3%82%92%E8%87%AA%E5%B7%B1%E8%A4%87%E8%A3%BD%E3%81%99%E3%82%8B%E3%80%8C%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%80%8D%E3%80%82Meiji%20Seika%E3%83%95%E3%82%A1%E3%83%AB%E3%83%9E%E3%81%8C%E5%9B%BD%E5%86%85%E3%81%AE%E4%BE%9B%E7%B5%A6%E3%83%BB%E8%B2%A9%E5%A3%B2%E6%A8%A9%E3%82%92%E5%8F%96%E5%BE%97%E3%81%97%E8%87%A8%E5%BA%8A%E8%A9%A6%E9%A8%93%E3%82%92%E9%80%B2%E3%82%81%E3%80%81%E5%90%8C%E6%97%A5%E3%80%81%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%A8%E3%81%97%E3%81%A6%E4%B8%96%E7%95%8C%E5%88%9D%E3%81%A8%E3%81%AA%E3%82%8B%E8%A3%BD%E9%80%A0%E8%B2%A9%E5%A3%B2%E6%89%BF%E8%AA%8D%E3%82%92%E5%8E%9A%E5%8A%B4%E7%9C%81%E3%82%88%E3%82%8A%E5%8F%96%E5%BE%97%E3%81%97%E3%81%9F%E3%80%82)[

![Favicon](https://www.google.com/s2/favicons?domain=https://www.kagaya-clinic.jp&sz=32)

レプリコンワクチン（コスタイベ）（コロナワクチン定期予防接種）｜千葉県松戸市東松戸駅の加賀谷正クリニック

https://www.kagaya-clinic.jp/replicon-vaccine/

](https://www.kagaya-clinic.jp/replicon-vaccine/#:~:text=Image%3A%20%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B32024%E5%B9%B410%E6%9C%881%E6%97%A5%E3%82%88%E3%82%8A%E3%80%81%E6%96%B0%E5%9E%8B%E3%82%B3%E3%83%AD%E3%83%8A%E3%82%A6%E3%82%A4%E3%83%AB%E3%82%B9%E3%81%AE%E3%82%AA%E3%83%9F%E3%82%AF%E3%83%AD%E3%83%B3%E6%A0%AAJN)[

![Favicon](https://www.google.com/s2/favicons?domain=https://www.kagaya-clinic.jp&sz=32)

レプリコンワクチン（コスタイベ）（コロナワクチン定期予防接種）｜千葉県松戸市東松戸駅の加賀谷正クリニック

https://www.kagaya-clinic.jp/replicon-vaccine/

](https://www.kagaya-clinic.jp/replicon-vaccine/#:~:text=%E3%80%8C%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%EF%BC%88replicon%EF%BC%89%E3%80%8D%E3%81%AF%E3%80%81%E3%80%8C%E8%A4%87%E8%A3%BD%E3%80%8D%E3%82%92%E6%84%8F%E5%91%B3%E3%81%99%E3%82%8B%E5%88%86%E5%AD%90%E7%94%9F%E7%89%A9%E5%AD%A6%E3%81%AE%E7%94%A8%E8%AA%9E%E3%81%A7%E3%80%81%E3%82%B3%E3%83%94%E3%83%BC%E3%81%95%E3%82%8C%E3%81%9FDNA%E3%82%84RNA%E3%82%92%E6%8C%87%E3%81%97%E3%81%BE%E3%81%99%E3%80%82%20%E5%BE%93%E6%9D%A5%E3%81%AEmRNA%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AF%E3%80%81%E4%BD%93%E5%86%85%E3%81%A7%E3%82%A6%E3%82%A4%E3%83%AB%E3%82%B9%E3%81%AE%E3%82%BF%E3%83%B3%E3%83%91%E3%82%AF%E8%B3%AA%E3%82%92%E7%94%9F%E6%88%90%E3%81%99%E3%82%8B%E3%81%93%E3%81%A8%E3%81%A7%E5%85%8D%E7%96%AB%E3%82%92%E8%AA%98%E5%B0%8E%E3%81%97%E3%80%81%E6%8A%97%E4%BD%93%E3%82%92%E5%BE%97%E3%82%8B%E4%BB%95%E7%B5%84%E3%81%BF%E3%81%A7%E3%81%99%E3%81%8C%E3%80%81%E3%81%9D%E3%81%AE%E7%94%9F%E6%88%90%E3%81%AF%E4%B8%80%E9%81%8E%E6%80%A7%E3%81%A7%E3%81%99%E3%80%82%E3%81%93%E3%82%8C%E3%81%AB%E5%AF%BE%E3%81%97%E3%80%81%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%EF%BC%88%20%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%EF%BC%89%E3%81%AFmRNA%E3%81%AB%E8%87%AA%E5%B7%B1%E8%A4%87%E8%A3%BD%E9%85%B5%E7%B4%A0%E3%82%92%E7%B5%84%E3%81%BF%E8%BE%BC%E3%81%BF%E3%80%81%E3%82%BF%E3%83%B3%E3%83%91%E3%82%AF%E8%B3%AA%E7%94%9F%E6%88%90%E3%82%92%E6%8C%81%E7%B6%9A%E7%9A%84%E3%81%AB%E8%A1%8C%E3%81%84%E3%81%BE%E3%81%99%E3%80%82%E3%81%93%E3%81%AE%E3%80%8C%E8%87%AA%E5%B7%B1%E5%A2%97%E5%B9%85%E3%80%8D%E3%81%AB%E3%82%88%E3%82%8A%E3%80%81%E5%BE%93%E6%9D%A5%E3%81%AEmRNA%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AB%E6%AF%94%E3%81%B9%E3%81%A6%E3%80%81%E3%82%88%E3%82%8A%E5%BC%B7%E5%8A%9B%E3%81%A7%E6%8C%81%E7%B6%9A%E7%9A%84%E3%81%AA%E5%85%8D%E7%96%AB%20%E5%BF%9C%E7%AD%94%E3%82%92%E8%AA%98%E5%B0%8E%E3%81%A7%E3%81%8D%E3%82%8B%E3%81%A8%E3%81%95%E3%82%8C%E3%81%A6%E3%81%84%E3%81%BE%E3%81%99%E3%80%82%20%E5%95%86%E5%93%81%E5%90%8D%E3%80%8C%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E3%80%8D%E3%81%AF%E3%80%81%E3%82%A2%E3%83%A1%E3%83%AA%E3%82%AB%E3%81%AEArcturus,Therapeutics%E7%A4%BE%E3%81%8C%E9%96%8B%E7%99%BA%E3%81%97%E3%80%81%E6%97%A5%E6%9C%AC%E3%81%A7%E3%81%AFMeiji%20Seika%E3%83%95%E3%82%A1%E3%83%AB%E3%83%9E%E7%A4%BE%E3%81%8C%E8%A3%BD%E9%80%A0%E3%83%BB%E8%B2%A9%E5%A3%B2%E3%82%92%E6%8B%85%E5%BD%93%E3%81%97%E3%81%A6%E3%81%84%E3%81%BE%E3%81%99%E3%80%82)[

![Favicon](https://www.google.com/s2/favicons?domain=https://www.kagaya-clinic.jp&sz=32)

レプリコンワクチン（コスタイベ）（コロナワクチン定期予防接種）｜千葉県松戸市東松戸駅の加賀谷正クリニック

https://www.kagaya-clinic.jp/replicon-vaccine/

](https://www.kagaya-clinic.jp/replicon-vaccine/#:~:text=%E7%89%B9%E5%BE%B4%E3%81%A8%E4%BB%8A%E5%BE%8C%E3%81%AE%E5%8F%AF%E8%83%BD%E6%80%A7)[

Meiji Seikaファルマ：次世代型mRNAワクチン「コスタイベ」、世界に先駆け承認［新薬開発・販売 FRONTLINE］｜Web医事新報|日本医事新報社

https://www.jmedj.co.jp/journal/paper/detail.php?id=23229

](https://www.jmedj.co.jp/journal/paper/detail.php?id=23229#:~:text=%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AF%E6%97%A2%E5%AD%98%E3%81%AEmRNA%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AB%E6%AF%94%E3%81%B9%E5%B0%91%E9%87%8F%E6%8A%95%E4%B8%8E%E3%81%A7%E6%B8%88%E3%81%BF%E3%80%81%E3%82%88%E3%82%8A%E5%8A%B9%E6%9E%9C%E3%81%8C%E6%8C%81%E7%B6%9A%E3%81%99%E3%82%8B%E3%81%A8%E3%81%95%E3%82%8C%E3%82%8B%E3%80%82%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E3%81%AF%E8%BF%BD%E5%8A%A0%E5%85%8D%E7%96%AB%E3%81%AE%E5%9B%BD%E5%86%85%E7%AC%AC3%E7%9B%B8%E8%A9%A6%E9%A8%93%E3%81%A7%E3%80%81%E3%83%95%E3%82%A1%E3%82%A4%E3%82%B6%E3%83%BC%E3%81%AE%E3%82%B3%E3%83%9F%E3%83%8A%E3%83%86%E3%82%A3%E3%81%AB%E6%AF%94%E3%81%B9%20%E6%8A%97%E4%BD%93%E4%BE%A1%E3%81%8C%E9%AB%98%E3%81%8F%E6%8C%81%E7%B6%9A%E6%80%A7%E3%81%AB%E5%84%AA%E3%82%8C%E3%81%A6%E3%81%84%E3%82%8B%E3%81%93%E3%81%A8%E3%81%8C%E7%A2%BA%E8%AA%8D%E3%81%95%E3%82%8C%E3%81%9F%E3%80%82)[

Meiji Seikaファルマ：次世代型mRNAワクチン「コスタイベ」、世界に先駆け承認［新薬開発・販売 FRONTLINE］｜Web医事新報|日本医事新報社

https://www.jmedj.co.jp/journal/paper/detail.php?id=23229

](https://www.jmedj.co.jp/journal/paper/detail.php?id=23229#:~:text=%E5%90%8C%E7%A4%BE%E3%81%AF%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E3%81%8C%E8%B5%B7%E6%BA%90%E6%A0%AA%E5%AF%BE%E5%BF%9C%E3%81%AE1%E4%BE%A1%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AE%E3%81%9F%E3%82%81%E4%BB%8A%E5%86%AC%E3%81%AF%E8%B2%A9%E5%A3%B2%E3%81%9B%E3%81%9A%E3%80%81%E6%9D%A5%E5%B9%B4%E3%81%AE%E7%A7%8B%E5%86%AC%E6%8E%A5%E7%A8%AE%E3%81%AB%E5%90%91%E3%81%91%E3%81%9F%E4%BE%9B%E7%B5%A6%E9%96%8B%E5%A7%8B%E3%82%92%E6%83%B3%E5%AE%9A%E3%81%97%E3%81%A6%E8%B5%B7%E6%BA%90%E6%A0%AA%E3%81%A8%E3%82%AA%E3%83%9F%E3%82%AF%E3%83%AD%E3%83%B3%E6%A0%AA%E3%81%AB%E3%82%88%E3%82%8B2%E4%BE%A1%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AE%E9%96%8B%E7%99%BA%E3%82%92%E9%80%B2%E3%82%81%E3%82%8B%E3%80%82%E5%8E%9F%20%E8%96%AC%E3%81%AF%E3%82%A2%E3%83%AB%E3%82%AB%E3%83%AA%E3%82%B9%E7%A4%BE%EF%BC%88%E7%A6%8F%E5%B3%B6%E7%9C%8C%E5%8D%97%E7%9B%B8%E9%A6%AC%E5%B8%82%EF%BC%89%E3%81%8B%E3%82%89%E8%AA%BF%E9%81%94%E3%80%81%E4%BB%8A%E5%BE%8C%E5%9B%BD%E5%86%85%E3%81%AB%E6%96%B0%E8%A3%BD%E9%80%A0%E6%A3%9F%E3%82%92%E5%BB%BA%E8%A8%AD%E3%81%97%E3%80%812027%E5%B9%B4%E3%81%AB%E3%81%AF%E7%B4%841%E5%84%84%E5%9B%9E%E6%8E%A5%E7%A8%AE%E5%88%86%E3%81%AE%E7%94%9F%E7%94%A3%E4%BD%93%E5%88%B6%E3%82%92%E6%A7%8B%E7%AF%89%E3%81%99%E3%82%8B%E6%96%B9%E9%87%9D%E3%80%8228%E6%97%A5%E3%81%AE%E8%AA%AC%E6%98%8E%E4%BC%9A%E3%81%A7%E5%90%8C%E7%A4%BE%E3%81%AE%E5%B0%8F%E6%9E%97%E5%A4%A7%E5%90%89%E9%83%8E%E7%A4%BE%20%E9%95%B7%EF%BC%88%E5%86%99%E7%9C%9F%EF%BC%89%E3%81%AF%E3%80%8C%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E6%95%97%E6%88%A6%E3%81%A8%E6%8F%B6%E6%8F%84%E3%81%95%E3%82%8C%E3%81%9F%E6%88%91%E3%81%8C%E5%9B%BD%E3%81%A7%E3%80%81%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E5%AE%9F%E7%94%A8%E5%8C%96%E3%81%AB%E3%81%8A%E3%81%84%E3%81%A6%E4%B8%96%E7%95%8C%E3%81%AB%E5%85%88%E9%A7%86%E3%81%91%E3%82%8B%E3%81%93%E3%81%A8%E3%81%8C%E3%81%A7%E3%81%8D%E3%81%9F%E3%80%82%E4%BD%95%E3%81%A8%E3%81%8B%E3%82%B4%E3%83%BC%E3%83%AB%E3%81%BE%E3%81%A7%E6%8C%81%E3%81%A3%E3%81%A6%E3%81%84%E3%81%8D%E3%81%9F%E3%81%84%E3%80%8D%E3%81%A8%E5%BC%B7%E8%AA%BF%E3%81%97%E3%81%9F%E3%80%82)[

![Favicon](https://www.google.com/s2/favicons?domain=https://www.kagaya-clinic.jp&sz=32)

レプリコンワクチン（コスタイベ）（コロナワクチン定期予防接種）｜千葉県松戸市東松戸駅の加賀谷正クリニック

https://www.kagaya-clinic.jp/replicon-vaccine/

](https://www.kagaya-clinic.jp/replicon-vaccine/#:~:text=%E8%87%A8%E5%BA%8A%E8%A9%A6%E9%A8%93%E3%81%AB%E3%81%8A%E3%81%84%E3%81%A6%E3%80%81%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%EF%BC%88%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%EF%BC%89%E3%81%AF%E6%9C%89%E5%8A%B9%E6%80%A7%E3%81%A8%E5%85%8D%E7%96%AB%E5%8E%9F%E6%80%A7%E3%81%8C%E7%A2%BA%E8%AA%8D%E3%81%95%E3%82%8C%E3%81%A6%E3%81%84%E3%81%BE%E3%81%99%E3%80%82%20%E4%B8%BB%E3%81%AA%E5%89%AF%E5%8F%8D%E5%BF%9C%E3%81%AF%E4%BB%A5%E4%B8%8B%E3%81%AE%E9%80%9A%E3%82%8A%E3%81%A7%E3%81%99%EF%BC%9A)[

![Favicon](https://www.google.com/s2/favicons?domain=https://www.kagaya-clinic.jp&sz=32)

レプリコンワクチン（コスタイベ）（コロナワクチン定期予防接種）｜千葉県松戸市東松戸駅の加賀谷正クリニック

https://www.kagaya-clinic.jp/replicon-vaccine/

](https://www.kagaya-clinic.jp/replicon-vaccine/#:~:text=Image%EF%BC%83%E3%83%88%E3%82%B8%E3%83%8A%E3%83%A1%E3%83%A9%E3%83%B3%3D%E3%83%95%E3%82%A1%E3%82%A4%E3%82%B6%E3%83%BC%E8%A3%BD%E3%82%B3%E3%83%AD%E3%83%8A%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3)[

https://www.mhlw.go.jp/content/10900000/001305412.pdf

](https://www.mhlw.go.jp/content/10900000/001305412.pdf#:~:text=Meiji%20Seika%E3%83%95%E3%82%A1%E3%83%AB%E3%83%9E%20%E6%A0%AA%E5%BC%8F%E4%BC%9A%E7%A4%BE%20%E8%B2%A9%E5%A3%B2%E5%90%8D%20%E3%82%B3%E3%83%9F%E3%83%8A%E3%83%86%E3%82%A3%C2%AE,%EF%BD%8DRNA%EF%BC%88%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%EF%BC%89%20%E8%96%AC%E4%BA%8B%E6%89%BF%E8%AA%8D%E3%81%AE%20%E7%8A%B6%E6%B3%81%20%E4%BB%A4%E5%92%8C%EF%BC%96%E5%B9%B4%EF%BC%98%E6%9C%88%EF%BC%98%E6%97%A5%20%E4%B8%80%E5%A4%89%E6%89%BF%E8%AA%8D%EF%BC%8A)[

https://www.mhlw.go.jp/content/10900000/001305412.pdf

](https://www.mhlw.go.jp/content/10900000/001305412.pdf#:~:text=%E8%B2%A9%E5%A3%B2%E5%90%8D%20%E3%82%B3%E3%83%9F%E3%83%8A%E3%83%86%E3%82%A3%C2%AE%20%E3%82%B9%E3%83%91%E3%82%A4%E3%82%AF%E3%83%90%E3%83%83%E3%82%AF%E3%82%B9%C2%AE%20%E3%83%80%E3%82%A4%E3%83%81%E3%83%AD%E3%83%8A%C2%AE%20%E3%83%8C%E3%83%90%E3%82%AD%E3%82%BD%E3%83%93%E3%83%83%E3%83%89%C2%AE,%E7%8A%B6%E6%B3%81%20%E4%BB%A4%E5%92%8C%EF%BC%96%E5%B9%B4%EF%BC%98%E6%9C%88%EF%BC%98%E6%97%A5%20%E4%B8%80%E5%A4%89%E6%89%BF%E8%AA%8D%EF%BC%8A%20%E4%BB%A4%E5%92%8C%EF%BC%96%E5%B9%B4%EF%BC%98%E6%9C%8823%E6%97%A5%20%E4%B8%80%E5%A4%89%E6%89%BF%E8%AA%8D%EF%BC%8A)[

![Favicon](https://www.google.com/s2/favicons?domain=https://www.fsight.jp&sz=32)

明治HD「コスタイベ」承認は、化血研不祥事の「貸し」の対価ではないのか：上昌広 | 医療崩壊 | 新潮社　Foresight(フォーサイト) | 会員制国際情報サイト

https://www.fsight.jp/articles/-/50989

](https://www.fsight.jp/articles/-/50989#:~:text=%E6%98%8E%E6%B2%BBHD%E4%BA%8B%E6%A5%AD%E5%AD%90%E4%BC%9A%E7%A4%BE%E3%81%AEMeiji%20Seika%20%E3%83%95%E3%82%A1%E3%83%AB%E3%83%9E%E3%81%8C%E9%96%8B%E7%99%BA%E3%81%97%E3%81%9F%E3%82%B3%E3%83%AD%E3%83%8A%E3%82%A6%E3%82%A4%E3%83%AB%E3%82%B9%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%80%8C%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E3%80%8D%E3%81%8C%E4%B8%96%E9%96%93%E3%81%AE%E9%96%A2%E5%BF%83%E3%82%92%E9%9B%86%E3%82%81%E3%81%A6%E3%81%84%E3%82%8B%E3%80%82SNS%E3%81%AB%E3%81%AF%E3%80%81%E3%80%8C%E3%82%B7%E3%82%A7%E3%83%87%E3%82%A3%E3%83%B3%E3%82%B0%E3%81%AB%E3%82%88%E3%82%8A%E3%80%81%E3%83%AF%20%E3%82%AF%E3%83%81%E3%83%B3%E6%8E%A5%E7%A8%AE%E8%80%85%E3%81%8B%E3%82%89%E5%91%A8%E5%9B%B2%E3%81%AB%E6%84%9F%E6%9F%93%E3%81%95%E3%81%9B%E3%82%8B%E3%80%8D%E3%81%AA%E3%81%A9%E3%81%AE%E3%83%87%E3%83%9E%E3%81%8C%E6%B0%BE%E6%BF%AB%E3%81%97%E3%81%A6%E3%81%84%E3%82%8B%E3%80%82%E3%80%8C%E3%82%B7%E3%82%A7%E3%83%87%E3%82%A3%E3%83%B3%E3%82%B0%E3%80%8D%E3%81%A8%E3%81%AF%E3%80%81%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E3%81%8C%E4%BD%93%E5%86%85%E3%81%A7%E5%A2%97%E6%AE%96%E3%81%97%E3%81%9F%E5%BE%8C%E3%80%81%E3%81%9D%E3%81%AE%E4%B8%80%E9%83%A8%E3%81%8C%E5%AF%BE%E5%A4%96%E3%81%AB%E6%94%BE%E5%87%BA%E3%81%95%E3%82%8C%E3%80%81%E5%91%A8%E5%9B%B2%E3%81%AB%E3%81%84%E3%82%8B%E4%BA%BA%E3%81%AB%E6%82%AA%E5%BD%B1%E9%9F%BF%E3%82%92%20%E4%B8%8E%E3%81%88%E3%82%8B%E3%81%93%E3%81%A8%E3%81%A0%E3%81%8C%E3%80%81%E3%81%93%E3%81%AE%E3%81%93%E3%81%A8%E3%82%92%E6%94%AF%E6%8C%81%E3%81%99%E3%82%8B%E7%A7%91%E5%AD%A6%E7%9A%84%E3%81%AA%E6%A0%B9%E6%8B%A0%E3%81%AF%E3%81%AA%E3%81%84%E3%80%82)[

https://www.mhlw.go.jp/content/10900000/001305412.pdf

](https://www.mhlw.go.jp/content/10900000/001305412.pdf#:~:text=%E2%97%8B%20%E3%83%95%E3%82%A1%E3%82%A4%E3%82%B6%E3%83%BC%E7%A4%BE%E3%80%81%E3%83%A2%E3%83%87%E3%83%AB%E3%83%8A%E7%A4%BE%E3%80%81%E7%AC%AC%E4%B8%80%E4%B8%89%E5%85%B1%E7%A4%BE%E3%80%81%E6%AD%A6%E7%94%B0%E8%96%AC%E5%93%81%E5%B7%A5%E6%A5%AD%E7%A4%BE%E3%81%AE%EF%BC%94%E7%A4%BE%E3%81%AB%E3%81%A4%E3%81%84%E3%81%A6%E3%81%AF%E3%80%81%E4%BB%A4%E5%92%8C%EF%BC%95%E5%B9%B4%E5%BA%A6%E3%81%BE%E3%81%A7%E3%81%AE%E8%87%A8%E6%99%82%E6%8E%A5%E7%A8%AE%E3%81%A7%E3%81%99%E3%81%A7%E3%81%AB%E4%BD%BF%E7%94%A8%E3%81%97%E3%81%9F%E3%83%AF%E3%82%AF%E3%83%81%20%E3%83%B3%E3%81%AB%E3%81%8A%E3%81%91%E3%82%8B%E3%80%81JN,1%E7%B3%BB%E7%B5%B1%E5%AF%BE%E5%BF%9C%E3%81%AB%E4%BF%82%E3%82%8B%E6%89%BF%E8%AA%8D%E4%BA%8B%E9%A0%85%E4%B8%80%E9%83%A8%E5%A4%89%E6%9B%B4%E3%82%92%E5%8F%96%E5%BE%97%E3%81%97%E3%81%9F%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%8C%E4%BE%9B%E7%B5%A6%E3%81%95%E3%82%8C%E3%82%8B%E8%A6%8B%E9%80%9A%E3%81%97%E3%81%A7%E3%81%82%E3%82%8B%E3%80%82%2017)[

Meiji Seikaファルマ：次世代型mRNAワクチン「コスタイベ」、世界に先駆け承認［新薬開発・販売 FRONTLINE］｜Web医事新報|日本医事新報社

https://www.jmedj.co.jp/journal/paper/detail.php?id=23229

](https://www.jmedj.co.jp/journal/paper/detail.php?id=23229#:~:text=%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AF%E6%97%A2%E5%AD%98%E3%81%AEmRNA%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AB%E6%AF%94%E3%81%B9%E5%B0%91%E9%87%8F%E6%8A%95%E4%B8%8E%E3%81%A7%E6%B8%88%E3%81%BF%E3%80%81%E3%82%88%E3%82%8A%E5%8A%B9%E6%9E%9C%E3%81%8C%E6%8C%81%E7%B6%9A%E3%81%99%E3%82%8B%E3%81%A8%E3%81%95%E3%82%8C%E3%82%8B%E3%80%82%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E3%81%AF%E8%BF%BD%E5%8A%A0%E5%85%8D%E7%96%AB%E3%81%AE%E5%9B%BD%E5%86%85%E7%AC%AC3%E7%9B%B8%E8%A9%A6%E9%A8%93%E3%81%A7%E3%80%81%E3%83%95%E3%82%A1%E3%82%A4%E3%82%B6%E3%83%BC%E3%81%AE%E3%82%B3%E3%83%9F%E3%83%8A%E3%83%86%E3%82%A3%E3%81%AB%E6%AF%94%E3%81%B9%20%E6%8A%97%E4%BD%93%E4%BE%A1%E3%81%8C%E9%AB%98%E3%81%8F%E6%8C%81%E7%B6%9A%E6%80%A7%E3%81%AB%E5%84%AA%E3%82%8C%E3%81%A6%E3%81%84%E3%82%8B%E3%81%93%E3%81%A8%E3%81%8C%E7%A2%BA%E8%AA%8D%E3%81%95%E3%82%8C%E3%81%9F%E3%80%82)[

![Favicon](https://www.google.com/s2/favicons?domain=https://www.fsight.jp&sz=32)

明治HD「コスタイベ」承認は、化血研不祥事の「貸し」の対価ではないのか：上昌広 | 医療崩壊 | 新潮社　Foresight(フォーサイト) | 会員制国際情報サイト

https://www.fsight.jp/articles/-/50989

](https://www.fsight.jp/articles/-/50989#:~:text=%E5%8C%BB%E7%99%82%E7%8F%BE%E5%A0%B4%E3%81%AF%E7%8F%BE%E6%99%82%E7%82%B9%E3%81%A7%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E3%82%92%E6%B1%82%E3%82%81%E3%81%A6%E3%81%84%E3%81%AA%E3%81%84%E3%80%82%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E3%81%AE%E5%8F%AF%E8%83%BD%E6%80%A7%E3%81%AF%E9%AB%98%E3%81%8F%E8%A9%95%E4%BE%A1%E3%81%95%E3%82%8C%E3%82%8B%E3%81%B9%E3%81%8D%E3%81%A0%E3%81%8C%E3%80%81%E4%B8%8D%E5%8D%81%E5%88%86%E3%81%AA%E8%87%A8%E5%BA%8A%E8%A9%A6%E9%A8%93%E3%81%A7%E3%80%8C%E4%BB%AE%E5%85%8D%E8%A8%B1%E3%80%8D%E3%82%92%E4%B8%8E%E3%81%88%E3%82%8B%E7%90%86%E7%94%B1%E3%81%AF%E3%81%AA%E3%81%84%E3%80%82%E3%81%93%E3%82%8C%E3%81%AF2015%E5%B9%B4%E3%81%AB%E7%99%BA%E8%A6%9A%E3%81%97%20%E3%81%9F%E5%8C%96%E5%AD%A6%E5%8F%8A%E8%A1%80%E6%B8%85%E7%99%82%E6%B3%95%E7%A0%94%E7%A9%B6%E6%89%80%EF%BC%88%E5%8C%96%E8%A1%80%E7%A0%94%EF%BC%89%E3%81%AE%E4%B8%8D%E7%A5%A5%E4%BA%8B%E3%81%A7%E3%80%81%E6%98%8E%E6%B2%BBHD%E3%81%8C%E5%8E%9A%E5%8A%B4%E7%9C%81%E3%81%AB%E4%BD%9C%E3%81%A3%E3%81%9F%E3%80%8C%E8%B2%B8%E3%81%97%E3%80%8D%E3%81%8C%E8%BF%94%E3%81%95%E3%82%8C%E3%81%9F%E3%81%A8%E3%81%84%E3%81%86%E3%81%93%E3%81%A8%E3%81%8B%E3%80%82%E4%BB%AE%E3%81%AB%E3%81%9D%E3%81%86%E3%81%AA%E3%82%89%E3%80%81%E4%B8%96%E7%95%8C%E3%81%A7%E6%9C%80%E3%82%82%E6%A0%B9%E6%B7%B1%E3%81%84%E6%97%A5%E6%9C%AC%E7%A4%BE%E4%BC%9A%E3%81%AE%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%AB%E5%AF%BE%E3%81%99%E3%82%8B%E4%B8%8D%E4%BF%A1%20%E6%84%9F%E3%81%AF%E3%80%81%E3%81%95%E3%82%89%E3%81%AB%E5%A2%97%E3%81%99%E3%81%B0%E3%81%8B%E3%82%8A%E3%81%A0%E3%82%8D%E3%81%86%E3%80%82)

すべての情報源

[

cidrap.umn

](https://www.cidrap.umn.edu/covid-19/who-adds-nb181-sars-cov-2-variant-under-monitoring#:~:text=The%20World%20Health%20Organization%20,1%20sublineage)[

![Favicon](https://www.google.com/s2/favicons?domain=https://www.cbsnews.com&sz=32)

cbsnews

](https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/#:~:text=Experts%20have%20been%20closely%20watching,19)[

cdn.who

](https://cdn.who.int/media/docs/default-source/documents/epp/tracking-sars-cov-2/23052025_nb.1.8.1_ire.pdf#:~:text=Lineage%2A%20Countries%C2%A7%20Sequences%C2%A7%202025,6%20Increase)[

![Favicon](https://www.google.com/s2/favicons?domain=https://www.kagaya-clinic.jp&sz=32)

kagaya-clinic

](https://www.kagaya-clinic.jp/replicon-vaccine/#:~:text=%E5%AF%BE%E3%81%97%E3%81%A6%E3%81%AF%E5%84%AA%E3%82%8C%E3%82%8B%E3%81%93%E3%81%A8%E3%81%8C%E7%A2%BA%E8%AA%8D%E3%81%95%E3%82%8C%E3%81%BE%E3%81%97%E3%81%9F%E3%80%82)[

jmedj.co

](https://www.jmedj.co.jp/journal/paper/detail.php?id=23229#:~:text=Meiji%20Seika%E3%83%95%E3%82%A1%E3%83%AB%E3%83%9E%E3%81%AF11%E6%9C%8828%E6%97%A5%E3%80%81%E6%96%B0%E5%9E%8B%E3%82%B3%E3%83%AD%E3%83%8A%E3%82%A6%E3%82%A4%E3%83%AB%E3%82%B9%E6%84%9F%E6%9F%93%E7%97%87%E3%81%AB%E5%AF%BE%E3%81%99%E3%82%8B%E6%AC%A1%E4%B8%96%E4%BB%A3mRNA%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%80%8C%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E7%AD%8B%E6%B3%A8%E7%94%A8%E3%80%8D%E3%81%AB%E3%81%A4%E3%81%84%E3%81%A6%E8%A8%98%E8%80%85%E8%AA%AC%E6%98%8E%E4%BC%9A%E3%82%92%E9%96%8B%E5%82%AC%E3%81%97%E3%81%9F%E3%80%82%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%20%E3%81%AF%E3%80%81%E7%B1%B3%E3%83%90%E3%82%A4%E3%82%AA%E4%BC%81%E6%A5%AD%E3%82%A2%E3%83%BC%E3%82%AF%E3%83%88%E3%82%A5%E3%83%AB%E3%82%B9%E3%83%BB%E3%82%BB%E3%83%A9%E3%83%94%E3%83%A5%E3%83%BC%E3%83%86%E3%82%A3%E3%82%AF%E3%82%B9%E3%81%8C%E9%96%8B%E7%99%BA%E3%81%97%E3%81%9F%E3%80%81%E6%8A%95%E4%B8%8E%E5%BE%8C%E3%81%AB%E4%BD%93%E5%86%85%E3%81%A7mRNA%E3%82%92%E8%87%AA%E5%B7%B1%E8%A4%87%E8%A3%BD%E3%81%99%E3%82%8B%E3%80%8C%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%80%8D%E3%80%82Meiji%20Seika%E3%83%95%E3%82%A1%E3%83%AB%E3%83%9E%E3%81%8C%E5%9B%BD%E5%86%85%E3%81%AE%E4%BE%9B%E7%B5%A6%E3%83%BB%E8%B2%A9%E5%A3%B2%E6%A8%A9%E3%82%92%E5%8F%96%E5%BE%97%E3%81%97%E8%87%A8%E5%BA%8A%E8%A9%A6%E9%A8%93%E3%82%92%E9%80%B2%E3%82%81%E3%80%81%E5%90%8C%E6%97%A5%E3%80%81%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%81%A8%E3%81%97%E3%81%A6%E4%B8%96%E7%95%8C%E5%88%9D%E3%81%A8%E3%81%AA%E3%82%8B%E8%A3%BD%E9%80%A0%E8%B2%A9%E5%A3%B2%E6%89%BF%E8%AA%8D%E3%82%92%E5%8E%9A%E5%8A%B4%E7%9C%81%E3%82%88%E3%82%8A%E5%8F%96%E5%BE%97%E3%81%97%E3%81%9F%E3%80%82)[

mhlw.go

](https://www.mhlw.go.jp/content/10900000/001305412.pdf#:~:text=Meiji%20Seika%E3%83%95%E3%82%A1%E3%83%AB%E3%83%9E%20%E6%A0%AA%E5%BC%8F%E4%BC%9A%E7%A4%BE%20%E8%B2%A9%E5%A3%B2%E5%90%8D%20%E3%82%B3%E3%83%9F%E3%83%8A%E3%83%86%E3%82%A3%C2%AE,%EF%BD%8DRNA%EF%BC%88%E3%83%AC%E3%83%97%E3%83%AA%E3%82%B3%E3%83%B3%EF%BC%89%20%E8%96%AC%E4%BA%8B%E6%89%BF%E8%AA%8D%E3%81%AE%20%E7%8A%B6%E6%B3%81%20%E4%BB%A4%E5%92%8C%EF%BC%96%E5%B9%B4%EF%BC%98%E6%9C%88%EF%BC%98%E6%97%A5%20%E4%B8%80%E5%A4%89%E6%89%BF%E8%AA%8D%EF%BC%8A)[

![Favicon](https://www.google.com/s2/favicons?domain=https://www.fsight.jp&sz=32)

fsight

](https://www.fsight.jp/articles/-/50989#:~:text=%E6%98%8E%E6%B2%BBHD%E4%BA%8B%E6%A5%AD%E5%AD%90%E4%BC%9A%E7%A4%BE%E3%81%AEMeiji%20Seika%20%E3%83%95%E3%82%A1%E3%83%AB%E3%83%9E%E3%81%8C%E9%96%8B%E7%99%BA%E3%81%97%E3%81%9F%E3%82%B3%E3%83%AD%E3%83%8A%E3%82%A6%E3%82%A4%E3%83%AB%E3%82%B9%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%80%8C%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E3%80%8D%E3%81%8C%E4%B8%96%E9%96%93%E3%81%AE%E9%96%A2%E5%BF%83%E3%82%92%E9%9B%86%E3%82%81%E3%81%A6%E3%81%84%E3%82%8B%E3%80%82SNS%E3%81%AB%E3%81%AF%E3%80%81%E3%80%8C%E3%82%B7%E3%82%A7%E3%83%87%E3%82%A3%E3%83%B3%E3%82%B0%E3%81%AB%E3%82%88%E3%82%8A%E3%80%81%E3%83%AF%20%E3%82%AF%E3%83%81%E3%83%B3%E6%8E%A5%E7%A8%AE%E8%80%85%E3%81%8B%E3%82%89%E5%91%A8%E5%9B%B2%E3%81%AB%E6%84%9F%E6%9F%93%E3%81%95%E3%81%9B%E3%82%8B%E3%80%8D%E3%81%AA%E3%81%A9%E3%81%AE%E3%83%87%E3%83%9E%E3%81%8C%E6%B0%BE%E6%BF%AB%E3%81%97%E3%81%A6%E3%81%84%E3%82%8B%E3%80%82%E3%80%8C%E3%82%B7%E3%82%A7%E3%83%87%E3%82%A3%E3%83%B3%E3%82%B0%E3%80%8D%E3%81%A8%E3%81%AF%E3%80%81%E3%82%B3%E3%82%B9%E3%82%BF%E3%82%A4%E3%83%99%E3%81%8C%E4%BD%93%E5%86%85%E3%81%A7%E5%A2%97%E6%AE%96%E3%81%97%E3%81%9F%E5%BE%8C%E3%80%81%E3%81%9D%E3%81%AE%E4%B8%80%E9%83%A8%E3%81%8C%E5%AF%BE%E5%A4%96%E3%81%AB%E6%94%BE%E5%87%BA%E3%81%95%E3%82%8C%E3%80%81%E5%91%A8%E5%9B%B2%E3%81%AB%E3%81%84%E3%82%8B%E4%BA%BA%E3%81%AB%E6%82%AA%E5%BD%B1%E9%9F%BF%E3%82%92%20%E4%B8%8E%E3%81%88%E3%82%8B%E3%81%93%E3%81%A8%E3%81%A0%E3%81%8C%E3%80%81%E3%81%93%E3%81%AE%E3%81%93%E3%81%A8%E3%82%92%E6%94%AF%E6%8C%81%E3%81%99%E3%82%8B%E7%A7%91%E5%AD%A6%E7%9A%84%E3%81%AA%E6%A0%B9%E6%8B%A0%E3%81%AF%E3%81%AA%E3%81%84%E3%80%82)